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Autophagy is a degradative intracellular process induced in response to 
various intrinsic and extrinsic stresses to prevent cell damage and promote cell 
survival. Dysregulated autophagy has been implicated in a wide range of age-
related dysfunction and disease, therefore methods are needed to for the 
quantification of autophagy flux. In this thesis, techniques are described for the 
measurement of autophagy flux at the individual cell level during myogenesis and 
in phenotypically separated cell subsets from young and geriatric murine skeletal 
muscle using mass cytometry. In addition, multiplexed measurements of individual 
autophagy-related organelles are discussed. These techniques provide insight to 
the heterogeneity of autophagy flux at the individual cell and organelle level, which 
could inform the fundamental understanding of the necessity of autophagy for the 
maintenance of skeletal muscle mass and function in aging tissues. 
A method was developed to measure autophagy flux in whole cells by mass 
cytometry. This method provides accurate quantification of autophagy-related 
cellular targets in whole cells via post-hoc non-specific binding correction and total 
antibody loading normalization and was able to detect small changes in autophagy 
flux induced via pharmacological treatment. Application of this method to 
heterogeneous cultures of differentiating myoblasts suggest that autophagy flux is 
increased during myoblast fusion, while specific degradation of mitochondria via 
mitophagy is increased during myoblast proliferation, expanding current 
knowledge of the regulation of autophagy flux during myoblast differentiation. 
Satellite cells, pro- and anti-inflammatory macrophages and fibroadipogenic 
progenitor (FAP) cells are key players in maintaining the regenerative potential of 
skeletal muscle. Using the method developed for monitoring autophagy flux in 
myogenesis above, the contribution of each cell type to the overall decrease of 
autophagy flux described in the literature was determined. This analysis provides 





age in skeletal muscle and revealed potential differences in the need for general 
or selective degradation of cargo via autophagy.   
Individual autophagy-related organelle heterogeneity was quantified using 
mass cytometry. Autophagy-related organelles from murine skeletal muscle, brain, 
and liver were labeled with a lipid membrane stain, DDD-Tb, which enabled 
detection of individual organelles via mass cytometry. Analysis of specific 
organelle types revealed organelle associations which can be used to understand 
the progression of autophagy. 
In the future, these methods can be expanded and applied to biological 
models of aging to gain high-resolution insight into the organelle types most 
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The global population of individuals over 60 years is expanding in parallel 
with increased life expectancy and is set to double by 2050.1-2 However, 
preservation of human health is not always sustained with increased life 
expectancy. Of the 1.5 million individuals over the at of 65 admitted to long-term 
care facilities each year in the United States, 33% are institutionalized solely due 
to their inability to perform activities of daily living often precipitated by a gradual 
but persistent decline in skeletal muscle mass and function, termed sarcopenia.3 
Undoubtedly, the study of this age-related decline is vital to ensuring the health 
and happiness of our aging population. 
Macroautophagy (herein referred to as autophagy) is a catabolic intracellular 
recycling process by which long-lived proteins and organelles are degraded. In 
short, autophagy encompasses the recognition, sequestration, delivery, and 
degradation of cytosolic cargoes and is constitutively active in nearly all eukaryotic 
cells.4 Autophagy is a predominately cytoprotective process that enables the 
adaption of individual cells or organs to changing conditions.5 Reduced autophagy 
has long been studied for its potential contribution to age-related dysfunction and 
disease.6 Indeed, the unifying theme in age-related autophagy studies is the 
maintenance of quality control mechanisms and their gradual loss with age7 
Considering this model, it is not hard to imagine that accumulation of damage over 
a relatively long period of time as quality control functions wane results in age-
related dysfunction. The mechanism by which autophagy flux decreases with age 
is unclear, but given its complex regulation and the prolonged, stochastic process 
of aging, it is likely complicated and heterogeneous. 
A major challenge in characterizing the contribution of decreased autophagy 
flux to aging-related pathologies is the heterogeneous nature of higher-order 
biological models of aging. In vitro cellular studies of autophagy have exponentially 
increased our current understanding of autophagy progression and regulation, but 
the complexity of higher-order biological models such as mice and humans 
confound analyses of autophagy flux via currently available methods8. Often, 





diverse cell types coexist and work together to maintain tissue health.9-11 Due to 
the diverse function of each cell type present in a given tissue, autophagy 
regulation and flux may differ in each cell type, thus bulk analyses of tissue may 
obscure the unique regulation of autophagy in each type. Similarly, individual cell 
analysis can confound the intricate inter-organelle type associations occurring 
inside individual cells.12 Cells contain many autophagy-related organelles at any 
time, and co-detection of all autophagy-related organelles in a single cell can lead 
to ambiguous interpretations of autophagy organelle trafficking and function. 
Better methods for the simultaneous characterization of heterogeneous cell 
or organelle populations and their unique autophagic function are required for a 
conclusive understanding of the contribution of decreased autophagy flux to age-
related dysfunction and disease in complex tissues. This thesis describes new 
methods for quantifying autophagy flux in heterogeneous whole cell populations 
and the detection of heterogeneous individual autophagy-related organelles 
isolated from specific tissues. 
Chapter 2 describes background information related to individual cell and 
organelle analysis and introduces the techniques used in this work. The current 
understanding of autophagy and its dysfunction in aged skeletal muscle is also 
discussed.  
Chapter 3 describes the development of a method for the relative 
quantification of autophagy flux in whole cells via mass cytometry. Post-hoc 
correction of individual cell data for non-specific antibody probe binding and 
normalization for total antibody probe loading into each cell resulted in accurate 
per cell antibody counts. Titration of antibody probes using this method identified 
optimal antibody staining concentrations for subsequent experiments. 
Differentiating myoblasts were analysed using the optimized antibody staining 
concentrations identified for the analysis of autophagy flux. We found that 
autophagy flux is increased specifically during myoblast fusion and quickly 
decreases in fully formed myotubes, but specific degradation of mitochondria is 





Chapter 4 describes the quantification of autophagy flux in the heterogeneous 
interstitial cell populations in young and aged skeletal muscle. The method allows 
for the analysis of individual cell subsets of interest including tissue resident stem 
cells (satellite cells), pro- and anti-inflammatory macrophages, and fibroadipogenic 
progenitor cells which were recently shown to have myogenic potential. The 
method revealed decreased autophagy flux in both satellite cells and 
fibroadipogenic progenitor cells with age, but not anti-inflammatory macrophages, 
providing a more detailed view of the contribution of decreased autophagy flux to 
decreased muscle mass and function observed with age. 
Chapter 5 describes a method to measure the heterogeneity of individual 
autophagy-related organelles from murine skeletal muscle, liver, and brain using 
mass cytometry. This method was used to identify unique organelle types involved 
in autophagy and profile their intra-organelle type heterogeneity and inter-
population associations. This method allows for the analysis of associations 
between organelles, providing insight into the progression of autophagy in each of 
the analysed tissues.  
Chapter 6 summarizes the conclusions and significance of this work. 
Specifically, we have developed methods to monitor the heterogeneity of 
autophagy progression at the whole cell and individual organelle levels. These 
methods may be valuable in the elucidation of the contribution of autophagy to 
decreased muscle mass and function with age.  
Chapter 7 describes possible improvements to currently available mass 
cytometry reagents described in Chapter 2, as well as the development of novel 
reagents for the detection of unique organelles. Individual organelles contain 
relatively few targets for antibody probe binding, thus the synthesis of a metal-
chelating dendrimer which could increase technique sensitivity nearly ten-fold is 
discussed in Chapter 7. Not all organelles of interest are easily identified using 
commercially available antibodies, thus Chapter 7 also describes the development 
of aptamers for the identification of unique autophagy-related organelles. and 





known that cellular protein abundance does not necessarily report on activity. 
Chapter 7 also discusses application of activity-based probes for the detection of 
enzyme activity via mass cytometry. 
Overall, the work described in this thesis represents a contribution of new 
methods for studying the heterogeneity of autophagy in whole cells and individual 
organelles via mass cytometry, which will advance the fundamental understanding 
of decreased autophagic flux in age-related declines in skeletal muscle mass and 
function. Elucidation of the role of decreased autophagy flux may contribute to the 





















 Potential impact of single-cell or single-organelle analysis 
Robert Hooke first observed heterogeneous cell types in plants and animals 
in 1665. For the last three and a half centuries, scientists have tried to catalog and 
understand the diverse functions of different cell types. How does cellular diversity 
arise? How do separate cell types in a single tissue work together? The 
advancements have been vast, but these same questions captivate us even now.  
The advent of single-cell analyses techniques at the genomic, transcriptomic, 
and proteomic levels represent a turning point in cell biology research. The 
observation and analysis of single cells in the fields of genomics, metabolomics, 
and transcriptomics have revealed that multiple cell types or functionally distinct 
subpopulations often coexist in biological systems. These variations at the single 
cell level are thought to be biologically meaningful, producing varying outcomes at 
the organism level. Similarly, heterogeneity exists at the sub-cellular organelle 
level.13 Organelles are adaptive to intrinsic and extrinsic stresses and subject to 
dysfunction with damage; therefore, organelle heterogeneity exists in regard to 
differences at the spatial, temporal, and functional levels.12 
Before single cell or organelle analyses were methodologically possible, 
population-level analyses were used for decades, contributing to monumental 
advances in human health such as the discovery of penicillin,14 statins,15 and the 
function of mitochondria as energy centers of cells.16 Population-level 
measurements capture population state and the associated change with 
perturbation. When making population-level measurements, it is assumed that the 
measured average state represents the dominant biological affect in single cells. 
In reality a population averaged measurement may not represent the true state of 
any single cell or organelle, confounding our understanding of complex biological 
systems. Simpson’s paradox describes the phenomena whereby the relationship 
between a pair of variables reverses when considering a third variable.17 
Partitioning data based on the third variable results in sign reversal of the observed 





by a distinguishing variable can lead to qualitatively incorrect interpretation of 










Figure 2.1. Single cell measurements preserve information lost via population-level analyses. 
Simpson’s paradox describes the misleading effect of averaging population-level data (a), when failing to 
consider other distinguishing variables (b).  
 
Single cell or organelle analyses are methodologically challenging given the 
high sensitivity necessary to detect material in a single bio-particle, the high 
throughput necessary to assess heterogeneity, and the desire for multiplexed 
single bio-particle analysis to probe complex interactions. Techniques for single 
cell analysis continue to emerge with notable contributions in the fields of 
microfluidic devices, capillary electrophoresis, and cytometry. Microfluidic 
analyses of single cell and organelle proteomes have been realized through cell 
arrays18-20and single cell barcode chips.21-26 Capillary electrophoresis with laser-
induced fluorescence has been employed for assessing the heterogeneity of 
organelle electrophoretic mobility and function.27-33 Multi-parameter fluorescence 
flow cytometry is perhaps the most well-known technique for multiple target 
detection and analysis in single cells.34 Developments of this technology have 
allowed for simultaneous analysis of up to 18 parameters,35 though more common 
analyses include far fewer parameters to eliminate the need for complicated 
deconvolution of fluorescence signals, which is inherent due to the similarity of 






















 Mass cytometry for multiplexed individual bio-particle analysis 
A related technique to fluorescence flow cytometry is mass cytometry. This 
technique uses inductively coupled plasma-mass spectrometry (ICP-MS) to detect 
and quantify lanthanide ions that report on the abundance of cellular targets in 
single cells. Due to the low abundance of lanthanides in biological particles such 
as cells and organelles, and the phenomenal sensitivity of ICP-MS for elemental 
analysis, mass cytometry has adequate sensitivity to measure a small number of 
proteins per cell. The mass resolution of time-of-flight mass spectrometry makes 
this technique adequate to detect a high number of pure isotopic elements 
(upwards of 50), surpassing the number of possible parameters detected by flow 
cytometry. Mass cytometry is similar to flow cytometry in that antibodies are used 
as specific target affinity reagents labeled with reporters, but whereas conventional 
flow cytometry uses fluorescent reporters, mass cytometry uses polymers 
chelating isotopically pure lanthanide ions.  
A unique feature of mass cytometry is the use of an ICP that fully ionizes all 
components in a sample, which then allows for detection of a wide range of lanthanide 
ions from the antibodies used to labeling cellular targets in single cells. Before the 
introduction of mass cytometry, ICP-MS had been used to detect metal tagged antibodies 
specific to cellular markers in cell lysates, but these findings could not be related back to 
specific cell types in a heterogeneous cell population.36 Other relevant prior work includes 
the ICP-MS analysis of single cells from suspensions that had been labeled with 
lanthanides and analyzed using conventional instrumentation.37-42 The work in single cells, 
led to the advancement of elemental analysis of individual, antibody-labeled cells, 
establishing mass cytometry as a new technique.43 The report of successfully using an 
ICP-MS for individual cell analysis was revolutionary in that it provided high resolution and 
unprecedented multiplexing capabilities necessary for thorough analysis of complex 
biological systems. The first commercialized CyTOF (Cytometry by Time Of Flight) 
instrument was available in 2009, and featured an analytical m/z range of 103-193, 
maximum throughput of ~1,000 events/second and had a dynamic range covering 4 
orders of magnitude. Subsequent models named CyTOF2 (second generation 
instrumentation) and Helios (third generation) further improved these and other 





of 50), peak sample introduction rates (2,000 cells per second), improved dynamic ranges 
(4.5 orders of magnitude). These figures of merit far surpass the abilities of currently 
available flow cytometers. Every method described in this work harness the multiplexed 
capabilities and wide dynamic range of the CyTOF2 instrument to profile cellular target 
abundance.  
2.2.1 Instrument description 
Mass cytometers contain three modules including: sample introduction microfluidics, 
ion optics, and a time-of-flight (TOF) mass spectrometer. The sample introduction system 
includes a port through which cells are flowed into the instrument followed by a series of 
specialized glassware to encapsulate cells in individual liquid droplets from which cells are 
vaporized, atomized and ionized (Figure 2.2, box 2). The ion optics system selects all ions 
of interest and guides them towards the mass spectrometer (Figure 2.2, box 2). The third 
module is a TOF mass spectrometer, used to identify and quantify the abundance of each 
ion of interest (Figure 2.2, box 3). These modules and their function are described in detail 
below. 
Sample Introduction and Ionization (Figure 2.2, box 1) 
The introduction of cell samples into the mass cytometer has evolved with each new 
version of CyTOF instrumentation. Introduction of cell samples into the first or second-
generation mass cytometer is accomplished using a syringe pump and one or two-sample 
loop microfluidic system. Via a syringe, an aliquot of the cell suspension is manually 
pushed into a sample loop. Then, a flow injection valve rotates so that flow from a syringe 
pump displaces the loop contents to deliver them to the nebulizer via a sample introduction 
capillary. The newest generation of mass cytometer, Helios, has a pneumatic sample 
introduction system that uses argon gas to force cell suspensions into the sample uptake 
probe and onward to the nebulizer. 
As cells from the cell suspension are introduced into the nebulizer via the sample 
introduction capillary, a fine spray of droplets containing individual cells is produced by the 
pressure exerted on the suspension from the argon gas exiting the tip of the concentric 
nebulizer (Figure 2.2, box 1). This aerosol is directly injected into a heated spray chamber 
(~200˚C) supplied with argon makeup gas where the cell-containing droplets are partially 
desolvated.43 The partially-desolvated droplets then travel through an ICP torch producing 





ionized.43-44 For each cell being ionized, the process results in a cloud of ions with a 
diameter of ~ 2 mm. The expansion of the ion cloud for each cell is diffusion-limited, 
meaning these clouds are roughly the same size, no matter the size of the cell 
introduced.44 Thus, the analysis of single cells in samples with cells of multiple sizes is not 




Figure 2.2. General overview of CyTOF hardware. After samples are introduced to the instrument, they are 
aerosolized via the nebulizer, desolvated in the spray chamber, and sequentially vaporized, atomized, and 
ionized as they exit the ICP torch (box 1). The resulting ion cloud is filtered, focused, and guided toward the 
detector via the RF quadrupole shown in box 2. Separation and detection of relevant metal ions takes place 










This allows for the technique to be truly quantitative as the number of metal ions 
detected is directly related to the number of ions introduced.44 However, despite the 
chemical similarity of the lanthanide series of metals, ion transmission through the 
instrument is not identical for each isotope. In fact, the transmission efficiency profile 
across the relevant mass range is unique to each mass cytometer. As has been 
reported,45-46 we observe an asymmetrical bell curve shape centered around the middle 
of the mass range. We also observe a nearly 3-fold change in transmission efficiency 
across the mass range for the CyTOF 2 at the University of Minnesota (Figure 2.3). Post-
hoc correction for variation in transmission efficiency for quantitative comparisons 
between mass channels is described in Chapters 3 through 5 of this work. 
Figure 2.3. Transmission Efficiency on CyTOF2 at the University of Minnesota. We observe an 
asymmetrical bell-shaped curve centered over the middle of the mass range for CyTOF2. We also observe a 
nearly 3-fold change in transmission efficiency across the mass range which has implications for the mass 
channel comparisons made in Chapters 3 through 5.  
 
Ion Optics (Figure 2.2, box 2) 
Ions produced at the ICP torch are sampled through a three-cone interface, 
which serves as a low-pressure, controlled entrance into the low vacuum ion optics 






































and focusing the ion cloud. A quadrupole ion deflector then filters out neutral atoms 
that will interfere with downstream analysis. Positively charged ions are directed 
perpendicularly out of the ion deflector toward downstream ion optics for eventual 
mass analysis, while neutral atoms follow an uninterrupted path toward a 
turbomolecular pump. Another quadrupole (RF QUAD in Figure 2.2, box 2) serves 
to filter out low mass ions (H+, C+, O+, N+, OH+, CO+, O2+, Ar+, ArH+, ArO+) that 
predominate in the ion cloud after ionization. Thus, ions leave the quadrupole in 
packets with a specific mass range, each packet corresponding to an ion cloud, 
which in turn corresponds to an individual cell. The filtered ion packets leaving the 
RF QUAD then pass through a DC quadrupole doublet (DC DOUBLET in Figure 
2.2, box 2) which flattens the ion stream to allow for injection into the TOF mass 
spectrometer.  
 
Time of Flight Mass Spectrometer (Figure 2.2, box 3) 
Ion packets are introduced through a vacuum interface (SLIT in Figure 2.2, box 3) 
to an accelerator where ions experience sequential voltage pulses at a frequency of 76.8 
kHz. The result is a portion of ions from each packet are sampled (pushed) into the TOF 
mass spectrometer every 13 µs, accelerated by the pulsed electric field which impinges a 
constant kinetic energy regardless of the ion mass to charge ratio (m/z). In total, the ion 
packet from each cell is sampled 20 – 75 times. 
The kinetic energy acquired by all ions through acceleration translates into a unique 
time of flight (t) corresponding to each m/z from the accelerator plate, via the reflector, to 
the detector. Using two empirically derived constants, t0 and A, the relationship between 
(t) and (m/z) is  
t	=	t0+A"mz                                           Equation 2.1 
As deduced from equation 1, the ions with smallest m/z value reach the 
detector first. Ions will continue to arrive according to increasing m/z order. 
Typically, isotopes with masses differing by 1 amu have ions arriving at the 





detector has a resolution better than 1 amu, which is sufficient to detect the various 
lanthanide isotopes used to labels antibodies.  
2.2.2 Signal integration 
A dynode electron multiplier detects ions as they arrive at the end of the TOF 
mass spectrometer drift tube. Depending on the number of ions with a given m/z 
reaching the detector during the 13 µs duration of a packet of ions, the detector 
operates in a pulse counting mode (for low number of ions) or an integration mode 
(for high number of ions). When the ion density approaching the detector 
increases, particles will simultaneously arrive resulting in an underestimate of 
counts. Thus, integration of the analog signal is a more useful quantification 
method in this case. The relevant concentration range at which CyTOF operates 
requires that dual data be collected, meaning both counting and integration modes 
are applied to each m/z value of interest (channel). A user-defined threshold 
defines when integrated intensity and pulse counting are selected for processing 
the signal. When the integrated intensity is used, outputs are converted to ion 
counts using the equation below, where the Dual Count Coefficient is a constant 
determined experimentally for each mass channel. 
 
Count = (Dual Count Coefficient) × Intensity                Equation 2.2 
 
Individual mass spectra containing counts for each m/z value (channel) are 
written into integrated mass data files (*.imd). To obtain meaningful data, the 
instrument user must set criteria to identify signals (events) corresponding to 
single cells. These criteria are minimal signal intensity and duration of the event, 
typically 20-50 spectra. Signals for each m/z value (channel) are integrated 
across all mass spectra collected for individual events (20-50 spectra / event) 
and written into text (*.txt) and/or flow cytometry standard (*.fcs) files which 
include metadata such as instrument conditions and channel annotations.44 
Events with an abnormally long, bi-modal signal correspond to overlapping 





events can be visualized during data acquisition in the form of a rain plot 
consisting of stacked mass spectra shown in Figure 2.4. Visualization of 
individual organelles on rain plots in Chapter 5 provided evidence of particle 
detection.  
Figure 2.4. Representative rain plot from CyTOF2. Consecutive mass spectra showing integrated signal 
for a single detected event. Each “push” is recorded as a separate mass spectrum. The y-axis identifies the 
spectra (in sequence) over which detected organelle event signals are integrated. The x-axis shows the 
relevant m/z channels. Dark lines in the plot area indicate detected ions. 
2.2.3 Data normalization 
The most common instrument data output is the *.fcs file type, which has standard 
content guidelines.47 Commonly, mass cytometry *.fcs files are normalized to correct for 
instrument response drift. Factors that contribute to response drift include: i) build-up of 
cellular debris and subsequent decrease in detection sensitivity, which is relevant after 
multiple hours of data collection,48 and ii) differences due to cleaning and daily 
calibration.49 
Correction for drifting is based on normalization of signal intensities relative to those 
of dedicated isotopes embedded in polystyrene beads.49 When detected in the mass 
cytometer, bead events are uniquely identifiable by the combination of isotopes present 
(140Ce, 142Ce 151Eu, 153Eu,165Ho, 175Lu, 176Lu). Because drift equally affects the signals from 
lanthanide ions originating from polystyrene beads and those attributed to other labeling 
reagents, the lanthanide ion signal from beads is used to define normalization factors for 
all other lanthanide ions in cell samples. 
Two approaches are available for signal intensity normalization. The first approach 
normalizes data to a global standard determined for each lot of lanthanide isotope 


















embedded polystyrene beads provided by the manufacturer, allowing for inter-and intra-
experiment normalization, including normalization across instruments. Specifically, it is an 
algorithm embedded within the mass cytometer operating software (version 6.0.626 and 
above). This data normalization algorithm was used in Chapters 3 through 5 to normalize 
mass cytometry data collected over long periods of time. The correction factor is defined 
as the ratio of the predetermined signal value (provided by the manufacturer) and the 
measured median value for each mass included in the bead standards. The algorithm 
linearly interpolates between measured mass channel intensities to apply the 
normalization factors to detected experimental mass channels. The second method 
normalizes data using the same lanthanide isotope embedded polystyrene beads, but 
median intensity values are normalized within a given experimental file instead of 
normalization to a predetermined standard. In this method, a moving median for the signal 
of each isotope mass included in the beads is calculated as a function of time to determine 
a “fitted slope value”, as shown in Figure 2.5. This “fitted slope value” is used as a 





























Figure 2.5. Normalization of mass cytometry data via calibration beads. The median signal intensity 
measured from calibration beads can be used to normalize data that would otherwise vary due to instrumental 
differences at the time of data acquisition. (a) Raw intensities from beads collected on four different days were 
plotted vs acquisition time. (b) Smoothed data results from the calculation of a moving median of each bead 
channel across 500 beads. Visible declines in intensity over acquisition time are apparent in each bead 
channel. (c) Normalization involves multiplying individual raw bead intensities by a correction factor, resulting 
in corrected intensities for all analyzed events. Figure reprinted with permission from Finck et al.48 
2.2.4 Available reagents 
A number of cell labeling reagents exist to identify specific cellular targets 
during mass cytometry analysis. Most often, antibodies covalently bound to metal 
chelating polymers (MCPs) are used to detect cellular targets of interest. In 
addition, cell identifying reagents are often used to label double-stranded nucleic 
acids or cellular debris. MCPs, described in detail below, are commonly used in 








Whole cell analyses in Chapters 3 and 4 also employed the metallointercalators 
and live/dead stains described below. 
 
Metal Chelating Polymers  
For the purpose of mass cytometry MCPs are loaded with a pure lanthanide 
isotope and conjugated to an antibody. The same MCP molecule can be used for 
labeling all antibodies, but each unique antibody clone is assigned a unique 
lanthanide isotope. Great similarity in chemical properties of the lanthanide series 
of metals makes it possible to use a wide range of isotopes with the same MCP 
chemistry. Furthermore, lanthanides have low natural abundance and are 
commercially availability as purified isotopes.50-52 Loading capacity (lanthanide 
ion/polymer chain) of each MCP is dictated by the molecular structure of MCPs. In 
general, the structure of MCPs includes three linked scaffolds with separate 
functions (Figure 2.6) including a polymer backbone, metal chelating ligand, and a 
linker.  
Figure 2.6. General structure of metal chelating polymer (MCP) for labeling antibodies. MCPs contain 
three main components. These include: i) a polymer backbone (“polymer backbone”), ii) metal chelating 
ligands (“ligand”), and iii) a linking moiety (“linker”) that connects the polymer backbone to an antibody 
(“antibody”). Metal chelating ligands, usually DTPA or DOTA, are covalently attached to the polymer backbone 
at periodic intervals. The polymer is connected to the antibody through a maleimide linkage that reacts with 
free sulfhydryl moieties in a partially reduced antibody. Together with the number of lanthanide ions (“Ln”) 
associated with each polymer, the number of polymers attached to each antibody determines the overall 










The most common metal chelating ligands are multidentate 
polyaminocarboxylates, such as diethylenetriaminepentaacetic acid (DTPA) and 
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), because they 
coordinate lanthanide ions with low dissociation constants.53 The most commonly 
used linker relies on the reaction of maleimide with sulfhydryl groups produced by 
reducing disulfide bonds within the Fc portion of an antibody. Although chemistries 
that would covalently bind the polymer to lysine residues in the antibody are also 
feasible, there exists a general concern that random lysine modifications could 
result in a loss of antibody specificity. 
Because sensitivity of mass cytometry and other ICP-MS techniques is 
expected to increase linearly with lanthanide content, developments in MCPs have 
attempted to chelate more lanthanide ions per polymer. The first report by Lou and 
coworkers described 33 DOTA ligands per polymer chain,50 representing the 
maximum number of lanthanide ions loaded onto a polymer. Later MCPs described 
by Majonis and coworkers were able to attach 68 ± 7 lanthanide-chelating ligands 
per polymer. They also determined that on average a conjugated antibody 
displayed, 2.4 ± 0.3 polymers, giving a total of 161 ± 4 lanthanide ions per 
antibody.51 To increase the utility of lanthanide-chelating polymer conjugated 
antibodies, dual-labeled antibodies have been reported,54-56 which contain both 
fluorophore and lanthanides as reporters to facilitate cross-platform validation of 
antibody localization or cell-subpopulation enrichment prior to mass cytometry 
analysis. 
Metallointercalators 
The ability to identify signals originating from intact cells is critical for accurate 
analysis of single cell suspensions. Ornatsky and coworkers describe the use of 
the well characterized polypyridyl metal complexes (metallointercalators) for this 
purpose.42 These reagents can help identify single cells among cellular debris, 
identify cell cycle phases, and normalize signal intensities across cell populations. 
Similar to the MCPs above, metallointercalators usually contain a transition metal, 





measurement of DNA content. In original reports, three ligands of the 
metallointercalator bind to the transition metal57-59 (Figure 2.7). 
 
Figure 2.7 DNA metallointercalator. 
usually contain three ligands bound to 
a transition element. Insertion of a 
planar aromatic ligand between 
double stranded DNA base-pairs 
have strong associated electrostatic 
interactions resulting in low 
dissociation constants a stable 
interaction monitored via mass 
cytometry. Reprinted with permission 
from Pyle60 and Schäfer57. 
 
The strong interactions between DNA and the metallointercalator are 
dominated by electrostatic forces and insertion of planar aromatic ligand between 
nucleotide base pairs.59 This interaction has a low dissociation constant (Kd < 10-8 
M), which allows for use of metallointercalators for accurate determination of DNA 
content within a cell. 
For proper use in mass cytometric analysis, the signal of a metallointercalator 
must increase linearly with its incubation concentration and not be affected by the 
presence of other labeling reagents. For instance, increasing incubation 
concentrations of iridium intercalator in cells resulted in a linear increase in 
measured signal (Figure 2.8). Importantly, signal originating from metal-labeled 
antibodies was not affected by increasing concentrations of iridium intercalator.42 
This behavior is also observed in commercially available metallointercalators used 
in mass cytometry experiments to identify nucleated cells.  
 
Figure 2.8. Expected DNA metallointercalator 
response. An essential characteristic of DNA intercalators 
is that they not interfere with the labeling of other cellular 
targets with antibodies. Ornatsky and coworkers showed 
that even with increasing concentrations of DNA 
intercalator (DNA-Ir), the measured signal from antibodies 
incubated at constant concentrations is unchanging. 
CD34-Tm, CD33-PR, CD45-Tb HLA-DR-Sm, are all metal 
labeled antibodies specific to surface proteins on immune 






Metallointercalator content is often used to trigger mass spectra integration 
thereby collecting detected events, and to and identify cells. To trigger mass 
spectra integration the distribution of the ion reporters (e.g. 191Ir and 193Ir) must be 
Gaussian over the spectra which define the event, and the full width at half max 
(FWHM) must be at least 200 µs. To identify a collected event as an intact cell, the 
number of integrated mass spectra and metallointercalator content are compared 
and must meet expected thresholds.42 Following mass spectra integration, 
collected single cell events are examined for abundance of other molecular 
markers reported by their respective antibody-MCP conjugates.  
 
Live/Dead Stains 
High throughput single cell analyses require identification and exclusion of 
non-viable cells in subsequent data analysis. In fluorescence flow cytometry, such 
cells can be identified by the accumulation of fluorescent dyes that do not cross 
intact plasma membranes. In mass cytometry, the chemotherapy drug cisplatin 
acts as a live-cell impermeable stain, which enters cells with compromised plasma 
membranes more quickly than cells with intact plasma membranes.61 Once inside 
the cells, it reacts with protein nucleophiles such as R-SH or R-S-CH362-63 to form 
covalent Pt-S bonds. This covalent modification is stable through subsequent 
fixation, permeabilization and antibody staining procedures, making it an ideal 
viability dye for mass cytometry. The accumulation of cisplatin in non-viable cells 
is observed as a signal in the 195Pt channel with overall intensity dependent on 
cisplatin incubation concentration and duration. The optimal concentration of 
cisplatin should provide a consistent distribution of viable/non-viable cells as 





Figure 2.9. Determination of cell viability 
via cisplatin content. Three incubation 
concentrations were titrated in both 
suspended (Jurkat) and adherent (HeLa) cell 
lines. A known percentage (determined via 
Trypan blue exclusion) of heat killed cells of 
the same type were added to viable 
suspensions of each cell line to assess the 
accuracy of each incubation concentration. 
They conclude that the dead cell population 
identified using the middle concentration of 
cisplatin (50 µM) correlates well with their 
trypan blue exclusion assay results. 
Reprinted with permission from Fienberg.61 
 
2.2.5 Data Analysis Strategies 
After normalization (see section 2.2.4), data are gated to select single-cell events 
and eliminate non-viable cells (see section 2.2.5) and then processed using algorithms 
such as those described below. 
Dimensionality Reduction (Highlighting: PCA & viSNE) 
While the highly-dimensional data produced via mass cytometry can be highly 
informative, visualization of the data in a manageable number of dimensions is critical to 
successful inference of biological meaning. The challenge of dimensionality reduction is 
accomplished through the projection of multi-dimensional data in 2D or 3D space using 
surrogate dimensions, while maintaining relationships. Approaches to dimensionality 
reduction can be grouped into two separate categories: linear and non-linear, with 
principle component analysis (PCA) and stochastic neighbor embedding (SNE) being an 
example of each applied to mass cytometry data. In Chapter 5, inter-organelle type 
heterogeneity was visualized using a variation of SNE.  
Linear dimensionality reduction as implemented via PCA condenses multi-
dimensional data into two or three principle components that can reproduce the major 
sources of variance. Data can be plotted against these principle component axes, with 
separation of single-cell populations along a given axis indicating large variance in a 
specific principle component. While PCA has been applied to mass cytometry64 data, a 
limitation of PCA is its inability to distinguish between geodesic and Euclidean space when 
analyzing biological data which has many non-linear relationships.  
Non-linear dimensionality reduction overcomes the limitations of its linear 





two or three dimensions. For mass cytometry, a variation of SNE called t-SNE is commonly 
used, in the form of viSNE. The viSNE algorithm represents data in as a highly dimensional 
point cloud where the number of dimensions (n), is defined by the number of measured 
parameters. Within viSNE, an optimization algorithm finds a projection of the points from 
highly-dimensional space into two, or three-dimensional space so that pair-wise distances 
between points are conserved, effectively conserving both the local and global geometry 
of the entire cloud.65 The resulting plot looks similar to a biaxial dot plot, but the positions 


























Figure 2.10. viSNE algorithm. (A) viSNE projects multi-dimensional data into two dimensions with high fidelity 
of spatial arrangement. This is confirmed by identification of cell subpopulations that are similar to one another 
by both manual gating and viSNE analysis (B, colored and gray clouds, respectively). (C) Signal intensity of 
cell populations is added back to viSNE maps for a given marker. Single cell resolution is retained, so that 
each dot in a viSNE map is representative of a single cell event. Modified and reprinted with permission from 
Amir.66 
 
The algorithm is sensitive to small subsets of cells and takes into account pairwise 
comparisons between all cells included in the analysis, giving confidence to cell 
positioning within the viSNE map. There are some inherent limitations to this algorithm, 
such as the domination of the viSNE map by highly abundant or intense structures, making 
small features difficult to resolve without prior sub-setting, and ii) the computational 
demand which limits the number of cells that can be mapped. However, its single cell 







of small subpopulations of phenotypically aberrant cells that have a “different - from - 


















Figure 2.11. viSNE can be used to detect “different – from – normal phenotypes”. Amir and coworkers 
show the ability of viSNE to detect these small subpopulations of cells by creating a “synthetic” sample with 
barcoded cells of a specific phenotype spiked into a sample with a different phenotypic profile at a 
concentration of 0.25%. They blind the viSNE algorithm to the channel indicating the phenotypic group of each 
cell, but the algorithm is still able to correctly identify the subpopulation of spiked cells that are different vs the 
control (A, arrow). When the analysis is repeated to include the barcoding channel indicating the phenotype 
(different or control), the algorithm shows that the subpopulation indicated in A is made from the “different” 
sample only. Modified and reprinted with permission from Amir.66 
 
Clustering (Highlighting: SPADE & X-shift) 
The existence of many phenotypically distinct cell types in a biological system, 
despite containing identical genomes, highlights the usefulness of high-dimensional 
single-cell analysis. Mass cytometry lends itself to studying these heterogeneous cell 
populations because of its unique ability to monitor many parameters per cell across 
thousands of cells. Clustering algorithms work to group cells that are similar to one another 
making the visualization and biological analysis of the resulting data more manageable. 
Similar to some dimensionality reduction algorithms, the first step in most clustering 
algorithms is to project the single cell data into an n dimensional point cloud. Where the 
mechanism of these algorithms tends to diverge is in the method of identifying and 
clustering cells that are similar to one another. Approaches have included agglomerative 
and k-nearest neighbor based clustering, implemented by the SPADE (spanning-tree 
progression of density normalized events) and X-shift algorithms, respectively.  






SPADE was the first reported algorithm used to successfully partition separate cell 
subtypes based on a curated set of phenotypic cell targets in mass cytometry data.46, 67 
The algorithm was designed to preserve rare cell sub-populations through density 
dependent down-sampling, which works to provide more equal representation of highly 
abundant and rare cell sub-populations. Following down-sampling cells undergo 
hierarchical, agglomerative clustering, an iterative process in which individual cells are 
merged into phenotypically similar clusters until a user-specified number of clusters has 
formed. Clusters are connected to their most phenotypically similar clusters via a minimum 
total edge length, forming a minimum spanning tree to enable an approximate 2D 
visualization of the point cloud geometry (Figure 2.12). Two major limitations of the original 
SPADE algorithm are the agglomerative clustering method, and the stochastic process of 
density-dependent down-sampling. The use of an agglomerative approach inherently 
reduces the resolution of single-cell data impeding down-stream high-resolution analysis 
of individual cells. The stochastic down-sampling process used to preserve rare cell sub-
populations and increase computational efficiency often provides inconsistent SPADE 

























Figure 2.12. Analysis of multi-dimensional cytometry data using the SPADE algorithm. Cytometry data 
is visualized on a biaxial dot plot (i), and down-sampled to normalize event density (ii). Agglomerative 
clustering defines sub-populations of cells with similar staining across all channels (iii). These clusters are 
visualized in a minimum-spanning tree (iv), where each node is a single cluster whose size is representative 
of the number of cells included. The data is then up-sampled and colored to represent the intensity of a given 






Many algorithms have been developed in recent years, some of which have 
overcome these issues. When comparing clustering algorithm performance, researchers 
can use a parameter called an F-measure statistic, which can compare the ability of 
clustering algorithms to reproduce clusters that match expertly gated cytometry data.68 A 
recently reported clustering algorithm, X-shift,69 produced the highest F-measure statistic 
(16.59) when tested against a number of algorithms including SPADE (14.86) and 
Phenograph70 (14.63), indicating it was capable of the most precise and accurate 
clustering. The X-shift algorithm clusters similar cells through searching for density 
maxima in k-nearest neighbor classified data, which become cluster centroids. Cells not 
originally captured in these clusters are assigned to existing or new clusters via an 
ascending or descending density estimation. Clusters are then tested for density 
separation, and where deemed appropriate, merged. This algorithm was demonstrated on 
phenotypically labeled samples of bone-marrow where X-shift was able not only 
phenotypically identify canonical hematopoietic cell sub-populations, but also identified 
previously undescribed populations that could aid in the further understanding of the 
hematopoietic lineage and its development.69 While clustering algorithms have improved 
the preservation of rare subsets since the original report of SPADE,67 this work will focus 
on the use of SNE dimensionality reduction algorithms to preserve single cell or organelle 
resolution. 
 
Trajectory Progression (Highlighting: Wanderlust) 
Most complex organisms have a continuum of transitional cell subsets from 
progenitor to mature cell populations. A number of algorithms have been designed to align 
single cells to an approximated trajectory describing their most likely developmental path 
de novo.71-73 Using the ergodic hypothesis that a snapshot of a cell ensemble can inform 
the behavior of an individuals over time, these algorithms accurately infer a temporal 
relationship between cells that would otherwise be hidden in conventional multi-parametric 






Figure 2.13. Pseudotime projection of cells to predict 
developmental trajectory progression. Cells of vastly 
different developmental stages can be close to one 
another in Euclidean space, masking the non-linearity in 
their pathway to maturity. The points X and Y in the 
developmental pathway are developmentally distant, but 
spatially close. The wanderlust algorithm has been shown 
to correctly identify the developmental pathway of a 





The first implementation was called Wanderlust, which calculates a trajectory score 
for each cell, identifying its location across a developmental path based on distance from 
a user-identified “early” cell. Initially, a random set of cells are chosen as waypoint cells 
whose use as “intermediates” help to refine the position of neighboring cells. After 
waypoint cells are chosen, the data are transformed into an ensemble of randomly 
generated graphs, where each cell is represented as a node, and is connected to its k 
nearest neighbors (cells most similar to it) via edges whose weight are based on the 
similarity of the two cells. The goal is to minimize the path length between similar cells, so 
that the developmental order of cells can be determined. The two steps of this algorithm, 
i) initiation and ii) trajectory calculation, are performed iteratively until the location of each 
individual cell converge. The position of each cell in the ensemble of graphs is then 
averaged to provide a temporal output map (Figure 2.14).  
The algorithm has been used to predict the developmental path of hematopoietic 
stem cells to naïve B cells. In Chapter 3, the algorithm was used to predict the expression 
of myogenic transcription factors during myoblast differentiation. Further iterations of this 
type of predictive trajectory progression algorithm have included branching over the 





















Figure 2.14. Trajectory prediction by Wanderlust. The wanderlust algorithm plots cells in n dimensional 
space where n is the number of user defined, phenotypic parameters. The user defines a “Start” cell, and the 
algorithm randomly chooses “Waypoint” cells whose positions are used as reference points when calculating 
the minimum distances between all cells in k-nearest neighbor graphs. An ensemble of k graphs is assembled 
and the shortest path from every cell to the “Start” and “Waypoint” cells is iteratively calculated for each graph. 
These values are averaged to give the final trajectory. Trends by parameter can be visualized on the 
wanderlust axis, showing increasing or decreasing expression over developmental time. Reprinted with 
permission from Bendall.71  
 
 Autophagy in skeletal muscle 
The global population of individuals over 60 years is expanding in parallel 
with increased life expectancy and is set to double by 2050.1-2 However, 
preservation of human health is not always sustained with increased life 
expectancy. Of the 1.5 million individuals over the at of 65 admitted to long-term 
care facilities each year in the United States, 33% are institutionalized solely due 
to their inability to perform activities of daily living.3 Skeletal muscle provides the 
contractile force necessary for motion and is the largest metabolic organ in the 
human body. Loss of skeletal muscle mass and function, termed sarcopenia, 
significantly contributes to the frailty and decreased mobility of our aging 





mass, function and regeneration is an unmet, urgent topic for translational bio-
medical research to identify possible areas for intervention which might increase 
the healthspan of our aging population.  
The cause of the observed loss of total mass and decline in function and 
regeneration in skeletal muscle with age is unknown, but most likely results as a 
combination of many disrupted cellular mechanisms, including macroautophagy.74-
77 Macroautophagy (hereafter referred to as autophagy) is normally responsible for 
the recycling of unnecessary or damaged proteins and organelles, such as 
mitochondria. In response to stress (e.g. nutritional deficiency, organellar damage) 
the proteins responsible for this intracellular recycling process either increase or 
decrease in abundance to maintain cellular homeostasis. When autophagy does 
not respond to these stresses, proteins and organelles within cells incur damage, 
but fail to be cleared, from the cytosol, resulting in cellular dysfunction and death. 
In general, current research points to autophagy as a critical molecular pathway 
for understanding the decline in mass, functionality and regenerative potential in 
skeletal muscle, though it is unclear whether the rate of autophagy flux is increased 
or decreased.78-79 Chapters 3 and 4 describe methods for direct measurement of 
autophagy flux in several unique cell subsets across biological models of 
myogenesis and aging, respectively. 
A confounding factor in the analysis of autophagy in skeletal muscle is the 
presence of many cell types with diverse functions80-81 (Figure 2.15). Those which 
participate in muscle function, repair, and maintenance include: i) muscle fibers, ii) 
macrophages, iii) satellite cells, iv) fibro-adipogenic progenitors (FAPs), v) 
PW1+/Pax7- interstitial cells (PICs), and vi) vessel-associated stem cells. In 
Chapter 4, autophagy flux is quantified in satellite cells, macrophages and FAPs 





































Figure 2.15. Skeletal muscle tissue is a highly heterogeneous tissue. (a) Whole skeletal muscle tissue 
is made up of bundles of myofibers. Myofibers are long, cylindrical multi-nucleated cells responsible for 
generation of contractile force. (b) Each myofiber is supported by repair and regenerative cell types such as 
satellite cells (SC). (c) Cross sectional view of a myofiber bundle shows the sub-sarcolemmal position of 
satellite cells on myofibers. Macrophages mediate the inflammatory response in muscle repair and operate 
between in the interstitial space.  
 
Muscle fibers are long cylindrical multi-nucleated cells whose main function 
is to contract and relax, giving rise to gross motor function in mammals. Increases 
in intracellular recycling, without equal or greater increases in total protein 
synthesis in this cell type would result in a loss of individual muscle fiber mass, 
consistent with the observed decline of muscle mass in aged muscles. 
Macrophages, part of the human immune system, are required for efficient repair 
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of muscle tissue after injury82 indicating that decreased functionality mediated 
though decreased autophagy flux may be responsible for the reduced regenerative 
potential of aged muscle. Injured muscle also requires a set of regenerative stem-
like cells, termed satellite cells, for muscle tissue repair. These cells proliferate, 
differentiate and fuse to other differentiating cells, or pre-existing myofibers to 
restore functionality and mass after injury. Current studies have shown that the 
number of satellite cells is reduced in aged muscles, which may be due, in part, to 
decreased autophagy flux.83 Each of these cell types may show a different degree 
and direction of dysfunctional autophagy, complicating analysis of bulk tissue. 
Because bulk tissue analyses average responses across many cells, no detail on 
individual cell type regulation of autophagy can be gained. Chapter 4 describes the 
relative autophagy flux in young and geriatric satellite cells, macrophages, and 
FAP cells. The analysis overcomes the hurdle of confounding results from bulk 
analyses and grows our knowledge of the contribution of autophagy flux from other 
cell types involved in skeletal muscle maintenance.  
2.3.1 Function and Regulation of Autophagy 
 Autophagy was first observed in 1963 by Christian de Duve, who observed 
how cells broke down their sub-cellular contents inside a specific vacuole he called 
a lysosome. The original discovery of autophagy-related proteins (ATGs) that were 
essential for cargo delivery to hydrolytic vacuoles in yeast occurred more 30 years 
ago via genetic screens. Since these initial observations, the field has exploded 
and the fundamental importance of autophagy to living cells has been observed. 
Autophagy is an intracellular degradative process that clears long-lived or 
damaged proteins and organelles from the cellular milieu through a set of unique 
sub-cellular organelles (Figure 2.16). Sequestration of cargoes marked for 
degradation by phagophore membranes produce mature autophagosomes. These 
double-walled organelles fuse with lysosomes containing hydrolyases which work 
to degrade autophagosome cargo in the autolysosome. Flux through this pathway 
is increased in times of cellular stress to break down existing, but damaged or 





nucleic or amino acids. Thus, cells reduce accumulating waste and produce the 
building blocks necessary to respond to stress. 
 
 
Figure 2.16. Autophagy proceeds through a unique set of sub-cellular organelles. A double-walled 
phagophore membrane encapsulates long-lived proteins and/or organelles. Fully-formed autophagosomes 
fuse with lysosomes containing hydrolases to form an autolysosome. The hydrolases present in the 
autolysosome degrade its contents, producing nucleic and amino acid building blocks. 
 
The process is carried out though coordinated interaction of many ATGs as 
well as other proteins known to participate in cellular homeostasis. The regulation 
of the autophagy process can be broken down into four sequential sections: i) 
initiation and phagophore nucleation, ii) phagophore expansion, iii) cargo 
sequestration and membrane sealing, iv) autophagosome maturation and fusion 
with lysosomes. Because autophagy is constitutively active, these processes 
occur sequentially, but constantly within individual cells. Precise mechanisms 
driving autophagy flux can be monitored through concurrent measurement of the 
autophagy machinery. For example, the protein microtubule-associated protein 
1A/1B-light chain 3 (LC3) is ubiquitous in mammalian cells, though it exists in two 
isoforms, LC3-I and LC3-II. LC3-I is a cytosolic protein that is processed by various 
ATGs to produce the LC3-II isoform which is conjugated to 
phosphotidylethanolamine (Figure 2.17). The LC3-II isoform is recruited to 
autophagosomal membranes in support of membrane elongation and closure. 
Metal-labelled antibodies specific to LC3 (cytosolic or membrane bound) are used 
throughout this work to monitor autophagy flux. In Chapters 3 and 4, total LC3 
(including LC3-I and LC3-II is quantified in whole cells. Chapter 5 reports the 

















Figure 2.17. Mechanism of LC3 protein lipidation. LC3 protein is processed by ATG4 to reveal a C-terminus 
glycine (LC3-I). ATG7 activates LC3-I and subsequently transfers it to ATG3. The ATG12/5/16L1 complex 
facilitates the conjugation of LC3-I to phosphotidylethanolamine (LC3-II), which associates with the elongating 
phagophore.  
 
Modulation of autophagy flux using genetic or pharmacological manipulation 
induces functional changes that can be monitored to determine their role in 
autophagy flux. Modulating the expression or function of ATGs that participate in 
the initial stages of autophagy block the formation of mature autophagy-related 
organelles. For example, genetic ablation or of ATG5 required for LC3-II lipidation 
results in the absence processed LC3-II and formation of mature autophagosomes 
(Figure 2.18). Genetic ablation of ATG7 is used in Chapter 3 to confirm accurate 
quantification of autophagy flux via mass cytometry in myoblasts. 
 
 
Figure 2.18. Effect of ATG5 ablation on autophagy 
flux. Genetic manipulation of ATGs participating in 
organelle formation results in a lack of mature 
autophagy-related organelles. Protein expression 
analysis of ATG5 deficient mouse embryonic fibroblasts 
via western blot show the absence of ATG5, and the lack 
of formation of LC3-II isoform indicating a lack of mature 
autophagy-related organelles. Reprinted with 
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Conversely, modulation of expression or function of ATGs that participate 
later in the autophagy process block the degradation of formed autophagy-related 
organelles. For example, the treatment of cells with bafilomycin A1 a V-ATPase 
inhibitor modulates lysosomal pH to prevent degradation of mature autophagy-
related organelles (Figure 2.19).  
 
Figure 2.19. Effect of V-ATPase inhibitor 
bafilomycin A1 on degradation of autophagy-
related organelles. Late stage inhibition of 
autophagy-related organelles results in the 
accumulation of LC3-II, and overall accumulation of 
total LC3. Primary fibroblasts from rat were treated 
with 200 μM Bafilomycin A1 in culture for 4 hrs. prior 
to harvest and western blot analysis. Modified and 
used with permission from Kogot-Levin.84 
 
 
Autophagy is often described as a general lysosomal degradative pathway 
however, it can also show incredible specificity. While general autophagy flux is 
increased during cellular stress such as nutrient deprivation, selective autophagy 
often functions in cell maintenance and homeostasis.85 An example of selective 
autophagy is the degradation of mitochondria (i.e. mitophagy) which proceeds via 
specific signalling mediated by PINK1 and ubiquitin86 (Figure 2.20). Mitochondria 
play an essential role in energy production in cells through oxidative 
phosphorylation (OXPHOS). A by-product of aberrant OXPHOS are reactive 
oxygen species (ROS), which can cause intracellular damage; thus, mitochondrial 
fidelity is critically important to cellular function. If damage due to ROS accumulate, 
mitophagy flux will increase to degrade the damaged organelles. In Chapter 3, the 
method described for the relative quantification of autophagy flux can also quantify 




























Figure 2.20. Selective degradation of mitochondria via mitophagy. Selective degradation of mitochondria 
proceeds by the formation and phosphorylation of chains of ubiquitin at the outer mitochondrial membrane by 
PINK1. Phosphorylated ubiquitin chains recruit and bind autophagy receptors, which in turn recruit LC3-II 
decorated phagophore membranes.  
2.3.2 Function of autophagy in myogenesis and muscle homeostasis 
Skeletal muscle has a remarkable regenerative capacity mediated by the 
presence of muscle stem cells, termed satellite cells. These tissue-resident stem 
cells remain mitotically and metabolically quiescent until the need for muscle repair 
or remodelling arises. In response to myofiber damage, quiescent satellite cells 
are activated and re-enter the cell cycle. They undergo asymmetrical division to 
produce progeny capable of differentiation and fusion, as well as an uncommitted 
stem cell population to serve as a reserve population for future proliferation.87 
Myoblasts produced through satellite cell proliferation activate a differentiation 
program which allows them to fuse with each other or existing myofibers.88 
Recent studies have shown that autophagy is a critical process in 
myogenesis, participating in both satellite cell proliferation83 and myoblast 
differentiation and fusion.89 Garcia-Prat and co-workers show that satellite cells 
from geriatric mice (>28 mo.) enter a non-proliferative senescent state, which 
results in fewer and non-functional satellite cells. Importantly, geriatric satellite 
cells display reduced autophagic flux compared to young (<3 mo.) control cells, 
indicating a decline in the cytoprotective effect of autophagy as a constitutively 
active “clean-up” process. Thus, autophagy is a necessary process for maintaining 
satellite cell stemness through the prevention of a senescent cell state.  
Proliferating satellite cells produce myoblasts capable of differentiation and 
fusion to repair myofibers (Figure 2.21). Differentiating myoblasts require active 
autophagy for successful formation of myofibers. Sin and co-workers show that the 












from primarily glycolytic state to reliance on OXPHOS for the production of 
adenosine triphosphate, to support the increased energetic demand of myofibers. 
A highly developed network of mitochondria is required for OXPHOS, resulting in 
increased rates of mitochondrial degradation via mitophagy and biogenesis during 

















Figure 2.21. Process of myogenesis. After an insult to muscle tissue satellite cells are activated and 
proliferate asymmetrically to form myoblasts and repopulate the satellite cell niche. Myoblasts undergo 
differentiation to form myocytes capable of fusion to form myotubes. Myotubes fuse to myofibers to repair 
damage. Modified and adapted from Pichavant.90  
 
As in myogenesis, autophagy is required for maintenance of mature 
myofibers. Abnormal organelles can be observed in age-related atrophy in skeletal 
muscle, and muscle fibers harbouring these organelles display sectional atrophy, 
splitting, and increased levels of oxidative damage.91-92 In agreement with these 
observations in aged skeletal muscle, Masiero and coworkers show that 
autophagy-related gene 7 (ATG7) knockout specifically in skeletal muscle of adult 
mice results in muscle atrophy, loss of force production, and morphological 
hallmarks of myopathies. Interestingly, the muscle-specific suppression of 













phenotype has been reported with muscle-specific knock-out of ATG5, with a 
significant reduction of muscle mass, and accumulation of excessive protein.93  
Similarly, recent studies have shown that the skeletal muscle resident 
immune compartment contributes to the maintenance of skeletal muscle mass and 
function. Macrophages maintain stem cell populations in numerous tissues 
including skin and bone marrow,94-97 and have been shown to give stem cells 
“license” to execute their differentiation program.98 Conversely, hyperactivity of this 
compartment has been observed with age.99 The term “Inflamm-ageing” was 
coined to describe the systemic, chronic inflammation100 characterized by this 
imbalance between pro- and anti-inflammatory immune function. Dysfunctional 
autophagy, resulting in the accumulation of damaged proteins and organelles is 
thought to be a main driver of the shift towards a pro-inflammatory state with 
age.101-102 
Taken together these studies illustrate the complex and tightly regulated flux 
of autophagy during myogenesis and skeletal muscle maintenance. While 
informative, these reports lack the single-cell resolution or multiplexed analysis 
necessary to unravel the mechanism driving autophagy flux dysregulation, and its 
contribution to decreased myogenesis. Chapters 3 and 4 of this work describe 
methods for the single cell or organelle analysis of autophagy flux in myogenesis 
and aging, increasing our fundamental understanding of dysregulated autophagy 









Single-Cell Analysis of Autophagy during Myogenesis in Murine 
Myoblasts via Mass Cytometry 
 
All data collection and analyses were done by H.M.G. Brown. Michelle Kuhns 






















Skeletal muscle is able to regenerate after insult, a property conferred by 
tissue resident stem-like satellite cells. Satellite cells are activated, proliferate, and 
differentiate to maintain skeletal muscle. Dysfunctional autophagy has been 
implicated in the muscle number and functional declines observed in satellite cells 
with age, though the mechanism by which this occurs has not been investigated. 
Due to the phenotypic diversity of myoblasts during myogenesis, and the complex 
regulation of autophagy function, a multi-dimensional, individual cell analysis of 
autophagy flux during myogenesis is required. Here we describe the first individual 
cell analysis of autophagy in differentiating myoblasts using mass cytometry. 
Myoblasts were phenotypically identified by their position in the myogenic lineage, 
followed by the quantification of autophagic flux in each identified subset. We found 
that autophagy is upregulated specifically during myoblast fusion and declines in 
myotubes. However, the specific degradation of mitochondria via mitophagy is 
upregulated much earlier in the myogenic lineage and is maintained though 
myotube formation. This observation is in line with the changing energetic needs 
of myoblasts as they shift from a glycolysis to oxidative phosphorylation. We report 
the development of a novel method for the multiplexed analysis of differentiating 
myoblasts used to probe the timing and expression of autophagy-related targets 
throughout the myogenic lineage. This work expands the current understanding of 
autophagy regulation in regenerating skeletal muscle. 
 Introduction 
Skeletal muscle is a highly heterogeneous tissue with a remarkable capacity 
for regeneration. This ability for self-renewal is conferred by myoblast progenitors 
termed satellite cells which follow a trajectory of activation and proliferation to 
expand the myoblast compartment. After expansion, myoblasts begin a myogenic 
differentiation program in which they fuse to other differentiating myoblasts or pre-
existing myotubes. This process proceeds in a highly heterogeneous manner, 
where not all myoblasts will express the transcription factors necessary to commit 
to myogenic differentiation103-104 providing a set of ‘reserve cells’ capable of 





decline in satellite cell populations,83 though the mechanism for decreased 
autophagy flux in aged satellite cells is unclear.  
Autophagy is a constitutively active biological process whose flux can be 
increased in times of changing cellular needs. For example, autophagic flux has 
been shown to be increased during cellular remodelling,105-106 such as is observed 
in the myogenic differentiation program.83, 107-108 Importantly, these reports do not 
specify the stage of myoblast differentiation in which autophagy flux is increased. 
We hypothesize that the reported changes in autophagy flux occur at a specific 
point in the myogenic lineage, in response to changing metabolic needs and 
intracellular remodelling. Due to the phenotypic diversity of myoblasts during 
myogenesis, and the complex regulation of autophagy function, a multi-
dimensional, individual cell analysis of autophagy flux during myogenesis is 
required.  
Mass cytometry is an emerging technique for multi-dimensional individual cell 
analysis using a single-particle inductively-coupled plasma mass spectrometer 
(ICP-MS).43 This technique detects and quantifies upwards of 45 separate cellular 
targets on the surface or within individual cells, expanding the multi-dimensional 
capabilities of individual cell analysis beyond what is currently possible with 
comparable techniques such as flow cytometry. Mass cytometry was recently used 
to further illuminate phenotypically unique satellite cell transition states in muscle 
regeneration.109 In this work we will focus on differentiating myoblasts, a later time 
point in the myogenic lineage. Differentiating myoblasts were phenotyped based 
on their expression of canonical myogenic markers such as MyoD, myogenin 
(MyoG), and myosin heavy-chain (MHC).88 These myogenic markers and other 
autophagy-related targets will be indirectly detected via antibodies covalently 
labelled with a polymer chelating isotopically pure lanthanide ions. Unique 
lanthanide isotopes are assigned to each antibody and are detected in individual 






The use of antibodies for detection of specific cellular targets has been widely 
applied in spite of the known pitfalls of promiscuous off-target binding and lot-to-
lot variability, sometimes producing questionable published research findings.110 
In individual cell analysis via immuno-labeling, as has been used to profile 
phenotypic variation of immune and myoblast progenitor cells,46, 109 the wide 
variety of distinct cell types present in a single sample provides inherent negative 
controls for estimations of non-specific antibody binding, negating the need for a 
genetically manipulated negative control animal or cell line. The individual cell 
analysis of autophagy is unique in that there are no known, genetically unaltered 
mammalian cell types that do not express autophagy-related proteins. Thus, the 
current limitation to quantifying autophagic activity using individual cell immuno-
labelling techniques, such as mass cytometry, lies in the need to create genetically 
modified knock-out biological models to estimate off-target antibody binding for 
each antibody used. Creating and characterizing genetic knock-out systems for 
the upwards of 45 cellular targets that can be measured using mass cytometry, 
exponentially increases the difficulty, time and resources of the investigation. To 
overcome the need for creating an excessive number of genetically knocked-out 
biological models to assess non-specific antibody interactions, we developed a 
signal correction and normalization method that reveals accurate antibody binding 
using isotype and total antibody loading controls. Specifically, off-target antibody 
binding is estimated by isotype control antibodies which lack a specific cellular 
target. Variation in cell size and permeability is assessed by quantifying a highly 
abundant and constitutively expressed protein such as glyceraldehyde 3-
phosphate dehydrogenase (GAPDH).  
First, we validated the use of the correction and normalization method by 
titrating the autophagy-related antibodies in both genetically knocked out and 
pharmacologically reduced models of autophagy flux in myoblasts to identify 
antibody exposure concentrations producing accurate measurements of 
autophagy flux. Then, we identified phenotypically unique cell subsets across the 





then quantified autophagy flux across the myogenic lineage and found it to be 
upregulated specifically during myoblast fusion, while mitophagy flux increases 
much earlier and persists through myotube formation.  
 Materials and Methods 
3.2.1 Materials, Reagents, Buffers, and Solutions. 
Phosphate buffered saline (10x, 0.2 M KH2PO4, 1.5 M NaCl, pH 7.2) was 
obtained from Rockland Immunochemicals (Limerick, PA). Methanol, Triton X-100, 
sucrose, Tris(hydroxymethyl)aminomethane hydrochloride (Tris-HCl), Bovine 
serum albumin (BSA), bafilomycin A1, rapamycin, sodium azide (NaN3), nitric acid, 
and hydrochloric acid and dimethyl sulfoxide (DMSO) was obtained from Sigma 
Aldrich (St. Louis, MO). Fetal bovine serum (FBS), horse serum (HS), Dulbecco’s 
Modified Eagle Medium (DMEM), Penicillin-Streptomycin (10,000 U/mL), trypsin-
EDTA (5% v/v), Prolong anti-fade mountant with DAPI, and AlexaFluor 594-
Phalloidin were obtained from Thermo Fischer Scientific (Waltham, MA). Maxpar 
X8 Multimetal Labeling Kit, Maxpar Fix & Perm Buffer, Nuclear Antigen Staining 
Buffer Set, Cell-ID Intercalator, cell-ID cisplatin, and 10× EQ Four Element 
Calibration Beads were obtained from Fluidigm (San Francisco, CA). Tween-20 
and Tris-buffered saline (TBS) were obtained from Bio-Rad (Hercules, CA). Water 
was purified with a Millipore Synergy UV system (18.2mΩ/cm, Bedford, MA). 
Phosphate-buffered saline (PBS) was diluted 1:10 in purified water. Cell staining 
buffer consisted of 1x PBS, 2% (w/v) BSA, and 0.02% NaN3. 
3.2.2 Antibody panel design and characterization.  
Specific antibodies were chosen after a preliminary screen using 
fluorescence microscopy and western blots to assess specificity and signal 
strength against an appropriate isotype control antibody. Where required, carrier 
protein was removed from purchased antibody formulations using buffer exchange 
and IgG purification kits (Thermo Scientific, Waltham, MA). Where suitable specific 
antibodies were not available, a hybridoma cell line (MHC; clone BF35) developed 
by Lucas and Schiaffino, were obtained from the Developmental Studies 





University of Iowa, Department of Biology, Iowa City, IA 52242. Hybridomas were 
sub-cultured at The University of Minnesota – Twin Cities, and sent to ProMab 
Biotechnologies (Richmond, CA) for large-scale antibody production and 
purification.  
Selected antibodies were metal-labeled using the Maxpar metal-labeling kit 
(Fluidigm, San Francisco, CA), per manufacturer instructions. Protein 
concentrations after metal-loaded polymer conjugation was calculated from 
measured A280 values (Jasco, Oklahoma City, OK). The average number of 
lanthanide atoms per antibody was calculated by quantifying the number of 
lanthanide ions and antibody molecules per unit volume. The number of lanthanide 
ions were quantified by comparison to a standard solution of lanthanide ions of 
known concentration. Briefly, metal-labeled antibodies were diluted 1:1,000 from 
their stock concentrations into 2% HCl, followed by two subsequent 1:1,000 
dilutions into 2% HNO3 for a total dilution factor of 1:10,000. Lanthanide standard 
solutions were prepared in 2% HNO3 to a final concentration of 50pM. Solutions 
were sequentially flowed into the CyTOF2 mass cytometer and data was acquired 
for all metal channels simultaneously in “solution mode” using the following 
parameters: step value = 1, settling time = 20 s, pushes / reading = 76,800. The 
steady signal resulting from the lanthanide standard was used to calculate the 
lanthanide atom concentration in the diluted antibody sample (see Appendix A, 
Table A1). 
3.2.3 Cell Culture Conditions 
C2C12 and L6 myoblasts (ATCC, Manassas, VA) were maintained at 37°C, 
5% CO2 in DMEM supplemented with 10% FBS containing 1000 units penicillin, 
and 10 µg/mL streptomycin. Cells were propagated at a ratio of approximately 1:30 
(v/v) every 48-72 hours, using 0.5% trypsin-EDTA in PBS. Differentiation of C2C12 
myoblasts took place over 120 hours in DMEM supplemented with 2% HS 
containing 1000 units penicillin, and 10 µg/mL streptomycin The ATG7 KO L6 
myoblasts were produced using CRISPR/Cas9 technology by the Genome 





3.2.4 Western Blot 
Cells were harvested into 250 mM sucrose, 10mM Tris-HCl buffer containing 
protease inhibitors (Pierce, Waltham, MA). Cells were lysed via sonication and 
total protein quantification of whole cell lysates was measured using a detergent 
compatible version of the Lowry assay (Bio-Rad, Hercules, CA). Whole cell lysates 
were separated via SDS-PAGE. Proteins were transferred to nitrocellulose (0.45 
µm) or PVDF (0.2 µm) membranes. Membranes were blocked in a solution of 4% 
milk in tris-buffered saline containing 0.1% Tween-20 (TBS/T). Membranes were 
probed overnight with anti-LC3, anti-GAPDH, anti-p62, and anti-ATG7 antibodies 
in 4% milk solutions in TBS/T. Membranes were subsequently probed with an anti-
rabbit HRP conjugated secondary antibody in TBS/T. All washes between antibody 
and substrate incubations were done in TBS/T. Completed blots were visualized 
on an X-ray film using chemiluminescent substrate. Films were digitized using a 
scanner. 
3.2.5 Fluorescence Microscopy 
C2C12 cells were differentiated in 4-well Lab-Tek chamber slides. At each 
differentiation time point (0, 24, 48, 72, 96, 120 hrs.) cells were stained with 
AlexaFluor 594 Phalloidin per manufacturer protocol to visualize actin. Briefly, cells 
were fixed in 3.7% MeOH-free formaldehyde for 10 min. at room temperature. 
Following fixation, cells were permeabilized with 0.1% Triton X-100 in PBS for 5 
minutes. Each chamber was washed twice with PBS and incubated in 165 nM 
AlexaFluor 594 Phalloidin in 1% BSA in PBS for 20 minutes at room temperature. 
Cells were washed twice with PBS, followed by preservation in ProLong Gold 
Antifade Mountant with DAPI to stain nucleic acids.   
Images were acquired on an Olympus IX81 inverted microscope equipped 
with a Hamamatsu C-9100 EM-CCD camera and operated using HCImage. 
3.2.6 Mass Cytometry Sample Preparation and Data Acquisition 
Two days prior to harvest, cells were expanded into four 75 cm flasks per 
condition (WT, KO, drug-treatment). At the time of harvest, cells from all four flasks 





samples were stained with Cell-ID cisplatin (5 µM) and quenched using cell 
staining buffer. Cells were aliquoted to ~600,000 cells / sample, fixed, and 
permeabilized. Permeabilized cells were incubated in serially diluted cocktails of 
antibodies described in Table A1, washed using cell staining buffer, and incubated 
at 4°C overnight in Cell-ID Intercalator-Ir (diluted to 62.5nM final concentration in 
Maxpar Fix & Perm buffer). Prior to analysis on the CyTOF2 mass cytometer 
(Fluidigm, San Francisco, CA), cells were washed with cell staining buffer and 
purified H2O (18.2 MΩ, Millipore, Bedford, MA). Data was acquired using the 
following instrument parameters: noise reduction, cell length = 10-150, lower 
convolution threshold = 0.2. Samples were then diluted to 5×105 in a solution of 1× 
EQ Four Element Calibration Beads in ultrapure water to attain an event detection 
rate of approximately 150-200 events / second. 
3.2.7 Data Analysis 
After acquisition data were normalized via instrument software (Helios 
software, version 6.7) and EQ normalization beads. Using equation 3.1 the number 
of unique ions associated with each event (# ionsAb) was calculated using the 
equation below, where DCAb represents the dual count signal of a single antibody 
chelating a unique metal isotope m from an individual organelle and the TEm is the 
empirically determined transmission efficiency of m. This was done on an 
individual cell basis for all isotopes monitored. 
# ionsAb = DCAbTEm                                           Equation 3.1  
Following quantification of each unique isotope per cell, we calculated the 
number of all antibodies represented per cell using equation 3.2, where correction 
factor represents the average number of metal ions chelated by a single antibody 
protein. 
# Ab per cell = # ionsAbcorrection factor                                 Equation 3.2 
These calculations allow for the quantitative comparison of the number of 





correction for non-specific binding and total antibody loading was performed using 
the equation below.  
corrected and normalized # Ab per cell = # specific Ab - # isotype Ab
# GAPDH Ab - # rabbit isotype Ab
          Equation 3.3 
After calculation of the corrected and normalized # antibodies per cell, data 
were subjected to a quality control check where cells containing equal or larger 
numbers of isotype than specific antibodies were removed from subsequent 
analyses (see Appendix A, Figure A1 and Table A2). This was done for all specific 
antibodies, including GAPDH.  
Mass cytometry data processing, plots, and histograms were made using 
software available at www.dvssciences.com, www.cytobank.org, www.flowjo.com, 
and custom R scripts. Densitometric analyses of western blot images were 
performed using ImageJ 2.0.0–rc-43/.1.51j (rsb.info.nih.gov/ij/). Background 
subtraction and scaling of epifluorescence microscopy images was done using 
HCImage. 
 Results and Discussion 
3.3.1 Non-specific Antibody Binding is Quantified Through Correction and 
Normalization 
We hypothesized that accurate signal arising from specific antibody binding 
can be calculated by correcting for promiscuous antibody-cell interactions and 
normalizing variation in per cell total antibody loading. This was accomplished 
through individual cell measurements of a host- and type-matched isotype control 
antibody and a housekeeping protein antibody, such as the commonly used 
GAPDH protein, followed by a mathematical correction and normalization to these 
two parameters in individual cells. This required a quantitative comparison 
between individual signals in a single cell event. Importantly, it has been 
established that lanthanide ion transmission efficiency varies across the relevant 
mass range of the CyTOF2 leading to unequal detection sensitivities.45 As 
discussed in Chapter 2, the pattern of transmission efficiency is unique to each 
CyTOF instrument (Figure 2.3), thus to facilitate the direct comparison between 





subsequent correction of isotope transmission efficiency in individual cell data is 
required (see Equation 3.1).  
To test our correction and normalization method, we assembled and 
characterized a panel of antibodies relevant to autophagy (see Appendix A, Table 
A1) including the relevant isotype and GAPDH antibody controls. This information, 
in conjunction with isotope transmission efficiency characteristics allow for the 
calculation and comparison of the number of antibodies bound per cell. We titrated 
the panel of antibodies in an autophagy-related protein 7 (ATG7) knock-out L6 rat 
myoblast cell line. ATG7 is an essential autophagy-related gene responsible for 
autophagy-organelle membrane formation. Elimination of this gene results in the 
accumulation of cytosolic LC3 (LC3-I) rather than the membrane bound isoform 





Figure 3.1 Representative western blot for ATG7 KO L6 myoblasts. (a) ATG7 KO prevents the lipidation 
of LC3-I to form LC3-II. (b) Densiometric analysis of the western blot in (a), showing a 70% reduction of total 
LC3 content in the ATG7 KO vs wild type. Error bar represents one standard deviation of two biological 
replicates. See Appendix A, Figure A2 for western blot analysis of p62 and Atg7 in this cell line. 
 
 
Titrations are useful to identify antibody probe staining concentrations that 
maximize signal resulting from specific epitope-paratope interactions and minimize 
signal resulting from non-specific interactions. Incorrect antibody probe incubation 
can significantly influence antigen quantification and confound biological 
interpretation. To visualize the resulting titration data, the matrices of measured 
single cell data were processed to calculate the number of antibodies bound to 
each cell using equations (3.1) and (3.2) (see Appendix A, Figure A3 for 
a 
LC3I 



































representative histogram visualizations of each autophagy marker before and after 
correction and normalization).  
As expected for an accurate antibody titration, as antibody incubation 
concentration increases the corrected and normalized number of anti-LC3 
antibodies bound per cell increases. As shown in Figure 3.2a, the median number 
of antibodies per cell begins to plateau at 2 μg/mL antibody concentration. The 
plateau starting at 2 μg/mL antibody staining concentration in the corrected and 
normalized titration curve (Figure 3.2a) indicates that antibody staining 
concentrations in excess of this value will show an increase in signal mainly due 



































Figure 3.2. Correction and normalization of specific antibody probe signal reveals expected trend for 
affinity reagent titration. (a) corrected and normalized titration curve for total detected LC3. The corrected 




































































K = 1.66 (mL/μg), Kd = 4.01×10-9 M-1, p = 0.0457), using equation 3.4. See Appendix A, Figure A4 for corrected 
and normalized titration curves of other autophagy-related targets. (b) unaltered titration curves show a linear 
trend of increasing signal with antibody staining concentration. The goodness of the linear fit (x variable = 
2163.1, y-intercept = 285.01, R2 = 0.997), indicates the influence of non-specific antibody probe binding on 
the number of antibodies bound per cell. Error bars represent a 95% confidence interval about the population 
median. 
The corrected and normalized titration plots can be fitted to a Langmuir 
isotherm for mono-layer adsorption using equation 3.4.111  
[B]= K$Ago%&Ab'(1 + K × &Ab')                                        Equation 3.4 
In equation 3.4, [B] is total concentration of bound antibody probe (μg/mL), K 
represents the equilibrium association constant assuming a single-step 
homogenous binding regime (mL/μg), 112 is the concentration of free antibody 
(μg/mL), and [Ago] represents the number of binding sites (μg/mL). The dashed 
line in Figure 3.2a, shows the fitted Langmuir isotherm for the corrected and 
normalized WT titration curve indicating that it is an acceptable estimate of true 
antibody binding (Ago = 20.20 (μg/mL), K = 1.66 (mL/μg), Kd = 4.01×10-9 M-1, p = 
0.0457).  
The same data without correction and normalization show a linear trend in 
signal intensity with increasing antibody staining concentration (Fig. 3.2b, see 
Appendix A, Figure A5 for unaltered titration curves of other autophagy-related 
targets). Taken together, these data suggest the correction and normalization 
protocol works to quantify non-specific antibody labeling in individual cells. 
3.3.2 Small Changes in Autophagy Flux can be Measured after Data Normalization 
Functionally ablated cell lines are useful for mechanistic understandings of 
cellular function, but do not always mirror the potential for gradual decline in 
function of in vivo systems. To assess the sensitivity of the correction and 
normalization method, we titrated the developed autophagy-related antibody probe 
panel in a C2C12 mouse myoblast cell line which had been treated with 





organelle degradation. Cells were treated with rapamycin (100 nM, 3 h), to inhibit 
the kinase-activity of mTORC1, which in turn increases autophagic activity. One 
hour later, cells were treated with bafilomycin A1 (100 nM, 2 h), to halt degradation 
of autolysosomes through the inactivation of lysosomal hydrolases. This 
pharmacological treatment induced a small but consistent accumulation of total 
LC3, of about 1.3 times that of the control (Figure 3.3). This same pharmacological 
treatment was used to prepare C2C12 cells for mass cytometry analysis, where 
treated and control cells were used to titrate antibodies against all autophagy-
related targets of interest. 
Figure 3.3. Induction of small changes in autophagy flux using rapamycin and bafilomycin A1. (a) 
representative western blot showing magnitude of change in autophagy in C2C12 myoblasts treated with 
rapamycin and bafilomycin A1. (b) densitometric analysis of biological triplicates shown in A. Error bars 
represent standard deviation of three independent measurements.  
 
The resulting matrices of single-cell data were corrected and normalized 
using the method described above (Equations 3.1-3). The resulting titration curve 
for the anti-LC3 antibody probe shows both pharmacologically treated and control 
titration curves behave as expected with a sharp rise in signal with increasing 
antibody probe incubation conditions. A distinct plateau is observed at 2 μg/mL 
antibody staining concentration for the control series indicating the optimal 
antibody staining concentration for this condition (Figure 3.4a, see Appendix A, 
Figure A6 for corrected and normalized titration curves of other autophagy-related 
targets). No distinct plateau is observed for the treated cells though the rate of 
increase slows between the 2 and 4 ug/mL interval relative to the 1 to 2 ug/mL 
interval. Remarkably, the relative increase in total LC3 content found via western 
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at the 2 μg/mL antibody staining concentration in the mass cytometry titration (1.25 
± 0.01, Figure 3.4a, dash box). Interestingly, a similar ratio for treated versus 
control cells is observed in the non-corrected and normalized mass cytometry data 
(1.20 ± 0.01, Figure 3.4b, solid box). This shows the ability of this method to 
remove signal attributable to non-specific antibody interactions and total antibody 
loading while preserving biologically relevant data allowing users to choose 
accurate antibody incubation concentrations for all future analyses. Taken 
together, these data show that the normalization and correction method maintain 
biologically relevant information while eliminating signal from non-specific antibody 
probe binding. We also assessed the robustness of the correction and 
normalization method using different isotype antibody clones and sample 
preparations and observed comparable results (see Appendix A, Figures A8-9). 
Figure 3.4. The correction and normalization is sensitive to small changes in protein abundance. (a) 
corrected and normalized titration curve for total LC3. In the control series, the median # of anti-LC3 antibodies 
per cell rise rapidly, then plateau at 2 μg/mL indicating the appropriate antibody staining concentration for 
future experiments. (b) unaltered titration curve for total LC3 content, showing a linear trend (R2 = 0.996). See 
Appendix A, Figure A7 for unaltered titration curves of other autophagy-related targets. Error bars are 95% 
confidence interval of the population median. 
 
3.3.3 Progression of Myoblast Differentiation Induces Autophagic Flux 
Myogenesis is a heterogeneous biological process in which myoblasts 
differentiate and fuse to other differentiating myoblasts or pre-existing myofibers. 
This process is driven by the timed expression of four myogenic regulatory factors: 
MyoD, Myf-5, MyoG, and MRF4. Because these regulatory factors control 







































































populations of differentiating myoblasts can be phenotypically identified through 
the expression of these myogenic regulatory factors.113 MyoD is a transcription 
factor known to regulate contractile protein synthesis and mitochondrial 
biogenesis.114 Expression of MyoD increases during myoblast proliferation and 
decreases as myocytes and myotubes are formed. MyoG primarily regulates 
expression of terminal differentiation genes needed for cell fusion.113 Thus, 
expression of MyoG is increased later in the myogenic program. Myosin heavy 
chain protein (MHC) isoform expression is increased in contractile myotubes 
relative to myoblasts and its relatively increased expression is used in this study 
as a marker for terminally differentiated myotubes.115 Antibodies specific for MyoD, 
myogenin and MHC isoforms were metal-labeled and used to phenotypically 
identify unique subsets of differentiating myoblasts based on the expression of 
these proteins.  
A powerful aspect of single-cell analysis is the ability to trace cell lineage. 
Myogenesis is hallmarked by the progression of cells from immature to mature 
states, conventionally represented as distinct cell subsets as described above. 
Using antibodies specific to the myogenic markers mentioned above (MyoD, 
MyoG, and MHC), C2C12 myoblasts were differentiated for 0, 24, 48, 72, 96 or 
120 hours (Figure 3.5), lifted using trypsin (see Appendix A, Figure A10), and 
analyzed using mass cytometry.  
Figure 3.5. Representative images of differentiating C2C12 murine myoblasts. At 0 hrs. of differentiation 
(left) only mononuclear cells are observed, in an irregular, round shape. After 48 hrs. of differentiation (center), 
myoblasts are elongated, some have fused to become multi-nucleated myotubes. After 96 hrs. of 
differentiation, many myotubes are observed, with numerous nuclei per myotube. Scale bar is 100 μm. 
Phalloidin 546 and DAPI were used to stain the cytoskeleton and nuclei, respectively. 
 
Rather than manually sub-setting individual cells based on their expected 
MyoD, MyoG, and MHC expression we employed the Wanderlust algorithm to 
Phalloidin, DAPI 





predict the progression of cell differentiation de novo by aligning cells from a given 
lineage to a unified trajectory.71 As was expected, Wanderlust analysis of a 
heterogeneous population of differentiating myoblasts and myotubes predicted 
that of the three phenotypic markers described above, MyoD expression increases 
first, followed by MyoG; MHC increases last, as MyoD expression declines (Figure 
3.6a). Manual gating of cell subsets was subsequently performed, adhering to the 
predicted phenotypic expression profile (see Appendix A, Figure A11). The 
proportion of cells in each subsequent cell subset in the myogenic lineage (Figure 
3.6a), increases with increased time in differentiation conditions (Figure 3.6b). 
Cells not exposed to differentiation conditions express MyoD, though two distinct 
populations MyoDhi and MyoDlo are apparent (see Appendix A, Figure A11). As 
reported previously, this set of MyoDlo cells are likely capable of differentiation but 
instead stay in the quiescent state as ‘reserve cells’.116 Notably, at 120 hours of 
differentiation the population of quiescent MyoDlo cells increases, presumably as 


































Figure 3.6. Prediction and characterization of unique phenotypic cell subsets. (a) We employed the 
Wanderlust algorithm to predict myogenic regulatory factor expression along the myogenic lineage. As 
expected, MyoD was expressed first, followed by MyoG and MHC. All subsequent manual gating followed the 
predicted pattern. (b) The proportion of cells in each unique cell subset in the myogenic lineage change with 
time spend in differentiation media, indicated in chart legend.  
 
 
It has been reported that autophagy flux is increased during myogenesis, 
though a single-cell analysis of autophagy flux during myogenesis has not been 
reported. We prepared a panel of metal-labeled autophagy-related antibodies to 
accurately assess autophagy flux during differentiation in the cell subsets identified 
above. Antibody staining concentrations were chosen through the analysis of 
titration curves constructed for each antibody included in the panel (Figure 3.4a, 
Figure A6). Myoblasts exposed to differentiation conditions for 0, 24, 48, 72, 96 or 
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120 hours were exposed to Bafilomycin A1 for 2 hours prior to harvest to halt the 
degradation of autophagy-related organelles, which would result in accumulation 
of these organelles and their markers. Such accumulation is a surrogate for 
autophagy flux, thus providing a read of the rate of autophagy flux in each unique 
cell subset. As was expected, autophagy flux was increased during myogenesis 






















Figure 3.7. Measurement of autophagy flux along the trajectory of the myogenic lineage. MyoDlo cells 
(column 1) represent the beginning of the myogenic lineage as proliferating but not differentiating myoblasts.  
The median signal intensity for each autophagy target (rows) in subsequent populations has been normalized 
back to its non-differentiating (MyoDlo) control. The number in each cell represents the fold change from the 
MyoDlo population for each autophagy target. Interestingly, general autophagy markers (Atg4a, Lrrk2, LC3, 
p62, Atg5, Bec1) peak during myoblast fusion (MyoGhi, MHC-), falling off abruptly after MHC is expressed. 
Conversely, expression of some mitophagy specific markers (Mfn1, Parkin) starts earlier in the myogenic 
program, and persists through myotube formation. Fold change is represented as mean of three biological 
replicates ± standard deviation. 
 
 
Notably, most general autophagy markers such as Atg5, LC3, and p62 do not 
significantly increase in relative abundance until cells express myogenin and MHC, 
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markers of mid-to-late differentiation of myoblasts. As differentiating myoblasts 
cease to express, myogenin autophagy flux is significantly decreased, indicating 
the lack of autophagy flux needed to maintain differentiated myotubes. Conversely, 
proteins specifically marking mitochondria for autophagic degradation (i.e. 
mitophagy) such as Pink1, Mfn1, Parkin, and Bec1 (a known binding partner of 
Pink1117) show a gradual increase in relative abundance that peaks as cells 
express both MyoG and MHC. The abundance of these proteins is largely 
maintained even as MyoG expression decreases. Taken together, these data 
suggest that while autophagy flux is increased in myogenesis the increase occurs 
almost exclusively in cells at mid-to-late time points in the myogenic lineage and 
decreases significantly in formed myotubes (Figure 3.7, MyoDlo, MHC+). However, 
mitophagy flux increases gradually throughout differentiation and is maintained in 
myotubes, likely due to the changing metabolic requirements of this cell type.89 
 
 Discussion 
This report describes the single cell analysis of autophagy flux in 
differentiating murine myoblasts, made possible through the development of a 
post-hoc data correction and normalization method for the accurate assessment 
of non-specific antibody binding in mass cytometry experiments. We found that 
non-specific antibody probe binding could be quantified and corrected using 
lanthanide-ion chelating isotype antibodies, and antibody loading into individual 
cells can be estimated using a lanthanide-ion chelating anti-GAPDH antibody as 
an individual cell internal standard analogous to loading controls used in bulk 
protein analyses (i.e. Western blots). The post-hoc data correction method 
described above shows that non-specific antibody binding and antibody loading 
can be corrected to reveal true, and biologically relevant signal. This method was 
used to choose appropriate antibody staining concentrations for the quantitative 
analysis of in vitro myogenesis.  
The asynchronous progression of myogenesis has thus far prevented a 





another, or pre-existing myotubes to regenerate damaged tissue. While bulk 
analyses of this process have provided the insight that autophagy flux is increased 
during myogenesis, the timing and magnitude of this increase in the frame of the 
myogenic lineage was largely unknown. We found that the order of myogenic 
regulatory factor expression could be predicted de novo from a heterogeneous 
population of cells representing a snapshot of continuous myogenic lineage. This 
analysis provided phenotypically unique cell subsets representing discrete points 
along the myogenic lineage for further study. Specifically, we found that a large 
portion of myoblasts will not express the myogenic regulatory factors required for 
differentiation despite increasing time spent in conditions known to induce 
differentiation. These cells are likely ‘reserve cells’ described in the literature that 
maintain quiescence despite the environmental stimuli inducing differentiation.103 
We also found that as myotube formation increased, the proportion of quiescent 
cells also increased, indicating replenishment of the myoblast compartment, likely 
in preparation for further differentiation.116 As expected, myoblasts left to 
differentiate for increasingly longer times, will contain proportionally increasing cell 
subsets expressing the myogenic regulatory factors MyoD and MyoG, and the 
terminal differentiation marker MHC. 
Autophagy flux is required for myogenesis108 and decreased autophagy flux 
has been implicated in the decreased number and function of regenerative satellite 
cells with age.83 However, the distinct point at which autophagy flux is impaired is 
unknown. We found that in an in vitro model of myoblast differentiation, 
accumulation of autophagy-related organelles indicative of autophagy flux 
increase during myoblast fusion and is significantly decreased in myotubes. 
Conversely, mitophagy-specific proteins (i.e. Pink1, Mfn1, Parkin, and Bec1) 
gradually increase in abundance throughout MyoG, peaking during myoblast 
fusion and is largely maintained in myotubes. These measures of autophagy and 
mitophagy flux show that while the autophagy machinery is indeed required for 





mitochondrial network. This agrees with the increased energetic requirements and 
shifting metabolism observed in myotubes versus myoblasts.89  
 Conclusions 
In conclusion, this study reports a method for the analysis of accurate 
antibody probe binding in multi-parameter mass cytometry experiments without the 
need for excessive genetically modified or pharmacologically biological models. 
This strategy is universally applicable to mass cytometry experiments where 
genetically knocked-out biological models are unavailable or impractical. Using 
accurate antibody incubation concentrations, we probed the rate of autophagy flux 
in distinct cell subsets present in asynchronous cultures of differentiating 
myoblasts, finding that autophagy flux spikes during myoblast fusion while 
mitophagy-specific protein expression gradually increases, likely due to changing 
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Skeletal muscle is a highly complex tissue capable of repair or regeneration 
in response to damage or stress. Aging muscle undergoes a loss of its myogenic 
potential, which may reflect a reduction in the number of satellite cells that are 
necessary for myogenesis, as well as a reduction in the myogenic capacity of 
tissue-resident stem cells. Due to the highly heterogenous nature of skeletal 
muscle, decreased autophagic flux cannot be assigned to any single cell type, 
confounding the biological interpretation of bulk analyses. We hypothesized that 
harnessing the multiparameter capabilities of mass cytometry, would allow for the 
phenotypic identification of satellite cells, M2 macrophages and FAPs and 
simultaneous profiling of autophagy flux in each cell type to understand the 
potential for each cell population to uniquely contribute to the observed overall 
decrease in autophagy flux with age in skeletal muscle. We observed a significant 
decline in the satellite cell subset in geriatric muscle compared to young. We also 
observed decreased autophagy flux in satellite and FAP cells, but not M2 
macrophages. These findings support the current perspective in the field that 
autophagy flux decreases with age in satellite cells, but also identifies decreased 
autophagy flux in FAP cells with age in skeletal muscle. 
 Introduction 
Skeletal muscle is a highly complex tissue capable of repair or regeneration 
in response to damage or stress. The ability to self-renew is mainly driven by the 
myogenic potential of tissue resident stem cells, termed satellite cells. Following 
muscle damage, satellite cells are activated by cytokines and growth factors.118 
Activated satellite cells asymmetrically proliferate to both expand the myoblast 
compartment and reproduce a mitotically quiescent subset of cells for later 
proliferation.87, 116 Myoblasts will differentiate and fuse to each other or existing 
myofibers to regenerate muscle mass and function. Beyond satellite cells, a wide 
variety of resident mononuclear cells also contribute to the satellite cell niche and 
participate in tissue homeostasis, such as macrophages and fibroadipogentic 
progenitor cells. Classically, macrophages promote phagocytosis through pro-





macrophages to an anti-inflammatory phenotype in muscle following damage 
fosters an environment where satellite cells can act to repair damaged 
myofibers.119 Fibroadipogenic progenitor (FAP) cells are characterized by their 
expression of platelet-derived growth factor receptor-alpha (PDGRFα). 
Upregulation of PDGRFα is observed in acute and chronic models of skeletal 
muscle damage, which contributes to the formation of excess fibrous connective 
tissue during repair.120 Thus, proper regulation of satellite cell, macrophage, and 
FAP populations contributes to overall skeletal muscle homeostasis and 
regenerative capacity. 
Aging muscle undergoes a loss in its myogenic potential,74 which may 
reflect a reduction in the number of satellite cells that are necessary for 
myogenesis,121 as well as a reduction in the myogenic capacity of aged satellite 
cells.83 Whether this observed decline occurs via extrinsic factors derived from the 
satellite cell niche, including macrophage or FAP signalling, or via cell-intrinsic 
regulation of the myogenic program is unclear.122 Whole tissue analyses of aged 
and young tissue via western blot implicate decreased autophagy flux as a 
contributing factor to reduced myogenic capacity.108 Autophagy is a constitutively 
active, catabolic intra-cellular process by which long-lived or damaged proteins 
and organelles are degraded. The decline of autophagic flux results in the 
accumulation of damaged proteins and organelles and eventually, apoptosis.4 Due 
to the highly heterogenous nature of skeletal muscle, decreased autophagic flux 
cannot be assigned to any single cell type, confounding the biological interpretation 
of these bulk analyses.  
Mass cytometry is an emerging technique for multi-dimensional individual cell 
analysis using a single-particle inductively-coupled plasma mass spectrometer 
(ICP-MS)43 43. This technique detects and quantifies upwards of 45 separate 
cellular targets on the surface or within individual cells, expanding the multi-
dimensional capabilities of individual cell analysis beyond what is currently 
possible with comparable techniques such as flow cytometry. The technique relies 





chelated to unique antibodies specific to cellular targets of interest. We 
hypothesized that harnessing the multiparameter capabilities of mass cytometry, 
would allow for the phenotypic identification of satellite cells, M2 macrophages and 
FAPs and simultaneous profiling of autophagy flux in each cell type to understand 
the potential for each cell population to uniquely contribute to the observed overall 
decrease in autophagy flux with age in skeletal muscle. We observed a significant 
decline in the satellite cell subset in geriatric muscle compared to young. We also 
observed decreased autophagy flux in satellite and FAP cells, but not M2 
macrophages. These findings support the current perspective in the field that 
autophagy flux decreases with age in satellite cells, but also identifies decreased 
autophagy flux in FAP cells with age in skeletal muscle.   
 Materials and Methods 
4.2.1 Reagents and Materials 
Ham’s F-10 media, horse serum, fetal bovine serum, HEPES buffer, 
Penicillin-Streptomycin (10,000 U/mL), collagenase II, Tris(2-carboxyethyl) 
phosphine hydrochloride (TCEP), and dispase II were obtained from Thermo 
Fischer Scientific (Waltham, MA). Dulbecco’s Modified Eagle Medium was 
obtained from GE Healthcare Life Sciences (Marlborough, MA). Phosphate 
buffered saline (10x, 0.2 M KH2PO4, 1.5 M NaCl, pH 7.2) was obtained from 
Rockland Immunochemicals (Limerick, PA). Bovine serum albumin (BSA), 
vinblastine, rapamycin, sodium azide (NaN3), and dimethyl sulfoxide (DMSO) was 
obtained from Sigma Aldrich (St. Louis, MO). Maxpar X8 Multimetal Labeling Kit, 
Maxpar Fix & Perm Buffer, Nuclear Antigen Staining Buffer Set, Cell-ID 
Intercalator, cell-ID cisplatin, and 10× EQ Four Element Calibration Beads were 
obtained from Fluidigm (San Francisco, CA). Cell strainers (40 μm), needles (16- 
and 18-gauge) and syringes (10 mL) were obtained from BD biosciences (Franklin 
Lakes, NJ). Debris removal kit was obtained from Miltenyi Biotec (Bergisch 
Gladbach, Germany). Water was purified with a Millipore Synergy UV system 
(18.2mΩ/cm, Bedford, MA). Rinsing buffer consisted of Ham’s F-10 media, 10% 





solution 1 consisted of DMEM, 0.2% (w/v) collagenase II, Penicillin-streptomycin 
(100 U/mL). Digestion solution 2 consisted of Ham’s F-10 media, 0.2% (w/v) 
collagenase II, 0.2% (w/v) dispase II. PBS was diluted 1:10 in purified water. Cell 
staining buffer consisted of 1x PBS, 2% (w/v) BSA, and 0.02% NaN3. 
4.2.2 Animal Care and Sample Preparation 
Female C57BL/6 mice were obtained from Jackson Laboratory or the 
National Institute on Aging. It has been reported that muscle mass and functional 
loss is noticeable in old mice (20-24 mo.) and is highly prevalent in geriatric mice 
(28-32 mo.).123 To minimize the number of mice needed for these pilot studies we 
choose  only one small range of ages to investigate in this study (25-28 mo.). 
Young mice (3-5 mo.) were used as relative controls for autophagy flux and cell 
enumeration studies. Young mice (<2 mo., n = 15), were obtained from Jackson 
Laboratory (Bar Harbor, ME) and housed four animals per cage for at least 1 week 
at the University of Minnesota prior to harvest. Geriatric mice were obtained from 
the National Institute on Aging at 21 mo. of age (n = 20). They were housed at the 
University of Minnesota (four animals / cage) for an additional four months prior to 
harvest. All mice were exposed to a 12-hour light/dark cycle and were provided 
food and water ad libitum. A power analysis from preliminary phenotyping 
experiments indicated a need for 14-17 animals for acceptable statistical power 
(0.8 to 0.9). Whole hind limb skeletal muscle was harvested over from all surviving 
mice over a two-month period. On each day of harvest two geriatric (>24 mo.) and 
one young (< 4 mo.) were euthanized with pentobarbital sodium (200 mg/kg body 
mass, ip) followed by tissue dissection. All tissues were stored on ice or at 4°C 
throughout sample preparation unless otherwise noted. All protocols were 
approved by the Institutional Animal Care and Use Committee at the University of 
Minnesota (protocol # 1602-33497A). 
4.2.3 Antibody Panel Design and Characterization 
Antibodies specific for autophagy-related targets were chosen after a 
preliminary screen using fluorescence microscopy and western blots to assess 





not shown). Phenotypic antibodies were chosen based on literature precedence 
and validated for their ability to identify specific cellular subpopulations. Where 
suitable specific antibodies were not available, a hybridoma cell line (α-MHC, 
clone: BF35) developed by Lucas and Schiaffino, was obtained from the 
Developmental Studies Hybridoma bank, created by the NICHD of the NIH and 
maintained at The University of Iowa, Department of Biology, Iowa City, IA 52242. 
Hybridomas were sub-cultured at The University of Minnesota – Twin Cities, and 
sent to ProMab Biotechnologies (Richmond, CA) for large-scale antibody 
production and purification.  
Where available, pre-metal-labeled antibodies were purchased from Fluidigm 
(San Francisco, CA). When appropriate metal-labeled clones were unavailable 
antibodies were metal-labeled using the Maxpar metal-labeling kit (Fluidigm, San 
Francisco, CA), per manufacturer instructions. Protein concentrations after metal-
loaded polymer conjugation was calculated from measured A280 values (Jasco, 
Oklahoma City, OK). The average number of metal atoms per antibody was 
calculated using the lanthanide concentration and the measured stock antibody 
concentration. Briefly, metal-labeled antibodies were diluted 1:10,000 from their 
stock concentrations into 2% HNO3. Lanthanide standards (Fluidigm, San 
Francisco, CA) were prepared in 2% HNO3 to a final concentration of 50pM. 
Solutions were sequentially injected into the CyTOF2 mass cytometer and data 
was acquired for all m/z ratios simultaneously in “solution mode” using the 
following parameters: step value = 1, settling time = 20 s, pushes / reading = 
76,800. The signal resulting from the lanthanide standard was used to calculate 
the lanthanide atom concentration in the diluted antibody sample. This value was 
divided by the number of antibody molecules present in the diluted antibody 
sample. See Appendix B, Table B1 for antibody panel characterization. 
4.2.4 Mass Cytometry Sample Preparation and Data Acquisition 
Satellite cell isolation protocol was adapted from Brack.124 Briefly, all hindlimb 
muscle was dissected and visible tendons, connective tissue and fat were trimmed. 





myofiber fragments. Myofiber fragments were subjected to digestion in digestion 
solution 1 for 90 minutes at 37°C. The resulting suspension was washed twice with 
rinsing buffer. Satellite cells were further released from myofiber segments via 
mechanical disruption through trituration though a jagged Pasteur pipette, followed 
by a wash to remove large pieces of adipose tissue. The resulting pellet was 
resuspended in digestion solution 2 and incubated at 37°C for 30 minutes. The 
digested suspension was further mechanically disrupted via tituration through 16- 
and 18-gauge needs, then filtered through 40 μm cell strainers. The resulting 
suspension was then titurated through an 18-gauge needle a second time and 
washed twice with rinsing buffer. 
Each sample was subjected to a debris removal protocol to remove remaining 
small particulate. Briefly, cell suspensions were resuspended in 6.2 mL of ice-cold 
PBS in a 15-mL conical tube. Debris removal solution was added to 8 mL total 
volume and the solution was mixed. Each sample was overlaid with 4 mL of ice-
cold PBS and centrifuged at 3,000 × g for 10 minutes at 4°C. Three phases were 
formed, the top two were aspirated and discarded. Ice-cold PBS was added to a 
total volume of 15-mL, inverted three times, and centrifuged at 1,000 × g for 10 
minutes at 4°C. The supernatant was aspirated to produce a reduced-debris pellet. 
Cells were resuspended in rinsing buffer and incubated in 110 nM rapamycin 
and 100 nM bafilomycin A1, or DMSO vehicle control (contralateral control) for 4 
hrs at 37°C, 5% CO2. Cells were collected, washed once with washing buffer and 
frozen in FBS containing 10% DMSO for storage.  
Cells were thawed and resuspended in a 1:10,000 dilution of benzonase in 
DMEM to digest free DNA. Cell samples were stained with cisplatin (5 µM, 
Fluidigm) in PBS, and quenched with cell staining buffer. After two washes in cell 
staining buffer, cells were incubated in a cocktail of extracellular antibodies (see 
Appendix B, Table B1) in cell staining buffer for 1 hour at room temperature. 
Following two washes in cell staining buffer, cells were fixed, permeabilized using 
the Nuclear Antigen Staining Buffer Set, and incubated in a cocktail of intracellular 





washed twice more with cell staining buffer and incubated at 4°C overnight in Cell-
ID Intercalator-Ir (diluted to 62.5nM final concentration in Maxpar Fix & Perm 
buffer). Prior to analysis on the CyTOF2 mass cytometer, cells were washed with 
cell staining buffer and purified H2O.  
4.2.5 Mass Cytometry Data Analysis 
Data was acquired on a CyTOF2 mass cytometer (Fluidigm, San Francisco, 
CA). Samples were diluted 1:106 in a solution of 1× EQ Four Element Calibration 
Beads in ultrapure water to attain an event detection rate of approximately 300 
events / second. Data was acquired using the following instrument parameters: 
noise reduction, cell length = 10-150, lower convolution threshold = 0.2. Flow 
cytometry standard (.fcs) files were bead normalized (Helios software, version 6.7, 
Fluidigm), and then converted to plain text (.txt) files for further analysis in R. The 
number of ions associated with each cell event (# ionsAb) was calculated using the 
equation below, where DCAb represents the dual count signal of the antibody 
chelating a unique lanthanide isotope, defined as m.  TEm is the empirically 
determined transmission efficiency of unique lanthanide isotope m for the CyTOF2 
at the University of Minnesota. 
# ionsAb = DCAbTEm                                       Equation 4.1 
Then, the number of each unique antibody present per cell (# Ab per cell) 
was calculated using a correction factor via the following equation.  
# Ab per cell = # ionsAb
correction factor
                             Equation 4.2 
 
The correction factor describes the number of lanthanide ions chelated to 
each antibody (see Appendix B, Table B1). This calculation was carried out for all 
antibodies, regardless of specificity.  
Cells were stained with host-matched, isotype control antibodies, each 
chelating a unique lanthanide isotope, to estimate the non-specific binding 
properties of each specific marker antibody. To obtain specific marker signal 





Ab) was subtracted from the number of specific antibodies per cell event (# specific 
Ab), using the following expression. 
corrected # specific Ab = 	# specific Ab - # isotype Ab   Equation 4.3 
 Results and Discussion 
4.3.1 Phenotypic Identification of the Mononuclear Fraction of Murine Skeletal 
Muscle 
It has long been hypothesized that the reduced regenerative capacity of aged 
skeletal muscle is due, in part, to a reduced pool of satellite cells.125-126 We 
hypothesized that the decline in the satellite cell compartment of aged skeletal 
muscle may also be accompanied by an increase in the population of mature, pro-
inflammatory macrophages, and a concurrent decline in anti-inflammatory 
macrophages. In addition, we expected an increase in the number of pro-fibrotic 
FAP cells. To investigate this hypothesis, we developed a panel of eight antibodies 
(see Appendix B, Table B1) to phenotypically identify satellite cells, pro- and anti-
inflammatory macrophages, and FAPs (see Appendix B, Figure B1 for gating 
scheme) in young (3-4 mo.) and geriatric (25-28 mo.) murine skeletal muscle.  
As expected, the muscle mass of young and aged mice varied with young 
mice maintaining approximately 1.6 times the muscle mass (reported as % of total 
body weight) as geriatric mice (Figure 4.1), indicating a functional loss of muscle 
maintenance in our aged skeletal muscle model.  
 
Figure 4.1. Percent muscle mass of young and 
geriatric C56BL/6 mice. The observed muscle 
mass of young and geriatric mice varied as 
expected with young mice maintaining 
approximately 1.6 times more tissue mass than 
geriatric mice (n = 6 for each age group). 
Student’s t-Test reveals a statistically significant 
difference (p = 0.00089). Error bars represent one 






































As was shown by Lepper127 and Sambasivan,128 paired box 7 protein positive 
(Pax7+) satellite cells are required for muscle repair following acute injury. Through 
phenotypic identification of satellite cells, we saw a significant decline in the 
number of identified satellite cells in geriatric skeletal muscle (94 % decrease of as 
a proportion of intact cells, p = 0.043, n = 8) compared to young controls (Table 
4.1). Thus, the depleted Pax7+ satellite cell pool we observed in aged skeletal 
muscle may significantly influence its myogenic capacity. 
 
Table 4.1. Percent phenotypically identified cell populations of interest. The abundance of satellite cells 
is significantly reduced by 94% in geriatric versus young hind limb skeletal muscle (Student’s t-Test, p = 0.043). 
No other cell type showed an age-correlated change in abundance. 
 
Recent studies have shown that the skeletal muscle resident immune 
compartment contributes to the myogenic potential of satellite cells after injury.129-
130 Macrophages maintain stem cell populations in numerous tissues including skin 
and bone marrow,94-97 and have been shown to give stem cells “license” to execute 
their differentiation program.98 For example, Sun and coworkers showed that when 
the macrophage-specific, critical inflammatory signaling receptor chemokine-CC-
motif receptor 2 (CCR2) is genetically knocked out, innate M1 macrophage 
signaling is blocked and muscle repair is abrogated.107 With this in mind, we 
hypothesized that a numerical decline of macrophages (either pro- or anti-
inflammatory) may also contribute to the atrophy and reduced regenerative 
capacity observed in aged skeletal muscle. However, we observed heterogenous 
range of abundance of both anti- and pro-macrophage abundance in biological 
 % population of detected cells 
 M1 Macrophages M2 Macrophages Satellite Cells FAP cells 
Young - 1 0.05 2.70 0.08 1.40 
Young - 2 0.05 2.02 0.04 2.47 
Young - 3 0.35 2.36 0.01 1.34 
Geriatric - 1 0.27 3.09 0.70 13.10 
Geriatric - 2 0.11 2.88 0.25 1.57 
Geriatric - 3 0.01 0.91 0.81 23.30 






replicates (Table 4.1). On average, we identified 0.2% and 0.1% of intact cells as 
pro-inflammatory M1 macrophages in geriatric and young skeletal muscle, 
respectively (%RSDgeriatric: 112%, n = 4, and %RSDyoung: 114%, n = 4). Similarly, 
only 1.8% and 2.1% of intact cells were identified as anti-inflammatory M2 
macrophages in geriatric and young skeletal muscle, respectively (%RSDM2 
macrophages, geriatric: 62%, n = 4, and %RSDM2 macrophages, young: 49%, n = 4). These data 
suggest that resident M1 and M2 macrophage abundance in skeletal muscle is not 
a significant factor affecting myogenic potential of aged skeletal muscle, though 
they lack the statistical power to confirm this hypothesis. The distribution of 
phenotypic marker intensity for each animal differed, which could affect the %RSD 
reported above. These inconsistencies could have been a result of non-normalized 
cell counts per sample prior to antibody staining. Non-normalized cell counts may 
affect the degree to which non-specific antibody binding contributes to signal used 
to identify individual cell types. Future experiments with an increased number of 
replicates and normalized cell counts may provide sufficient statistical power to 
confirm the extreme heterogeneity we observed in this study. In addition, future 
experiments should include markers to compare the efficacy of innate immune 
system signalling in aged versus young skeletal muscle. 
As noted above, Pax7+ satellite cells are required for skeletal muscle 
maintenance. In the absence of efficient muscle repair via satellite cells, other non-
myogenic mesenchymal progenitors, such as FAPs, can produce excessive 
fibrous or adipose tissue.10, 131 The accumulation of ectopic tissues is deleterious 
to injured skeletal muscle and propagate weakness though further destruction of 
myofibers.131 Enumeration of the FAP populations in young and geriatric skeletal 
muscle showed extreme heterogeneity in FAP abundance across age. Of detected 
intact cells, 1.2% and 12.2% were identified as FAP cells from geriatric and young 
mice, respectively (%RSD% FAP, geriatric: 77%, n = 4, and %RSD% FAP, young: 73%, n = 
4). We also compared the relative abundance of each phenotypically identified 
population within the same sample, and across age-matched samples. We found 





4.3.2 Changes in Autophagy Flux across Macrophages, Satellite and Fibro-
adiopogenic Precursor Cells in Young versus Geriatric Mice 
In accordance with our original hypothesis, we sought to measure autophagy 
flux in each identified cell type to understand the potential for each to uniquely 
contribute to the observed overall decrease in autophagy flux with age in skeletal 
muscle. Previous work83 had measured total LC3 content as a marker of 
autophagy flux in single satellite cells from geriatric and young mice. Though to 
our knowledge, autophagy flux has not been quantified in skeletal muscle resident 
M2 macrophages or FAP cells. Thus, we sought to provide a more thorough 
description of autophagy flux in aged skeletal muscle through the analysis of 
autophagy flux in satellite cells, M2 macrophages and FAP cells. 
It has been shown that autophagy is required for satellite cells to maintain 
stemness83 therefore, we expect to find decreased autophagic flux in satellite cells 
in our analysis. We hypothesize that the age-related chronic low grade 
inflammatory state known as “inflamm-ageing”,132 may be related to decreased 
anti-inflammatory M2 macrophage function via insufficient autophagic flux. 
Additionally, recent reports suggest that interactions between FAP and satellite 
cells regulate satellite cell fate,133 thus insufficient autophagy in FAP cells may 
contribute to dysregulated satellite cell activation in geriatric skeletal muscle.  
Using the multiplexing capacity of mass cytometry, we simultaneously 
identified satellite cells, M2 macrophages and FAPs and measured the total LC3 
content of each as a surrogate for autophagic flux (Figure 4.2a, see Appendix B, 
Figure B3 for additional autophagy markers). We found that after bafilomycin A1 
treatment ex vivo, satellite and FAP cells from young skeletal muscle had 
increased levels of total LC3 over geriatric muscle, indicating higher rates of active 
autophagy flux. Conversely, M2 macrophages showed no change between 
geriatric and young skeletal muscle, though bafilomycin A1 treatment did cause a 
slight increase in total LC3 signal (ratio >1), indicating autophagy flux in M2 






p62 is one of many adaptor proteins that facilitates selective autophagy via 
interactions between the inner membrane of a phagophore and polyubiquitinated 
cargoes labelled for degradation134. In the absence of selective autophagy, p62 is 
constantly turned over and therefore is often used as a marker for general 
autophagy flux. Concurrently with selective autophagy, p62 is post-translationally 
modified to induce its function as an autophagy adaptor, both through increased 
affinity for cargoes and ability to interact with LC3 at the phagophore inner 
membrane135. We measured total p62 content concurrently with LC3 above to 
confirm changes in autophagy flux in bafilomycin A1 treated satellite cells, M2 
macrophages and FAP cells (Figure 4.2, right). As was expected, slight 
accumulation of p62 in both geriatric and young M2 macrophages indicates 
autophagy flux is active and occurring at similar rates in both groups. Similarly, 
differential accumulation of p62 in young FAP cells indicates autophagy flux is 
active. No accumulation of p62 was observed in geriatric FAP cells indicating 
attenuated autophagy flux in this cell subset.  
Interestingly, we observed an accumulation of p62 in geriatric satellite cells 
treated with bafilomycin A1. This was unexpected based on the observation of 
decreased autophagic flux in geriatric satellite cells made above. Taken together, 
these data suggest that while autophagy flux is decreased in geriatric satellite cells, 
accumulation of p62 at selected cargoes still occurs. In Chapter 3, we showed that 
autophagy flux is increased during myoblast differentiation and fusion, and that 
mitophagy is specifically increased in these processes. Thus, signalling for 
selective degradation of cargoes maybe intact in geriatric satellite cells even 









Figure 4.2. Ratio of the number of antibodies detected in bafilomycin A1 treated versus control cells. 
Mononuclear cells isolated from skeletal muscle of the whole hindlimb of geriatric and young mice were treated 
ex vivo with bafilomycin A1 (100 nM, 4h.) or a DMSO vehicle control. Analysis of the cells via mass cytometry 
allowed for the phenotypic separation of M2 macrophages, FAP cells, and satellite cells, and subsequent 
quantification of total LC3 and p62 in each. The ratio shown indicates the relative abundance of LC3 or p62 in 
the treated and control samples. Error bars represent 95% confidence intervals. These data represent four 
separate samples from two animals. * indicates p<0.05 between geriatric and young samples.  
 Conclusions 
This work describes the first single cell analysis of phenotype and function in 
skeletal mononuclear cells. We found that satellite cells had significantly 
decreased abundance in geriatric skeletal muscle while there was no age-
correlated change in abundance for either M2 macrophages or FAPs. We also 
evaluated the autophagic flux of each cell type via quantification of total LC3 and 
found that autophagy flux in M2 macrophages is not changed from young to 
geriatric skeletal muscle. Conversely, we found that autophagy flux is decreased 
in FAP and satellite cells from geriatric skeletal muscle. These results were 
confirmed via concurrent analysis of p62 in each cell type for each age group. 
Interestingly, accumulation of p62 in satellite cells from geriatric skeletal muscle 
indicates that while autophagy flux may be attenuated, selective autophagy 
signalling is intact.  
This analysis used 21 of nearly 50 available lanthanide isotopes, so future 









































mononuclear fraction of skeletal muscle. Ideally, additional interstitial cell types will 
be investigated including vessel-associated stem cells136 and PW1+/Pax7- 
interstitial cells (PICs).137 In addition, expanding the breadth of autophagy-related 
markers monitored in each cell type will provide more detail on the role of 
decreased autophagy flux in FAP and satellite cells. Other functional aspects of 
each cell type could also be monitored to probe their contribution to the satellite 
cell niche. For example, while autophagy flux in M2 macrophages does not change 
with age, other functions such as cytokine signalling has yet to be investigated. 
Harnessing the multiplexing power of mass cytometry for the concurrent analysis 
cell phenotype and function in aged skeletal muscle will provide unprecedented 







Mass Cytometry for Monitoring Autophagy at the Individual 
Organelle Level 
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Macroautophagy is a complex degradative intracellular process by which 
long-lived proteins and damaged organelles are cleared. Common methods for the 
analysis of autophagy are bulk measurements which mask organelle 
heterogeneity and complicate the analysis of inter-organelle association and 
trafficking. Thus, methods for individual organelle quantification are needed to 
address these deficiencies. Current techniques for quantifying individual 
autophagy organelles are either low through-put or are dimensionally limited. We 
make use of the multiparametric capability of mass cytometry to investigate 
phenotypic heterogeneity in autophagy-related organelle types that have been 
isolated from murine brain, liver, and skeletal muscle. Detection and phenotypic 
classification of individual organelles were accomplished through the use of a 
lanthanide-chelating membrane stain and organelle-specific antibodies. Post-hoc 
sample matrix background correction and non-specific antibody binding 
corrections provide quantitative measures of inter-organelle associations and 
heterogeneity. This is the first demonstration of multiparametric individual 
organelle analysis via mass cytometry. The method described here illustrates the 
potential for further investigation of the inherently complex inter-organelle 
associations, trafficking and heterogeneity present most eukaryotic biological 
systems. 
 Introduction 
A growing body of evidence demonstrates organelle of various types 
interact with each other to coordinate complex biological processes.138 For 
example, bulk intra-cellular recycling (macroautophagy) degrades long-lived 
proteins and damaged organelles releasing biomolecules that are used as 
biological building blocks. Macroautophagy is constitutively active and proceeds 
through at least four phenotypically unique organelle types whose interactions are 
dynamically coordinated to respond to intra- and extra-cellular stimuli. 
Dysfunctional macroautophagy has been implicated in age-related health decline, 





where autophagy activity is generally decreased. Currently, the role of organelle 
heterogeneity in the development of these and other diseases hallmarked by 
dysfunctional organelle-related processes is unclear because bulk or whole-cell 
analyses (i.e. western blots, flow cytometry) cannot distinguish different organelle 
types. Previously reported methods for individual organelle analysis include: 
transmission electron microscopy,140 capillary electrophoresis with laser-induced 
fluorescence detection,27, 29-30 and flow cytometry.141-142 These techniques are 
either low-throughput, lack sensitivity or are dimensionally-limited. 
Here, we report a multi-dimensional analysis of individual organelles 
detected via mass cytometry to reveal organelle population heterogeneity in 
macro- and mitophagy across multiple tissues. Mass cytometry has been used to 
conduct multi-dimensional analyses of individual cells,46 but has not been used for 
analyses of organelles. Mass cytometry relies on the use of antibodies, in which 
each unique antibody of the panel binds and identifies its specific molecular target. 
Each antibody is conjugated to a chelating polymer loaded with a different 
lanthanide isotope. Labeled particles are flowed through a micro-nebulizer to 
produce single-particle droplets which are vaporized, atomized and ionized via an 
inductively coupled plasma to produce ion clouds corresponding to individual 
particles. The temporally resolved ion clouds are analyzed via a time-of-flight mass 
spectrometer where the amount of lanthanide bound to each particle is 
quantified.43 
Post-hoc correction for sample matrix background signal and non-specific 
antibody interactions were carried out on an individual organelle basis to reveal 
true signal for each reporter in each organelle. We confirm the analysis of 
individual particles rather than organelle aggregates through the analysis of filtered 
organelle suspensions, assessing the changing distribution of membrane stain 
intensity as a marker for aggregates. The corrected, individual organelle data are 
visualized using the Barnes-Hut implemented T-distributed stochastic neighbor 
embedding algorithm (t-SNE) to assess intra-population heterogeneity that is 





 Materials and Methods 
5.2.1 Materials, Reagents, Buffers, and Solutions. 
Sucrose, hydroxyethyl piperazineethanesulfonic acid (HEPES), mannitol, 
ethylenediaminetetraacetic acid (EDTA), ethylene-bis(oxyethylenenitrilo) 
tetraacetic acid (EGTA), 3-(N-morpholino) propanesulfonic acid (MOPS), 
Tris(hydroxymethyl)aminomethane (Tris), Tris(hydroxymethyl)aminomethane 
hydrochloride (Tris-HCl), potassium chloride, sodium chloride, potassium 
phosphate monobasic (KH2PO4), sodium azide, Methanol-free formaldehyde 
(16%), nitric acid, hydrochloric acid, sodium hydroxide, 
diethylenetriaminepentaacetic acid (DTPA), dodecan-1-amine, 
dimethylformamide, chloroform (CHCl3), trifluoroacetic acid (TFA), and α-Cyano-
4-hydroxycinnamic acid (αCHCA) were obtained from Sigma-Aldrich (St. Louis, 
MO). Tris(2-carboxyethyl) phosphine hydrochloride (TCEP), and terbium (III) 
chloride hexahydrate (TbCl3·6H2O) were obtained from Thermo Scientific 
(Waltham, MA). Phosphate buffered saline (PBS, 10× concentration, 1.37 M NaCl, 
27 mM KCl, 80 mM Na2HPO4, and 20 mM KH2PO4, pH 7.4), and Tween-20 was 
obtained from Bio-Rad (Hercules, CA). Percoll density gradient media was 
obtained from GE Healthcare Life Sci-ences (Marlborough, MA). Maxpar X8 
Multimetal Labeling Kit, Maxpar Fix & Perm Buffer, Cell-ID Intercalator, and 10× 
EQ Four Element Calibration Beads were obtained from Fluidigm (San Francisco, 
CA). Water was purified with a Millipore Synergy UV system (18.2mΩ/cm, Bedford, 
MA). Polytetrafluoroethylene (PTFE) syringe filters (0. 2 µm pore size) were 
obtained from Pall Industries (Port Washington, NY). Polycarbonate membranes 
were obtained from EMD Millipore (Burlington, MA). MSEGTA buffer consisted of 
225 mM mannitol, 75 mM sucrose, 5 mM HEPES, 1 mM EGTA, pH 7.4. When 
necessary additives were included such as 3 µM bovine serum albumin (MSEGTA-
BSA), or percoll density gradient media (12% or 24% Percoll-MSEGTA). Liver 
isolation buffer (IBL) consisted of 13 mM Tris, 14 mM MOPS, 10 mM EGTA, 200 
mM sucrose, pH 7.4. Muscle isolation buffer 1 (IBm1) consisted of 67 mM sucrose, 





buffer 2 (IBm2) consisted of 250 mM sucrose, 2 mM EGTA, 15 mM Tris-HCl, pH 
7.4. Cell staining media (CSM) consisted of 20 mM KH2PO4, 150 mM NaCl, 7.5 
µM bovine serum albumin, 800 µM NaN3, pH 7.2. 
5.2.2 Antibody Panel Design and Characterization.  
Selected antibodies were metal-labeled using a Maxpar metal-labeling kit, per 
manufacturer instructions. Briefly, isotopically pure lanthanide (Ln) ions were 
loaded into linear Ln-chelating polymer (similar structure to those published by 
Lou50). IgG antibodies were reduced using TCEP, and then incubated with Ln-
chelating polymers for 90 minutes. Conjugates were rinsed to remove unbound 
Ln-chelated polymer and resuspended at 0.5 mg/mL. The average number of 
lanthanide atoms per antibody was calculated by quantifying the number of 
lanthanide ions and anti-body molecules per unit volume. The number of 
lanthanide ions were quantified by comparison to a standard solution of lanthanide 
ions of known concentration. Briefly, metal-labeled antibodies were diluted 1:1,000 
from their stock concentrations into 2% HCl, followed by two subsequent 1:1,000 
dilutions into 2% HNO3 for a total dilution factor of 1:10,000. Lanthanide standard 
solutions were prepared in 2% HNO3 to a final concentration of 50pM. Solutions 
were sequentially flowed into the CyTOF2 mass cytometer and data was acquired 
for all metal channels simultaneously in “solution mode” using the following 
parameters: step value = 1, settling time = 20 s, pushes / reading = 76,800. The 
steady signal resulting from the lanthanide standard was used to calculate the 
lanthanide atom concentration in the diluted antibody sample (see Appendix C, 
Table C1).  
5.2.3 Didodecyl-DTPA-Tb Synthesis and Metallation 
DDD-Tb was synthesized as reported by Leipold and co-workers, using 
99.9% pure terbium chloride (aq.) rather than the reported europium chloride 
(aq.).143 Briefly, diethylenetriamine pentaacetic acid dianhydride (1.5 g, 4.2 mmol) 
was dissolved in DMF (75 mL) and maintained at 40ºC. Dodecan-1-amine (2.2 g, 





stirred overnight. The solid product was collected via filtration and resuspended in 
ultrapure H2O (100 mL) containing minimal NaOH (1 M, 10 mL) to solubilize the 
solid.  The resulting solution was lyophilized, then resuspended in CHCl3 (70 mL) 
and filtered to remove excess NaOH. The solid was dried under reduced pressure 
to afford the tri-sodium didodecyl-DTPA salt (2.4 g, 301 µmol, 77 % yield). Matrix-
assisted laser desorption / ionization – mass spectrometry (MALDI-MS, positive 
reflectron mode, αCHCA matrix with 0.1% TFA) (m/z): [M+3Na-H]+ calculated for 
C38H73N5O8Na3, 797.00; found 796.62. Electrospray ionization – mass 
spectrometry (ESI-MS, negative mode) (m/z): [M+H]- calculated for C38H70N5O8, 
725.0; found 724.9. 1H NMR (400 MHz, D2O): δ 3.7-2.9 (m, br, 18 H, CH2), 1.22 
(m, br, 44 H, CH2), 0.79 (t, 6 H, J = 5.6 Hz, CH3). 
Didodecyl-DTPA-3Na ligand (200 mg, 252 µmol) was dissolved in 25 mM 
aqueous TbCl3 (141 mg, 378 µmol) and left at room temperature for 15 minutes. 
The solution was lyophilized and excess TbCl3 was removed using a CHCl3 
extraction resulting in the metallated DDD-Tb ligand (200 mg, 227 µmol, 90% 
yield). DDD-Tb was dissolved to 0.2 mM in aqueous 50 mM NaCl and filtered 
through a 0.2 µm PTFE filter.   
5.2.4 Organelle Isolation and Immunolabeling 
Female C57BL/6 mice were obtained from Jackson Laboratories or the 
National Institute on Aging. Mice were euthanized with sodium pentobarbital (200 
mg/kg body mass, ip) followed by tissue dissection. All tissues were stored on ice 
or at 4°C throughout organelle sample preparation unless otherwise noted. All 
protocols were approved by the Institutional Animal Care and Use Committee at 
the University of Minnesota (protocol # 1602-33497A). 
Organelles were isolated from tissues of interest (brain, hind limb skeletal 
muscle, and liver) using procedures adapted from Chinopoulos or Frezza.144-145 
Brain tissue was dissected and placed into MSEGTA-BSA buffer. The tissue was 
homogenized using a Potter-Elvehjem homogenizer (Wheaton, Millville, NJ) and 
stroked ten times at 1,600 r.p.m. The homogenate was transferred to clean 





supernatant was transferred to clean micro-centrifuge tubes as the post-nuclear 
fraction and centrifuged at 14,000 × g for 10 minutes. The pelleted organelle 
fraction is resuspended in 12% Percoll – MSEGTA buffer, layered over 24% 
Percoll – MSEGTA, and centrifuged for 16,100 × g for 25 minutes. The resulting 
sample had two opaque layers sandwiching a clear band. The top two portions of 
the sample were removed, and the opaque bottom layer was washed twice with 
MSEGTA buffer producing a visible organelle pellet after the final wash. 
Dissected liver was transferred to IBL. The tissue was rinsed with IBL until free 
of blood, then minced in a petri dish with a flat razor blade. The minced tissue was 
homogenized using a Potter-Elvehjem homogenizer stroked four times at 1,600 
r.p.m. The homogenate was transferred to clean microcentrifuge tubes and 
centrifuged at 600 × g for 10 minutes. The cloudy supernatant was transferred to 
clean microcentrifuge tubes as the post-nuclear fraction and centrifuged at 10,000 
× g for 10 minutes. The resulting organelle pellet was washed once with IBL 
producing a final organelle pellet. 
Dissected hind limb skeletal muscle was transferred to PBS containing 10 
mM EDTA. Visible tendons, connective tissue and fat were trimmed, and tissue 
was minced using a flat razor blade on a petri dish, then rinsed with PBS containing 
10 mM EDTA. Minced muscle tissue was enzymatically digested (0.05% trypsin, 
10 mM EDTA) for 30-45 minutes at 37°C. Following digestion, tissue was 
centrifuged at 200 × g for 5 minutes and resuspended in IBm1. The tissue was 
homogenized using a Dounce homogenizer. Each sample was stroked 10 times 
with pestle A (clearance: 0.114 ± 0.025mm), followed by 10 strokes with pestle B 
(clearance: 0.05 ± 0.025mm). The homogenate was transferred to microcentrifuge 
tubes and centrifuged at 600 × g for 10 minutes. The resulting cloudy supernatant 
was transferred to clean microcentrifuge tubes as the post-nuclear fraction and 
centrifuged at 10,000 × g for 10 minutes. The resulting organelle pellet was 
resuspended in IBm2, and centrifuged at 10,000 × g for 10 minutes, producing a 





The organelle pellet for each tissue was resuspended in IBL and aliquoted to 
obtain samples with similar opacity. Each sample was washed once with IBL, then 
stained with antibodies in CSM for one hour at room temperature. Organelles were 
washed twice with CSM and resuspended in 4% formaldehyde for 30 minutes at 
room temperature. Fixed organelles were washed twice with PBS, then 
resuspended in 0.2 mg/mL DDD-Tb in 0.09% NaCl for 30 minutes at room 
temperature. Organelles were washed twice with PBS supplemented with 0.05% 
Tween-20 and resuspended in Maxpar Fix & Perm Buffer containing 63 nM Cell-
ID Intercalator-Ir for 24 hours. Prior to data acquisition, organelles were washed 
twice with CSM, and twice with ultrapure water. 
5.2.5 Mass Cytometry Data Acquisition and Pre-processing 
Data was acquired on a CyTOF2 mass cytometer (Fluidigm, San Francisco, 
CA). Samples were diluted 1:106 in a solution of 1× EQ Four Element Calibration 
Beads in ultrapure water to attain an event detection rate of approximately 300 
events / second. Organelle event data was acquired using the following instrument 
parameters: noise reduction, cell length = 10-150, lower convolution threshold = 
0.2. To define a blank for each sample, the 1:106 diluted organelle suspension was 
filtered through a 0.2 µm polycarbonate filter to remove intact organelles. The 
resulting filtrate was analyzed in solution mode using the following parameters: 
step value = 1, settling time = 20 s, pushes / reading = 50. Intra-assay precision 
was assessed via technical replicates and showed detected event signal intensity 
was relatively stable in each monitored mass channel over thirteen hours of data 
acquisition (see Appendix C, Figure C1). 
5.2.6 Mass Cytometry Data Analysis 
Threshold values for signal above sample matrix noise for each monitored 
mass channel were calculated for each sample as the mean signal in a given 
channel plus three times the standard deviation (see Appendix C, Figure C2 and 





identifying phenotypically distinct organelle populations (see Appendix C, Figure 
C3, red bars). 
The number of ions associated with each organelle event (# ionsAb) was 
calculated using the equation below, where DCAb represents the dual count signal 
of the antibody chelating a unique lanthanide isotope, defined as m. TEm is the 
empirically determined transmission efficiency of unique lanthanide isotope m for 
the CyTOF2 at the University of Minnesota. 
DCAb
TEm
 = # ionsAb                                   Equation 5.1 
Then, the number of each unique antibody present per organelle (# Ab per 
organelle) was calculated using a correction factor via the following equation. 
# ionsAb
correction factor
 = # Ab per organelle            Equation 5.2   
The correction factor describes the number of lanthanide ions chelated to each 
antibody (listed in Table C1). This calculation was carried out for all antibodies, 
regardless of specificity. Organelle suspensions were stained with host-matched, 
isotype control antibodies, each chelating a unique lanthanide isotope, to estimate 
the non-specific binding proper-ties of each specific marker antibody. To obtain 
specific marker signal (corrected # specific Ab), the number of isotype antibodies 
per organelle (# isotype Ab) was subtracted from the number of specific antibodies 
per organelle (# specific Ab), using the following expression. 
# specific antibodies		-  # non-specific antibodies	=		corrected # of specific antibodies 
Equation 5.3 
Where appropriate, the corrected # of specific antibodies was normalized to the 
number of DDD-Tb molecules pre-sent in each organelle (corrected # specific Ab 
per organelle). This was done using the following equation, where DCDDD-Tb is the 
dual count signal measured for the DDD-Tb mass channel and TE159Tb is the 
empirically derived trans-mission efficiency specific to the 159Tb mass channel.	 
 
corrected # of specific Ab
*DCDDD-Tb TE159Tb+ ,






t-SNE analysis was done using the Rtsne package in the R statistical 
programming environment. The following parameters were used: perplexity = 20, 
ϴ = 0.5, maximum iterations = 5,000, and eta = 10, resulting in a set of two-
dimensional coordinates for each organelle used to plot clusters of individual 
organelles in two-dimensional space. Distributions for each relevant marker in a 
phenotypically identified population of organelles were binned into deciles. 
Coloring of the individual organelles in each t-SNE plot indicate the decile in which 
a given organelle falls. 
 
 Results and Discussion 
5.3.1 Individual Organelle Detection via Didodecyl-DTPA-Tb Ligand 
As discussed in Chapter 2, mass cytometry analysis of whole cells requires 
a diagnostic signal that distinguishes intact particles from debris and triggers mass 
spectra integration. In the case of whole cells, this is accomplished through the 
use of pentamethylcyclopentadienyl-Ir(III)-dipyridophenazine (Figure 5.1a). The 
generic identification of organelles by mass cytometry makes use of a didodecyl-
diethylenetriaminepentaacetic acid (DTPA) ligand chelating 159Tb3+ (DDD-Tb, 
Figure 5.1b). The long alkyl chains of DDD-Tb are incorporated into lipid 
bilayers,146 making it an ideal reagent to label organelle membranes for mass 
cytometry analysis. A variation of the reagent was first described for use in mass 






















Figure 5.1 Structure and function of event identification ligands. (a) Structure of 
pentamethylcyclopentadienyl-Ir(III)-dipyridophenazine, a cell identification reagent commonly used 
in whole cell mass cytometry experiments. The planar aromatic portion of the ligand inserts into 
DNA base pairs with a low dissociation constant afforded through highly favorable electrostatic 
interactions, providing a stable measure of DNA per cell. Reprinted with permission from Schäfer.57 
(b) Structure of DDD-Tb, a general membrane stain used in this study to identify organelles. The 
long alkyl chains of DDD-Tb intercalate into lipid membranes providing an identifying signal for 
intact organelles. (c) Rain plot showing low background between two detected organelle events, n 
= 29,858 organelle events. The y-axis identifies the spectra (in sequence) over which detected 
organelle event signals are integrated. The x-axis shows the relevant m/z channel, 159Tb. Dark lines 
in the plot area indicate detected 159Tb3+ ions. 
To define signals of organelle events a background signal was obtained by 
mass spectrometric analysis of filtrates resulting from filtering organelle 
suspensions through a 0.2-µm polycarbonate membrane (see Appendix C, Figure 
C2). Thus, the filtrate is devoid of organelles (>0.2-µm), the resulting signal plus 3 
times the standard deviation was used as an organelle event identification 
threshold (see Appendix C, Table C2). We also sought to understand how 
organelle aggregates, detected as single events, would affect the results. Mass 
spectrometric analysis of filtrates of an organelle suspension filtered through 8.0- 
or 1.2-µm polycarbonate membranes, did not affect the modes of the DDD-Tb 
signal distributions (Figure 5.2a). Also, a QQ-plot comparison of the 8.0-µm filtered 
and unfiltered distribution show almost no variation (Figure 5.2b), indicating that 



















represent the detection of individual organelles. Autophagy-related organelles 
regularly fuse during the autophagy process, thus absolute autophagy-related 
organelle sizes will vary and likely be larger than that of the individual organelle 
alone. 
 
Figure 5.2 Individual Organelle Detection via Mass Cytometry. (a) Distributions of organelle 
frequency vs DDD-Tb dual count (DC) signal obtained after filtration through polycarbonate filters. 
The similarity in the mode of DC signal (unfiltered: 294 ± 2.5 dual counts, 8.0 µm: 323 ± 4 dual 
counts, 1.2 µm: 287 ± 4 dual counts), indicates that detected events represent are likely individual 
organelles rather than aggregated organelles. (b) QQ-plot comparing the DDD-Tb distributions of 
0.1-, 1.2-, 8.0-µm filtered or unfiltered samples. The adherence of the 8.0-µm trace to an y = x line 
indicates the detection of organelles <8.0-µm as individual organelles. 
 
5.3.2 Identification of Phenotypically Separate Organelle types via Antibodies in 
Multiple Tissues 
Autophagy progression involves various organelle types. Here, these 
organelle types were identified by the unique pattern of antibodies bound to each 
organelle. Notably, autophagosomes and phagophores were detected through the 
binding of anti-LC3 antibodies and lysosomes were detected through the binding 
of anti-LAMP2 antibodies (see Appendix C, Figure C3). These organelle types 
made up 6% and 46% of the total number of phenotyped organelle events, from 
murine brain (Figure 5.3). That is, their relative number abundance was ~ 1:8. The 
only surrogate for comparisons of relative abundance of organelles found in the 
literature were cross-sections in TEM images of murine brain, which showed 
autophagosomal vacuoles and lysosomes, occupying 0.8 and 3.3% of the 
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While the relative abundance in this source and our data show the same trend, the 
remarkable feature of the mass cytometric results is the ability to deepen the 
classification of organelles detected, including autolysosomes (6%) and 
autolysosomes with mitochondrial association (4%), (Figure 5.3). Association 
between autolysosomes with their cargo (e.g. mitochondria) is critical to assess 
selective forms of autophagy (e.g. mitophagy) and to uncover their roles in 
biological systems. 
 
Figure 5.3 Phenotypically identified autophagy organelle populations via Mass Cytometry. 
Phenotypically identified organelles can be assigned to the unique organelles which make up the 
autophagy process. The percentage of each identified organelle type that participates in either 
macroautophagy or mitophagy in brain tissue is shown (see Appendix C, figure C4 for 
corresponding analysis of liver and skeletal muscle tissue). 
 
Mass cytometry measurements allows for the calculation of the number of 
antibodies of each type bound to each organelle (equation 5.1-2 and Figure 5.4). 
Taking the number of DDD-Tb molecules per organelle as an indicator of relative 
total membrane volume, the number of antibodies of each type per organelle, 
normalized by membrane volume provide additional insight into autophagy 
progression. Whether monitoring the LAMP marker (lysosome → autolysosome, 
Figure 5.4a), TOM22 marker (mitochondria → mitochondria associated with the 






































or LC3 marker (autophagosome, phagophore → autolysosome, Figure 5.4c), the 
relative abundance of each marker decreases with autophagy progression, 
supporting a general increase of membrane content with a consistent number of 
markers per organelle. This decrease displays different rates for brain (B), liver (L), 
and muscle (M) (Figure 5.4), which may indicate custom responses to tissue-
specific, autophagy-relevant stimuli such as nutrient availability. For LAMP2+ 
organelles (lysosomes, Figure 5.4a), the number of normalized LAMP2 tags per 
event is lower for LC3+-LAMP2+ organelles representing autolysosomes (auto-
lyso) and auto-lyso-mito events relative to lysosomes. This trend is less 
pronounced in organelles from liver. For TOMM22+ organelles (mitochondria, 
Figure 5.4b), the number of normalized TOM22 tags per event was lower for dual-
positive LC3+-TOMM22+ organelles representing autophagosomes associated 
with mitochondria (auto-mito), and even lower for triple positive LC3+-LAMP2+-
TOMM22+ organelles representing autolysosomes associated with mitochondria 
(auto-lyso-mito). This may be the result of an increase of lipid-rich membrane 
stained with DDD-Tb as multiple organelles associate, but the unchanging 
abundance of TOMM22 proteins per organelle. For LC3+ organelles 
(phagophores, autophagosomes and autolysosomes, Figure 5.4c), the number of 
normalized LC3 tags is higher for autophagy organelles prior the association with 
lysosomes (auto-lyso), or mitochondria (auto-mito and auto-lyso-mito). It is worth 
noticing that the normalized abundance of LC3 tags is higher for auto-mito 
suggesting that a more extensive LC3-decorated membrane is required for 
processing mitochondria (mitophagy) than for other forms of autophagy. Thus, 
comparison of the number of specific markers between organelle types is a 
quantitative measure of autophagy progression in each tissue type (see Appendix 







Figure 5.4 Normalized number of antibody tags per detected autophagy organelle. The number of 
specific marker antibodies per organelle was calculated and normalized by DDD-Tb abundance and then each 
marker was compared across phenotypically unique organelle populations from the same sample and across 
biological replicates. The number of specific antibodies varies across tissue but is consistent across biological 
replicates. See Appendix C, Figure C5 for non-normalized count of antibodies bound per organelle. Error 
represented as 95% confidence intervals of the median. B = brain, L = liver, M = skeletal muscle, R1 = 































































5.3.3 Multiplexed Analysis of Organelle Interactions 
The true power of multi-parameter individual organelle analysis lies in the 
ability to detect heterogeneity in phenotypically identified organelle populations. 
Because organelles often traverse entire biochemical pathways, organelle 
heterogeneity may influence individual cell heterogeneity through significant 
changes in function. For example, heterogeneous changes in intracellular 
mitochondrial membrane potential have been associated with dysregulated gene 
expression of MFN1, MFN2 and OPA1 which normally facilitate mitochondrial 
fusion events. The dysregulation of these genes has been associated with a 
number of neurodegenerative diseases.149-151 In order to assess inter-population 
organelle heterogeneity, organelles were clustered using the t-SNE algorithm,152 
such that organelles containing similar normalized levels of each antibody type, 
were close to one another in high-dimensional space. Based on relative cluster 
position, two dimensional coordinates are assigned to each organelle allowing for 
the two-dimensional projection of multi-dimensional data (Figure 5.5). Each 
column represents the two-dimensional projection of a given marker, while each 
row represents different combinations of organelle specific markers. Panels for 
triple positive organelles (Figure 5.5, first row) represent autolysosomes engaged 
in mitophagy. The second row of panels represent autophagosomes enveloping 
mitochondria, while the third row of panels represent autolysosomes sans 
mitochondria.  The large variation in color (heat map) of each panel is indicative of 
inter-population heterogeneity. As expected, it is evident that even phenotypically 
similar organelles are not identical. Subpopulations of autolysosomes (Figure 5.5, 
third row) show fairly low heterogeneity as the decile classification for each marker 
is relatively similar (green dashed circles). This is not necessarily the case for the 
autophagosomes enveloping mitochondria (Figure 5, second row). The circled 
subpopulation indicates a relatively high abundance of the autophagosome marker 
LC3, but moderate abundance of TOMM22, a marker for mitochondria. The 
relative size of this subpopulation is very heterogeneous as indicated by the wide 





particular subpopulation is a collection of autophagosomes at distinct points of 
closure around mitochondria. This same reasoning could be employed in the 
analysis of autophagosomes engaged in mitophagy (Figure 5.5, first row), in that 
the large variation in the circled subpopulation could represent different stages of 
degradation of mitochondria and release of LC3. 
 
Figure 5.5 Two-dimensional cluster analysis of heterogeneous autophagy organelle sub-populations. 
t-SNE plots from brain tissue show phenotypically identified populations of organelles. Distributions of specific 
markers on individual organelles were binned into deciles and color-coded according to their assigned decile. 
Wide variation in color across specific markers in t-SNE plots indicate heterogeneous sub-populations 
(dashes), which may have significantly different function (see Appendix C, Figure C6 for analysis of liver and 
Figure C7 for analysis of skeletal muscle tissue). 
 
 Conclusions 
Further analysis of these heterogeneous organelle populations will be 
possible using an expanded antibody panel to include other markers of 
macroautophagy and mitophagy such as the ubiquitous nucleoporin p62, PTEN-
induced putative kinase 1, and Parkin. This type of high-dimensional individual 
organelle analysis could illuminate functional, morphological or phenotypic 
variation that drive disease development. This analysis used 6 of nearly 50 
available mass channels, leaving room for many additional markers. We expect 

























































































































































































































































The main outcomes of the work described in this thesis include the 
development of methods to i) correct for non-specific antibody binding in mass 
cytometry analyses enabling the measurement of autophagy flux in individual 
differentiating myoblasts, ii) measure autophagy flux in phenotypically identified 
cell subsets from skeletal muscle via mass cytometry, and iii) a method for the 
detection and characterization of individual autophagy-related organelles via mass 
cytometry.  
In Chapter 3, we report a method for measuring autophagy flux in 
differentiating myoblasts made possible through identification of appropriate 
autophagy-related antibody staining concentrations. Optimization of autophagy-
related antibody staining concentrations through post-hoc processing of titration 
data corrected for non-specific antibody binding and total antibody loading. Using 
the optimized antibody staining concentrations, we measured autophagy flux in an 
asynchronous culture of differentiating myoblasts. We found that autophagy is 
upregulated during mid-to-late differentiation as differentiating myoblasts fuse to 
one another or pre-existing myotubes and drops off as myotubes are formed. 
However, mitophagy flux increases earlier in the myogenic program, and persists 
past fusion through the formation of myotubes. This method is useful to identifying 
the point in myogenic lineage during which autophagy flux is required. One 
limitation of the method is the low cellular abundance of useful phenotypic and 
autophagy-related markers; improvements to the available mass cytometry 
reagent to address this limitation are described in Chapter 7.  
In Chapter 4, we describe a method to measure autophagy flux in 
phenotypically identified mononuclear cells from murine skeletal muscle. We found 
that the satellite cell populations are significantly reduced in geriatric skeletal 
muscle, but no age-related correlation existed between the pro- or anti-
inflammatory macrophages or fibroadipogenic progenitor cells. Autophagy flux 
was simultaneously quantified in each cell type. We found that autophagy flux is 
unaffected by age in anti-inflammatory macrophages. Conversely, we found that 





from geriatric muscle. Interestingly, while autophagy flux was attenuated in both of 
these cell types, autophagy signalling (via p62) seemed to be intact in satellite 
cells. This work represents the first single cell analysis of autophagy flux 
fibroadipogenic progenitor cells and muscle-resident macrophages. Application of 
this method to additional biological replicates to validate our initial observations will 
provide insight into the observed decrease in autophagy flux reported at the bulk 
tissue level. One limitation of this method is the inability to relate cellular target 
abundance to function; one way to address this issue is to design mass cytometry 
compatible probes that report on function or specific protein activity as described 
in Chapter 7. 
In Chapter 5, we describe a method for the detection and characterization of 
individual autophagy-related organelles from multiple tissue types via mass 
cytometry. This is made possible through the use of a lipid-intercalating, lanthanide 
chelating reagent and phenotypic antibodies. Due to the quantitative nature of 
mass cytometry detection, we were able to quantify the number of antibodies 
bound per organelle. We found extensive inter- and intra-population heterogeneity 
within and across tissue types. This tool will be useful in future studies 
characterizing organelle-organelle interactions. We recognized two limitations to 
this method. First, the low abundance of some cellular targets on individual 
organelles limits the range of possible biological questions that could be probed, 
though as mentioned above this is addressed in Chapter 7. Second, the availability 
of reliable antibodies against autophagy-related organelles is quite low. Chapter 7 
describes a selection of aptamers specific to autophagosomes for their specific 
detection. In addition, Chapter 7 also describes the synthesis of a novel small 
molecule for the functional labelling of mitochondria for individual organelle 
analyses via mass cytometry. 
Overall, the work described in this thesis represent the development of new 
methods for the measurement of autophagy flux via mass cytometry. Further 
development of these methods to include additional relevant autophagy-related 





understanding of the contribution dysregulated autophagy plays in the 
development of age-related muscle mass and functional decline. The insight 
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Current limitations to the comprehensive analysis of autophagy flux in skeletal 
muscle via mass cytometry include inadequate sensitivity for low abundance 
cellular targets and morphological constraints of cells. The sensitivity of mass 
cytometry analyses is limited by inherent design of biological reporters. 
Specifically, the relatively low number of lanthanide ions chelated per antibody 
limits analyses to cellular targets that are in high abundance in each cell, and the 
unavailability of reliable antibodies for each cellular target of interest limits the 
range of most studies involving autophagy. The analyses presented in each 
chapter of this work could be enhanced by the addition of other low abundance 
markers of selective autophagy processes. The method describing the analysis of 
individual organelles by mass cytometry (see Chapter 5) is also limited by the 
relatively low abundance of cellular targets per organelle but has the added 
conundrum of non-unique phenotypic cellular targets. For instance, detection of 
autophagy-related organelles via metal-labelled anti-LC3 antibodies will provide 
data encompassing all autophagy organelles labelled with LC3-II (i.e. phagophore, 
autophagosomes, autolysosomes), regardless of their unique function.  
Morphological constraints on cells for mass cytometry analysis originate with 
the design of the instrument which affect the delivery of large and non-spherical 
cells to the ICP torch. While chapters 3 and 4 describe autophagy flux in a variety 
of cell types involved in myogenesis and the maintenance of skeletal muscle via 
mass cytometry, monitoring autophagy flux in other important cell types such as 
segments of muscle fibers is currently hindered by the unique morphology of these 
multi-nucleated, cylindrical cells. The future work described here will focus on both 
available labelling reagents to address the issues for quantifying autophagy flux 
using mass cytometry at the individual cell or organelle level and improvements to 





 Improving Available Mass Cytometry Reagents 
Available mass cytometry reagents can be categorized by function into two 
main categories, intact cell identification and biological reporters. 
Metallointercalators are an example of an intact cell identification reagent, which 
works towards identification of intact cells via intense, detectable signal in 
individual cells after intercalation into dsDNA. Antibodies labelled with MCPs are 
an example of a biological reporter, which report on the biological phenotype or 
function of a given cell or organelle. As described in Chapter 2, metal chelating 
polymers commonly used in mass cytometry are composed of a linear polymer 
backbone decorated with multidentate polyaminocarboxylates, such as 
diethylenetriaminepentaacetic acid (DTPA), which coordinate lanthanide ions with 
relatively low dissociation constants (Kd = 10-16).53 The polymer is covalently bound 
to an antibody though a maleimide linker which reacts with sulfhydryl groups 
produced by reducing disulfide bonds within the Fc portion of the antibody50 (see 
Figure 2.5). Each antibody can bind four to five polymers each containing about 
30 lanthanide atoms each, for an average of 120-160 reporter ions per antibody.153 
A main limitation in quantifying autophagic flux is a lack of unique markers for 
each type organelle involved in the cellular process. With nearly 30 known ATG 
proteins, the variety of proteins expressed at each step of the autophagic process 
is astonishing, but with some organelles containing many of these proteins 
constitutively, it is difficult to unambiguously identify each organelle 
simultaneously.154 Table 7.1 shows that some organelles uniquely express a target 
protein that can be detected using antibodies as a selective marker in quantitative 
Table 7.1. Unique target proteins for autophagy organelles. A lack of unique target proteins for 
autophagy organelles complicates the analysis of autophagy flux.  
 
Autophagy Organelle of Interest Unique Target Protein 
Phagophore LC3-II 
Autophagosome LC3-II 








assays. Conversely, autophagosomes and phagophores lack uniquely expressed 
proteins, making them difficult to specifically observe. As described in Chapter 2, 
LC3 detected in individual cells using commercially available antibodies can be 
attributed to either organelles (LC3-II) or unprocessed, cytosolic protein (LC3-I). 
For these reasons, improvements to lanthanide chelating molecules and 
specificity conferring reagents would drastically improve the analyses of 
autophagy flux via mass cytometry.  
7.1.1 Development of Dendrimers for Improving Technique Sensitivity 
The main limitation of the currently available linear lanthanide loaded polymer 
is the possibility of false negatives for low abundance cellular targets such as the 
transcription factor Pax7 used in Chapter 3, and most targets found on individual 
organelles analysed in Chapter 5. Due to the relatively low number of lanthanide 
atoms associated with each antibody, low abundance cellular targets (< 5,000 
copies/cell) may not be effectively sampled by the ICP-TOF-MS leading to a false 
negative result. This is due to the low number of ions that successfully navigate 
the three-aperture interface that serves to sample only the middle of the ion beam 
exiting the ICP torch.42, 153 Two approaches to resolve this problem include: i) 
improve the limit of detection for the ICP-TOF-MS by major hardware 
improvements, or ii) chelate more lanthanide atoms per polymer. Improvements to 
lanthanide chelating polymers would need to increase the number of chelated 
lanthanide ions between 7-9 fold to achieve limits of detection similar to flow 
cytometry.155  
 
Extending the length of the commonly used linear polymer50 to add additional 
DTPA-containing monomers is a possibility, but other challenges arise when an 
extremely long tail-like polymer is able to wrap around the antibody and interfere 
with the specificity-conferring hypervariable region.156 Lanthanide ion nanocrystals 
were recently reported157-158 as mass tags for improved sensitivity in mass 





the number of lanthanide ions per antibody, improving sensitivity, the wide 
distribution in the number of lanthanide ions per nanocrystal is not suitable for 
analytical analysis of cellular target abundance. A more efficient and controlled 
method of increasing the number of lanthanide atoms chelated per antibody 
without interfering with cellular target binding is to synthesize a metallo-dendrimer 
with a globular macrostructure that can be tethered to the non-variable region via 
a relatively short carbon chain. 
Synthetically derived dendrimers are generally described as containing a 
central core with radially stemming monomers, often creating large tree-like 
macrostructures.159 The overall structure of a dendrimer can be described as 
having three separate regions: the core, the interior (branches), and the periphery 







Figure 7.1. Schematic of G3 dendrimer scaffold. Each generation is shown in a different layer with dotted 
lines showing branch points. Figure modified with permission from Lee. 160 
 
The number of points at which the interior structure branches defines the 
generation (G1, G2, G3). The step-wise synthesis of dendrimers result in 
theoretically mono-disperse synthesis, as opposed to statistically controlled 
synthesis typically used for linear polymers. The final size of the dendrimer is 
ultimately governed by the lack of three-dimensional space available for further 
growth.160 Metallo-dendrimers have been reported161-162 with a number of different 









periphery, scattered throughout the interior branches, or a combination of all 
three.159 In order to increase the sensitivity of mass cytometry, a maximum number 
of lanthanide atoms would need to fit into each dendrimer.  
 
In collaboration with Dr. Valerie Pierre and Dr. Evan Weitz, a lanthanide 
containing dendrimer we have designed a synthetic plan to produce a dendrimer 
capable of chelating 1,093 lanthanide reporter ions in six generations. The 
synthesis will be accomplished in four synthetic schemes. To date, attempts to 
complete this synthetic plan have produced products in low yield hindering 
progress. These issues are addressed in the “Improvements for synthetic 
schemes” sub-heading of this section (see page 99). 
 
In short, this synthetic plan describes a divergent dendrimer synthesis. Three 
separate schemes will provide three unique macrocycles (CORE, MONOMER A, 
and MONOMER B) bearing four pendant arms in a 1:3 ratio. The core macrocycle 
will be used as a scaffold to which Monomers A and B will be added in a stepwise 
fashion to assemble the macrostructure. To minimize the number of synthetic 
steps needed to attach each subsequent shell of monomer, a two-step 
deprotection-reaction scheme will be used. The reaction is based on the original 
1,3-Huisgen cycloaddition “click” chemistry, which consists of a Cu(I)-catalyzed 
alkyne azide [3 + 2] cycloaddition (CuAAC) to form a 1,4-disubstituted 1,2,3-
triazole group.163 There are many practical advantageous characteristics of the 
CuAAC reaction in the context of dendrimer construction, including quantitative 




In each scheme, a common synthetic method is used to install pendant arms 
on each nitrogen of 1,4,7,10-tetraazacyclododecane (cyclen). The common 





bromoacetamide, whose substitution on each of the nitrogens of cyclen forms an 
appropriate lanthanide chelating environment. Each pendant arm contains an alkyl 
chain terminated with a primary amine, which forms the α-bromoacetamide after 
reaction with bromoacetyl bromide. Another common theme in each monomer 
synthesis one unique arm and three identical others. Each monomer is first mono-
substituted with one pendant arm165 and then exhaustively alkylated to yield a fully-
substituted DOTA-tetramide ligand. The second alkylation is accomplished by 
reacting one equivalent of the mono-substituted cyclen with an excess of the 
second pendant arm. As shown in the following sections, the monomer arm 
composition changes for each monomer, but all arm installations follow a common 
reaction pathway. 
 
Dendrimer Core (Scheme 7.1) 
 The first pendant arm of the dendrimer core contains a 3400 MW 
polyethylene glycol (PEG) moiety that will serve as an attachment point when the 
completed dendrimer is conjugated to a specificity conferring reagent. This tether 
is attached to the core to take advantage of the selectivity afforded by a single 
attachment point. Specifically, a commercially available 3400 MW PEG, 
terminated with an Fmoc-protected amine on one side and carboxylic acid on the 
other side (CORE-2), will be coupled to UV-active 2-(9,10-dioxo)anthrylmethyl 
group to yield a an ester (CORE-3). The resulting pendant arm is UV-active to aid 





Scheme 7.1. Synthesis of dendrimer core. Reagents and conditions: (a) MOM, SOCl2, DMSO; (b) 
piperidine, CH2Cl2; (c) bromoacetyl bromide, K2CO3, CH2Cl2, H2O; (d) bromoacetyl bromide, K2CO3, CH2Cl2, 
H2O; (e) CORE-6, K2CO3, MeCN. 
 
will be used following reports that the anthrylmethyl moiety is stable to TFA.166 This 
functionalization will be done using thionyl chloride in DMSO which should quickly 
and efficiently yield the ester through an acid chloride intermediate. If the thionyl 
chloride coupling conditions are found to affect the functionality of the Fmoc-





HOBT/HBTU will be used. Following purification and characterization, the Fmoc-
protected amine will be deprotected using piperidine (CORE-4) and reacted with 
bromoacetyl bromide to yield the heterobifunctionalized PEG pendant arm (CORE-
5). As previously described, this pendant arm will be mono-substituted on cyclen 
(CORE-6). The second arm on the dendrimer core will be an alkyl azide, achieved 
by reacting the commercially available 5-azidopentan-1-amine (CORE-7) with 
bromoacetyl bromide to yield the completed azide pendant arm (CORE-8). Should 
it be needed, flash chromatography will be used to purify the completed arm. The 
azide arm will then be mono-substituted onto the mono-substituted cyclen (CORE-
6) to yield the fully-alkylated DOTA-tetramide core (CORE-1). The resulting 
completed dendrimer core will be purified by size exclusion chromatography 
(SEC), and characterized using 1H and 13C NMR, and high resolution ESI-MS.  
 
Monomer A (Scheme 7.2) 
Completed Monomer A (A-1, Scheme 8.2) will be reacted with the 
synthesized CORE-1 product (Scheme 8.1) resulting in a G1 dendrimer. 
Therefore, a pendant arm with a terminal acetylene group is needed on A-1 to 
react with the azide functional arms of the dendrimer core (CORE-1) using “click” 
chemistry. This will be achieved by reacting commercially available 
propargylamine (A-2) with bromoacetyl bromide, to substitute the terminal amine 
with a bromoacetamide group yielding the completed propargylic pendant arm (A-
3). If needed, flash chromatography will be used to purify the resulting product. 
The propargyl arm will then be mono-substituted onto cyclen (A-4). The other 
pendant arm will be a heterobifunctional PEG, terminated by α-bromoacetamide 
on one end and BOC-protected terminal amine on the other (A-7). This molecule 
will be produced by a selective mono-protection of commercially available bis(3-
aminopropyl)diethylene glycol (A-5) with di-tert-butyl-dicarbonate (BOC2O). Mono-
BOC protection of a terminal amine will prevent a single PEG diamine substituting 
onto the cyclen ring in later synthetic steps. The product will be purified, if 





5) will then be functionalized with an α-bromoacetamide group, through treatment 
with bromoacetyl bromide (A-7) and purified with flash chromatography. The 
purified product will be used to fully alkylate the mono-substituted cyclen (A-4) to 
form the tetra-substituted DOTA-tetramide monomer (A-1). The monomer product 
(A-1) will then be purified by SEC. The final product as well as intermediates will 
be characterized by 1H and 13C NMR and high resolution ESI-MS. 
 
Scheme 7.2. Synthesis of monomer A. Reagents and conditions: (a) bromoacetyl bromide, K2CO3, CH2Cl2, 
H2O, 1 h; (b) Cyclen, Et3N, CHCl3, 60°C, 18 h; (c) BOC2O, CH2Cl2, 18 h; (d) bromoacetyl bromide, K2CO3, 
CH2Cl2, H2O, 1 h; (e) K2CO3, MeCN 60°C, 18h. 
Monomer B (Scheme 7.3) 
Of the four pendant arms on completed monomer B (B-1, Scheme 7.3), only 
one will react with the three terminal amine pendant arms on monomer A (A-1, 
Scheme 7.2). A carboxylic acid on completed monomer B (B-1), will react with the 
deprotected primary amine on monomer A (A-1) to form the amide. This pendant 
arm will be formed in four synthetic steps. First, the carboxylic acid of 6-(Fmoc-
amino) hexanoic acid (B-2) will be protected via Fischer esterification (B-3). 
Methoxy methanol (MOM) was chosen as a protective group due to its ease of 
installation and mild orthogonal deprotection reaction conditions (MgBr2, DMF). 





terminal amine (B-4), which will be subsequently treated with bromoacetylbromide 
to yield the completed arm (B-5). The completed arm will then be mono-substituted 
onto cyclen (B-6). The products and its preceding intermediates will be purified by 
flash chromatography, where needed. The remaining pendant arm will be the 
same azide arm synthesized and substituted onto cyclen in the dendrimer core 
scheme (CORE-8). The mono-substituted cyclen (B-6) from scheme 8.3 will be 
alkylated with the azide pendant arm (CORE-8), from scheme 1 to form the fully 
alkylated DOTA-tetraamide monomer B. Following purification by SEC, the final 
monomer will be characterized by 1H and 13C NMR and high resolution ESI-MS. 
 
Scheme 7.3. Synthesis of monomer B. Reagents and conditions: (a) MOM, H2SO4, H2O; (b) piperidine, 
CH2Cl2; (c) bromoacetyl bromide, K2CO3, CH2Cl2, H2O; (d) Cyclen, Et3N, CHCl3, 60°C, 18 h; (e) B-6, CORE-
9, K2CO3, MeCN; (f) MgBr2, DMF. 
 
Final Dendrimer Construction (Scheme 7.4) 
Once all three monomers are synthesized, the dendrimer can be assembled. 
Before beginning assembly, the choice must be made whether to chelate the 
lanthanides pre- or post-assembly. The ability to add the lanthanide post-assembly 





could be chelated by an empty polymer directly before use in mass cytometry, as 
is currently done. However, some dendrimer assembly reaction conditions require 
the use of tetrafluoroacetic acid (TFA), which could work to unseat a lanthanide 
from any of the DOTA tetraamides. Conversely, as the dendrimer is synthesized, 
each DOTA moiety becomes progressively more sterically hindered. This could 
result in difficult metallation, reducing the magnitude of the expected increase in 
sensitivity obtained by using a high lanthanide-capacity dendrimer. At this time, the 
more important characteristic to be assessed is the gain in sensitivity obtained 
when using this dendrimer scaffold. To that end, metalated monomers are 
preferable. 
To assemble the dendrimer, three distinct synthetic steps are performed 
(Scheme 7.4). First, one equivalent of the dendrimer core (CORE-1) and three 
equivalents of monomer A (A-1) will be reacted together in the presence of five 
equivalents of copper (I) ascorbate at an acidic pH. The resulting product, a G1 
dendrimer (FA-2) will then be purified by SEC. Following purification, the G1 
dendrimer will be subjected to standard TFA deprotection will remove the BOC-
protecting groups from the primary amines at the periphery of the molecule (FA-
3). In the second step, one equivalent of the product from the previous step, a 
deprotected G1 dendrimer (FA-3), will be added to three equivalents of monomer 
B (B-1) in standard amide coupling conditions, linking G1 and G2 (FA-4). The G2 
dendrimer will be purified using SEC. In the next step, one equivalent of the G2 
dendrimer (FA-4) formed in the 
previous step, will be reacted with 
three equivalents of monomer A 
(A-1) in the presence of copper (I) 
Figure 7.2. Simplified representation of 
synthesized metallodendrimer. Each shape 
represents a unique monomer (A or B 
synthesized in schemes 8.2 or 8.3, 
respectively) which chelates a single 
lanthanide ion. Assuming complete metallation 
of all monomers, the G3 dendrimer shown will 





ascorbate at an acidic pH. The resulting G3 dendrimer (FA-5) will then be purified 
by SEC. The G3 dendrimer with peripheral BOC-protected primary amines will 
then be subjected to standard TFA deprotection. The second and third steps are 
then repeated in order and as described, until the dendrimer is of desired size 
(Figure 8.2). Following final construction of the dendrimer the UV-active moiety 
from the exposed, tail end of the 3400 MW PEG will be cleaved to reveal a 










Scheme 7.4. Dendrimer Final Construction. Reagents and conditions: (a) Cu (I) Asc., pH 4.5, RT; (b) TFA, CH2Cl2, 0°C to RT; (c) EDCI, HOBt, (iPr)2, EtN, DMF; 
(d) Cu (I) Asc., pH 4.5, RT; (e) TFA, CH2Cl2, 0°C to RT. Azides on CORE-1 and B-1 will react with alkynes in A-1. Primary Amine revealed in FA-3 will react with 
carboxylic acids in B-1. A simplified depiction of the final product is shown in Figure 8.2. 
Step 1: Attach monomer A 





 Final characterization of the dendrimer will determine the total number of 
lanthanide ions chelated by each dendrimer. In addition, it will be important to 
understand how many dendrimers of a particular size can be conjugated to each 
specificity conferring reagent. The number of chelated lanthanides increases 
exponentially (Figure 7.3). If similar sensitivity can be achieved by labelling an 
antibody with a single G6 dendrimer (1,093 chelated lanthanides) or multiple G5 
dendrimers (364 chelated lanthanides) synthesis could be simplified.  
 
Figure 7.3. Exponential increase in chelated lanthanides with each generation. The synthetic goal was 
to chelate at least 1,000 lanthanide ions per polymer. In reality, the attachment of multiple, lower generation 
dendrimer could produce similar technique sensitivity and provide a less complicated synthesis. 
 
Improvements for Synthetic Schemes 
The designed dendrimer synthesis spans four schemes that are not 
synthetically trivial. Initial attempts at the synthesis of monomer A showed the 
monoprotection of bis(3-aminopropyl)diethylene glycol (Scheme 7.1, A-6) using 
BOC produced product in low yield (15%) with the di-protected species as the 
dominate product. To circumvent these issues, improvements can be made to the 
proposed schemes to take advantage of newly commercially available reagents 
such butyne-DOTA (Macrocyclics, Plano, TX), which would simplify the synthesis 




























(A-4) with the synthesized propargyl arm (A-3). The availability of carboxylic acids 
on DOTA also eliminates the need for the mono-functionalization of the bis(3-
aminopropyl)diethylene glycol, which we found was difficult to synthesize with high 
yield. In addition to the improvements to Scheme 7.1 described above, a recent 
report showed an improved method for covalently linking MCPs to specificity 
conferring reagents using strain-promoted copper-free azide–alkyne [3+2] 
cycloaddition chemistry (SPAAC) or tetrazine-strained alkene [4+2] inverse 
electron demand Diels–Alder cycloaddition to conjugate MCPs to specificity 
conferring molecules.167 The authors describe MCPs with a terminal azide or trans-
cyclooctene moieties, chelating 50 lanthanide ions per MCP. This method could 
be incorporated to the final dendrimer assembly, providing site-specific control 
during covalent linking to an antibody or other specificity conferring reagent. The 
inherent limitation to this approach lack of availability of cyclooctene or tetrazine 
moietites on most commercially available antibodies.  
The successful completion of this synthesis will yield a G6 dendrimer capable 
of chelating at least 1,093 lanthanide ions per molecule. Used as a mass tag for 
antibodies specific to low abundance cellular targets will unlock a new dimension 
biological inquiry probed using mass cytometry. Specifically, it will be possible to 
reliably measure low abundance transcription factors and post-translational 
modifications involved in myogenesis and autophagy flux, adding new dimensions 
to the analyses performed in Chapters 3 and 4. In addition, the use of lanthanide 
chelating dendrimers could improve the detection of individual organelles through 
the expansion of detectable targets that are too low in abundance on individual 
organelles.  
7.1.2 Development of Aptamers Against Autophagosomes 
Immuno-labelling via antibodies is frequently used to specifically label a 
cellular target of interest. In autophagy-related research an antibody against 
microtubule light chain 3 (LC3) is routinely used to specifically identify the presence 
of autophagy-related organelles, as was done in Chapters 3 through 5. Not only 





bound; see Chapter 2, Figure 2.17), autophagy proceeds through at least four 
functionally unique organelle types, all of which contain LC3-II protein. Therefore, 
immuno-labelling LC3 for individual cell or organelle analysis is insufficient for the 
elucidation of a fundamental understanding autophagy flux.  
In the case where a cellular target (i.e. an organelle) does not have a unique 
characteristic that can unambiguously identify it, alternate probes are needed. 
Aptamers are ssDNA or single stranded RNA oligonucleotides that fold in on 
themselves to form distinctive three-dimensional secondary structures that 
specifically bind unique surface characteristics of a desired target.168 Aptamer 
secondary structure is made up of common motifs, such as: hairpin stems and 
loops, bulges flanked by helical regions, pseudoknots, and G quartets. Generally, 
aptamers are 40-80 bp, with longer sequences able to form more complex 
secondary structures sometimes resulting in higher affinity products.169 Aptamers 
have been developed against whole cells without a particular surface target in 
mind.170. The same logic could be applied to the development of an aptamer 
specific to individual autophagy organelles. 
Functionally, antibodies and aptamers are similar in that both interact with 
specific substrates based on favorable electrostatic, H-bonding, and dipole-dipole 
interactions. The most favorable interactions occur between a target and ligand 
that have mirror image surface shapes and compatible charge distributions.171 A 
major morphological difference that distinguishes them from one another is the 
relative rigidity of oligonucleotides as compared to the hypervariable regions of 
antibodies. Of the functional groups that make up aptamers, only the ribose ring, 
phosphodiester and glyosidic bonds have any significant torsional mobility, with 
base pairing further restricting movement within aptamers. Therefore, during 
aptamer development poor conformational or unfavorable energetic fits to a target 
cannot be selected, due to rigidity of the structure. In this way, it is unlikely that an 
aptamer will be developed that has high affinity (Kd = 10-6 – 10-9)172 without having 
high specificity. In contrast, hypervariable regions of antibodies are comprised of 





the backbone and side chains more torsional mobility. A more flexible structure in 
antibody hypervariable region can result in less selective binding.171 
Aptamer sequences are selected from a large (1014) pool of ssDNA 
oligonucleotides via selective evolution of ligands by exponential enrichment 
(SELEX), first described by Tuerk173 and Ellington174 in 1990. In the case of 
Organelle-SELEX, a random library of about 1014 single stranded DNA sequences 
is first incubated with a suspension of organelles (Figure 7.4). A fractionation step 
follows where unbound oligonucleotides are removed, and the remaining target-
bound aptamers are amplified via a polymerase chain reaction (PCR). The PCR 
reaction produces many sequences with higher overall affinity for the target than 
the original DNA library. The SELEX process is iterative in that the new library is 








Figure 7.4. Schematic for Organelle-SELEX. An organelle population of interest is incubated with a library 
of ssDNA sequences, and unbound sequences are discarded. Bound sequences are collected and PCR 
amplified to produce a new DNA library more specific for the organelle of interest in subsequent rounds of 

























affinity for its target is assessed, with the number of rounds necessary for optimal 
affinity being reached as the dissociation constant (Kd) shows little change from 
round to round of selection.175 For organelle aptamer development, a specific outer 
membrane target does not need to be identified before selection, and in many 
cases, the ambiguity of the target makes selecting a high affinity aptamer specific 
to a cell or organelle type easier than a specific protein.175 However, Organelle-
SELEX should include round(s) of negative selection for contaminating organelles. 
Specifically, after exposing the ssDNA library to an organelle of interest and 
collecting bound sequences, the sequences should be subjected to a negative 
control population of organelles (i.e. contaminating).170 This is a round of selection 
where sequences that bind to contaminating organelles are discarded, and 
unbound sequences, specific to the organelle of interest are collected and 
subjected to PCR, thus in proving the specificity of the selected aptamer. 
A particularly challenging aspect of Organelle-SELEX is the preparation of 
phenotypically pure fractions of organelles. Commonly used methods for sub-
cellular fractionation, including differential centrifugation and density gradient 
centrifugation do not produce phenotypically pure fractions. This limitation can be 
overcome in two ways, i) increasing the abundance of the organelle of interest in 
cells before isolation, and ii) the use of individual organelle sorting via fluorescence 
activated sorting (FACS)176. In an attempt to increase the number of 
autophagosomes present in cells prior to organelle isolation, we subjected C2C12 
myoblasts to nutrient depravation conditions for 1 hour to increase cellular 
autophagosome content. Cells were then subjected to disruption and differential 
centrifugation to obtain a post-nuclear organelle fraction. The organelle fraction 
was subjected to a phenotypic purification via adsorption to anti-LC3 antibody 
coated magnetic beads (or IgG isotype coated magnetic bead control). We 
collected the organelles adsorbed to the magnetic beads to analyse the efficacy of 
the purification. Western blot analysis of the resulting fractions show enrichment 





detected in a “pure” organelle fraction (Figure. 7.5). Selection of organelles via 





Figure 7.5. Western blot analysis of autophagosome organelle fractions immune-captured on 
magnetic beads. α-LC3 coated magnetic beads enrich for LC3-I protein over IgG coated magnetic beads. 
Vinblastine treatment increases the capture of LC3-II+ organelles. This method may be useful to increase the 
number of autophagosomes present in cells prior to collection for Organelle-SELEX (see Figure 7.4). 
 
The successful selection of an aptamer specific to autophagosomes would 
yield a revolutionary tool in the field of autophagy research, allowing for the specific 
detection of autophagosomes across many techniques (i.e. CE-LIF, mass 
cytometry, microscopy, MS-based proteomics, and western blots). The specific 
detection of autophagosomes would allow for detailed study of organelle dynamics 
via individual organelle mass cytometry experiments (Chapter 5), providing new 
insight from organelle progression from phagophore to autolysosome (see Chapter 
2, Figure 2.16). In addition, it would enable a detailed profile of autophagy flux 
measured in Chapters 3 and 4. 
  
7.1.3 Functional Labelling 
As described in Chapter 5, individual organelle analysis via mass cytometry 
is a promising technique to probe inter-organelle interactions. While organelle 
detection is possible using conventional MCP-labeled antibodies, increasing the 
sensitivity of the method and eliminating the potential for non-specific binding could 
be accomplished using small molecule probes. Function-based probe are of 
particular interest, as they will eliminate complicate compensations for non-specific 
interactions, as was required in Chapters 3 through 5. Two distinct parameters are 
required for mass cytometry reagents: the inclusion of a specific probe to a cellular 
α-LC3 captured + - + 
IgG captured - + - 








target of interest, and a metal ion with a mass within the detectable range of the 
time of flight mass detector. Cellular targets or biological processes for which 
reliable antibody clones are unavailable present an area for novel small 
molecule177-178 or nucleotide-based reagent179 development (see Chapter 7, 
Section 7.1.2).  
An organelle of interest in monitoring autophagy-related organelle dynamics 
is mitochondria, which are known to be recycled via mitophagy.180-181 Thus, a small 
molecule probe specifically targeted towards mitochondrial identification that 
afforded increased numbers of lanthanide ions present per organelle would 
increase the flexibility of individual organelle detection via mass cytometry, both by 
increasing confidence of identification and reserving more sensitive channels (see 
Chapter 2, for transmission efficiency) for the quantification of less abundant 
organelle targets; A common approach to direct small molecules to mitochondria 
is via conjugation to a lipophilic cation.182-183 The triphenylphosphonium (TPP) 
cation is widely used for the delivery of small molecules to the mitochondrial matrix 
driven by the mitochondrial membrane potential. This accumulation is dictated by 
the Nernst equation (equation 7.1) which dictates that the uptake of singly charged 
cations increases 10-fold for every 61.5 mV of membrane potential (∆ΨM) at 
37°C.184 
∆ΨM= - RTZF  ln !
Cmatrix
Coutside
"                                            equation 7.1 
Where ∆ΨM is the membrane potential, Z is the charge on the ion, R is the 
ideal gas law constant, T is the absolute temperature, and Cmatrix and Coutside are 
the concentrations in the mitochondrial matrix and outside, respectively. 
We hypothesize that the specific delivery of lanthanide ions to isolated 
mitochondria can be accomplished through labelling with a TPP-DOTA ligand 
chelating a lanthanide ion, as was described by Li185 and Hardy186 for use in 
magnetic resonance imaging. In collaboration with Dr. Sylvie Pallioux, we 





Scheme 7.5. Synthetic Scheme for TPP-Ho-DOTA. Reagents and conditions: (a) CH3CN, N2, reflux, 18 hrs. 
(b) NH2NH2, EtOH, reflux, 15 hrs. (c) TEA, p-SCN-Bn-Ho-DOTA, anhydrous DMSO. See Appendix D for 1H, 
13C, and 31P NMR, and ESI-MS characterization. 
 
While this probe has not yet been tested, it is possible that it will not be 
sequestered inside mitochondria during fixation. While the TPP-Ho-DOTA reagent 
synthesized above would be sufficient for labelling functional, isolated 
mitochondria, upon fixation (required for mass cytometry) this label would likely 
leak out of isolated mitochondria due to a lack of membrane potential. This issue 
is common to most mitochondria targeting probes containing lipophilic cations but 
has been overcome by the inclusion of a thiol-reactive chloromethyl moiety to 
anchor the probe in place.183 In the event the probe leaks from fixed mitochondria, 
modification of this synthesized material at either secondary amine with a 
chloromethyl group would yield a reagent appropriate for functional labelling of 
mitochondria that would be stable during required sample preparation procedures.  
This synthesis yielded TPP-Ho-DOTA, a functional probe for the 
unambiguous identification of polarized mitochondria via mass cytometry, enabling 





required process during myogenesis. This will benefit analyses of mitophagy flux, 
such as was done in Chapter 3 through unambiguous identification of functional 
mitochondria, and a measure of autophagy adaptor protein (i.e. p62) accumulation 
at less functional mitochondria.  
  
7.1.4 Activity-Based Probes 
Incredible detail of biological processes has been elucidated relying solely on 
quantification of steady state protein abundance using commercially available 
reagents by mass cytometry. However, protein expression levels do not always 
directly correlate to their activity as many proteins are regulated by post-
translational modifications.187 Of interest to the field of autophagy research is the 
post-translational modification known as prenylation. Prenyl modification of select 
proteins increases their hydrophobicity via covalent binding of a farnesyl (15-
carbon) or geranylgeranyl (20-carbon) isoprenoid.188 This modification anchors 
proteins to lipid membranes and influencing their function. Known proteins targed 
for prenylation include the master regulators of vesicle-trafficking, Rab 
GTPases.189 The Rab GTPases localize to the hydrophobic membrane of vesicles 
via their prenyl moiety to exert control over membrane trafficking.190 Prenylation 
activity has been shown to be increased in autophagy deficient cell systems.191 
The application of this activity-based probe (ABP) for prenylation in measurements 
of autophagy flux by mass cytometry will unlock a new dimension of biological 
information regarding the regulation of autophagy organelle trafficking. This will be 
useful in autophagy flux measurements similar to those made in Chapters 3 and 4 
of this work.  
ABPs are advantageous in that they directly report on protein activity though 
quantification of the specific incorporation of a detectable probe. This approach 
has been extensively used in proteomics192 and pharmaceutical development193, 
among other fields. ABPs are generally made of three distinct modules: a i) 
reactive group, ii) selectivity conferring element, and iii) reporter moiety. The 





specific mechanism. Selective labelling is achieved through the selection of an 
appropriate selectivity conferring element, and labelling is detected via the 
reporter. Common labelling moieties include fluorophores and affinity tags.187 
Many variations of ABPs exist to decrease non-specific signal,194 increase 
membrane permeability, or increase multiplexing ability.195   
ABPs for protein prenylation has been reported,196-199 usually exploiting the 
C-terminal CAAX motif common to most prenylated proteins. Within this motif, C 
is a cystine residue, AA are two aliphatic amino acids, and X is any amino acid. 
The cystine residue specifically serves as the attachment point for the prenyl 
pyrophosphate via protein prenyltransferase enzymes.200 The metabolic labelling 
and detection of prenylation in whole cells via fluorescent reporters has been 
reported by Palsuledesai191 (Figure 7.6). This approach utilizes an alkyne 
isoprenoid analog (C15Alk) which is metabolically incorporated as a prenyl post-
translational modification on select proteins. The bio-orthogonal alkyne handle is 
reacted in situ with a fluorescent azide reporter (5-FAM-PEG-N3), and resulting 





Figure 7.6. Metabolic labelling of prenylated proteins using an alkyne modified isoprenoid analog. 
Palsuledesai and coworkers report the in situ labelling of protein prenylation via an alkyne isoprenoid analog 
(C15Alk) which reacts with a fluorescent azide reporter (5-Fam-PEG-N3), via a Cu-catalyzed alkyne azide 
cycloaddition (CuAAC). Resulting fluorescence signal is quantified via flow cytometry or confocal microscopy. 
Modified with permission from Palsuledesai.191 
 
In collaboration with Dr. Mark Distefano and Kiall Suazo, we have exploited 
the same ABP for detection of protein prenylation via mass cytometry. To make 
the approach compatible with mass cytometry detection, we replaced the 
fluorophore azide reporter with an azide modified DOTA moiety chelating 159Tb 
(Tb-azide), similar to the molecule reported by Shaklee201 (Figure 7.7). In addition, 
we employed a diphosphate C15 isoprenoid analog (C15AlkOPP) developed by 
the Distefano lab, rather than the farnesol isoprenoid analog (Figure 7.7). Despite 
its negative charge, the diphosphate isoprenoid analog has improved incorporation 











Figure 7.7. Structure of Tb-azide and diphosphate isoprenoid analog (C15AlkOPP) substituted for use 
in mass cytometry. The Tb-azide (a) reacts with the alkyne moiety of the C15AlkOPP probe (b) via a CuAAC 
reaction in situ following metabolic labelling of prenylated proteins.  
 
In preliminary experiments, we applied the reported labelling protocol191 using 
Tb-azide201 in L6 myoblasts to profile the off-target interactions of Tb-azide in situ. 





















Figure 7.8. Histograms showing Tb-azide signal in individual cells detected via mass cytometry. All 
cell samples were metabolically labelled with 10 µM C15AlkOPP probe, then treated with 0, 0.13, 0.25 or 0.50 
mM Tb-azide. Tb-azide signal increases in a dose dependent manner (median signal in parenthesis) but is 
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The optimized labelling conditions were used to probe the prenylation profile 
of autophagy deficient L6 myoblasts via mass cytometry. L6 myoblasts were 
treated with siRNA targeting ATG7 (or a scrambled negative control oligo) to 
knock-down Atg7 activity, halting autophagy flux. In contrast to previous 
experiments, the signal to noise ratio for Tb-azide signal resulting from non-specific 
interactions of the Tb-azide reporter was relatively high (ten-fold increase, see 
Figure 7.9). This is likely an artifact of transfection, indicating the need to optimize 
labelling conditions for each biological model in use. Future experiments will repeat 
this experiment in the ATG7 deficient L6 myoblasts described in Chapter 3, which 
have been genetically modified via CRISPR-Cas9. This will eliminate transfection-
related artifacts in metabolic incorporation of the C15AlkOPP probe or labelling 
with Tb-azide. Additional controls will greatly improve the optimization of in situ 
reaction conditions and should include an azide deficient lanthanide-chelating 
DOTA molecule, and modulation of probe incorporation via prenyltransferase 
inhibitors.  
Figure 7.9. Prenylation profile for ATG7 
siRNA KD L6 myoblasts.  siRNA KD L6 
myoblasts (a-b), and associated negative 
controls (c-d) were treated with Tb-azide (0.5 
µM) after metabolic labelling of prenylation (a & 
c) or vehicle control treatment (c-d). The ratio of 
median Tb-azide signal between ATG7 KD and 
negative control were very similar for cells 
exposed to the C15AlkOPP probe and for those 
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Successful use of the prenylation ABP used above will highlight the 
contribution of protein prenylation autophagy flux. It could be included in analyses 
such as those carried out in Chapters 3 and 4, to enable the investigation into the 
requirement of active protein prenylation during autophagy flux.  
 
 Analysis of Autophagy Flux in Individual Muscle Fiber Segments via Mass 
Cytometry 
As described in Chapter 2, skeletal muscle is a highly heterogeneous tissue 
composed of phenotypically and functionally distinct cell types responsible for 
maintaining tissue mass and function. Myofibers are a unique multi-nucleated, 
cylindrical cell type responsible for producing the contractile force necessary for 
controlled movement.202 In mature skeletal muscle these multi-nucleated cells 
show functional and structural heterogeneity and can be sub-categorized (type 1, 
2A, 2B, 2X) by their predominate metabolic mechanism of ATP generation.  
Muscle mass homeostasis is attained through a balance between protein 
synthesis and degradation, processes which are regulated by a variety of intra- 
and extra-cellular signals. Protein synthesis serves to build muscle mass in times 
of nutrient excess while autophagy functions to degrade cytosolic components to 
be used for energy production in times of nutrient deprivation. Recent reports show 
type 2 fibers are relatively more prone to degradation with age than type 1 fibers, 
though the cellular mechanism(s) responsible for these observations remain 
unclear.203-205 These observations may indicate a role for dysfunctional autophagy 
in aged myofibers as autophagy flux is greater in type 2 fibers than type 1 fibers.206 
Thus, a comprehensive investigation into the role autophagy dysfunction in the 
development of age-related musculoskeletal diseases requires the development 
of a method for the analysis of autophagy flux in individual muscle fibers. 
As was shown in Chapters 3 and 4, functional measurement of autophagy 
flux is possible across a phenotypically diverse cell sample collected from murine 





currently limited by the unique morphology of muscle fibers. The large, non-
spherical size of muscle fibers hinder their movement through the microfluidic 
sample delivery system of CyTOF2 resulting in few fibers reaching the ICP torch 
for analysis in the instrument.  
7.2.1 Development of a Methods for Muscle Fiber Segment Phenotyping via Mass 
Cytometry by MHC Expression 
Individual muscles are comprised of bundles of myofibers with similar 
structural and functional properties, though individual fibers show considerable 
plasticity in structure in function.202 Type 1 fibers are contain high numbers of 
mitochondria and have high oxidative capacity, making them suited to continuous 
activity (i.e. slow twitch). Type 2 fibers (including subcategories A, B, and X) 
contain fewer mitochondria and rely primarily on glycolytic generation of ATP for 
punctuated bursts of activity;202 though type 2A fibers also contain a compliment 
of oxidative enzymes.207. A common method for the identification of the distinct 
sub-categories of myofibers is based on the expression of a unique myosin heavy 
chain (MHC) protein isoform throughout a fiber, though recent single-fiber studies 
have shown the existence of fibers with hybrid MHC expression.208-209 The 
presence of multiple MHC isoforms follows the scheme of fiber type switching 
shown below (Figure 7.10). Despite the plasticity of MHC expression in individual 









Figure 7.10. Organization Scheme for Hybrid Muscle Fiber Types. Individual muscle fiber transitions 
between types generally proceed according to the scheme shown here, though it is not always the case.  
 
To phenotypically identify myofiber segments, we assembled a metal-labelled 
panel of antibodies to identify MHC isoforms found in type 1, type 2A and types 
2B, shown in table 7.2. These particular clones were chosen based on their ability 
to identify a fiber type of choice, and their IgG structure which is amenable to metal-
1 ⟷ 1/2A ⟷ 2A ⟷ 2A/2X ⟷ 2X ⟷ 2X/2B ⟷ 2B 
 
Oxidative                                               Glycolytic 





labelling with currently available reagents based on maleimide chemistry. 
Hybridoma cell lines producing each antibody clone were purchased from the 
Developmental Studies Hybridoma Bank at the University of Iowa, sub-cultured at 
UMN, and sent to ProMab Biotechnologies (Richmond, CA) for culture scale-up 
and purification.  
 
Table 7.2. Fiber Type Phenotyping Antibody Panel. The following three antibody clones were metal-
labelled and used to phenotypically identify myofiber segments by fiber type. 
 
 Antibody Clone – Metal Label 
Fiber Type BAF8 - 169Tm 2F7 – 152Sm BF35 – 145Nd 
Type 1 + - - 
Type 2A - + + 
Type 2B - - + 
 
Myofiber segment preparations (see Appendix D, Supplementary Methods) 
were stained with the metal-labelled anti-MHC antibodies shown in Table 7.2 and 
analysed via mass cytometry. SPADE analysis of the resulting data indicated some 
specific antibody binding as indicated by the differential abundance of each isoform 
on unique clusters of myofiber segments in Figure 7.11. While promising, this 
analysis also indicated a significant amount of non-specific antibody binding 
evidenced by consistent detection of all MHC isoforms in the bottom clusters of 





























































Figure 7.11. SPADE Analysis of Muscle Fiber Segments. Clusters with differential expression of unique 
MHC isoforms (solid line boxes) can be grouped and identified by fiber type. The SPADE analysis also 
revealed clusters of fibers in which all three MHC isoforms were detected (broken line box), likely due to non-
specific binding of the anti-MHC antibodies. 
 
Subsequent confocal microscopy experiments to confirm the non-specific 
binding of each anti-MHC antibody revealed very little antibody binding and almost 
no penetration of staining reagents into the inner body of the fiber (see Appendix 
D, Figure D8). To improve permeability suspensions of muscle fiber segments 
were incubated in a glyceration buffer prior to fixation (see Appendix D, 
Supplemental Methods). Confocal microscopy of glycerated fibers stained with 
anti-MHC (BF35) and a secondary antibody showed improved permeability of 
prepared muscle fiber segments (Figure 7.12). 
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Figure 7.12. Confocal Microscopy Slices of Glycerated Muscle Fiber Segments. Incubation in glyceration 
buffer effectively permeabilized muscle fiber segments. Glycerated and fixed fibers were stained with anti-
MHC (BF35) antibody and a secondary Alexafluor 488 antibody for fluorescence visualization via confocal 
microscopy. Each sequential panel is an individual z-axis slice through a single muscle fiber. Scale bar 
represents 20 μm. 
 
Future experiments will test the usefulness of the glyceration 
permeabilization scheme in the preparation of muscle fiber segments for mass 
cytometry analysis of fiber type. If successfully tested via mass cytometry for fiber 
typing, the glyceration permeabilization scheme will also allow for the analysis of 
autophagy-related cellular targets in individual muscle fiber segments due to the 
vastly improved accessibility of the inner fiber to antibody cocktails. The successful 
analysis of autophagy flux in muscle fiber segments and mononuclear cells will 
provide a comprehensive analysis of autophagy flux in skeletal muscle. 
1 14 27 40 
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 Antibody Panel Characterization 
Table A1. Metal-Labeled Antibody Panel Characterization. The following antibodies were metal labeled 




Isotope Isotype Vendor & p/n 
Average Lanthanide 
Ions / Antibody 
Mouse IgG #1 141Pr ----- Invitrogen, 026502 42.5 
LC3 142Nd rabbit Novus, NB100-2220 59.2 
BF35 145Nd mouse DSHB / promab, custom 56.6 
CC3 147Sm Rabbit R&D Systems, MAB835 68.3 
Atg5 149Sm mouse Novus, NB110-53818 31.3 
MyoD 153Eu mouse BD Pharmingen, 554130 48.0 
Goat IgG 155Gd ----- Invitrogen, 02-9602 66.9 
Mfn1 156Gd mouse Abcam, ab57602 174.9 
Mouse IgG #2 160Gd ------ Thermo Scientific, 10400C 48.8 
Bec1 / Atg6 161Dy mouse R&D Systems, MAB 5295 92.1 
Mouse IgG #3 163Dy ----- Thermo Fisher, 31903 46.6 
Lrrk2 165Ho goat R&D Systems, AF6674 14.2 
p62 166Er mouse Abnova, H00008878-M01 51.1 
Rat IgG 168Er ----- R & D Systems, MAB005 69.8 
Rabbit IgG 171Yb ----- Invitrogen, 026102 61.9 
GAPDH 172Yb rabbit Rockland, 600-401-A33 98.8 
Yb1 174Yb rabbit Abcam, ab12148 95.7 
MyoG 175Lu mouse affymetrix, 14-5643 84.2 







 Quality Control of Corrected and Normalized Mass Cytometry Data 
 
 
Figure A1. Quality assessment of mass cytometry data after correction and normalization. (a) general 
gating scheme performed on EQ bead normalized files. Contours represent 2% increases in population 
density, and percent from parent gate are indicated under gate name. (b) representative biaxial dot plot 
showing a fraction of population with a lower GAPDH signal than corresponding isotype. Histogram showing 
negative values for normalized anti-LC3 signal where the isotype is greater than GAPDH. The population 
























Table A2. Percentage of cells from each sample removed from analysis. As shown in Figure A2, a 
bimodal distribution can be observed in normalized and corrected data and is attributable to a larger number 
of isotype antibodies bound per cell than specific antibodies. We removed these cells from subsequent 
analyses. The percentage of cells removed from each cell sample are shown below. Similar percentages of 
cells were removed from biological replicates (data not shown). 
 
  













WT_0.25 μg/mL 23033 6692 29 
WT_0.50 μg/mL 21408 5783 27 
WT_1.00 μg/mL 27417 7428 27 
WT_2.00 μg/mL 18277 4534 25 
WT_4.00 μg/mL 33098 7917 24 
ATG7 KO_0.25 
μg/mL 28255 8409 30 
ATG7 KO_0.50 
μg/mL 22135 6328 29 
ATG7 KO_1.00 
μg/mL 14260 4101 29 
ATG7 KO_2.00 
μg/mL 19248 4395 23 
ATG7 KO_4.00 





NC_0.25 μg/mL 26618 4373 16 
NC_0.50 μg/mL 25410 3700 15 
NC_1.00 μg/mL 31262 4971 16 
NC_2.00 μg/mL 34471 3828 11 
NC_4.00 μg/mL 22336 3105 14 
Treated_0.25 μg/mL 30189 4353 14 
Treated_0.50 μg/mL 26096 3420 13 
Treated_1.00 μg/mL 49321 5837 12 
Treated_2.00 μg/mL 35315 4317 12 
























Figure A2. Western blot Autophagy Markers in ATG7 KO L6 Myoblast Cell Line. The ATG7 knock-out 
cell line was produced using CRISPR-Cas-9 technology by the Genetic Engineering Resource Center at the 
University of Minnesota and characterized using TIDE sequencing. This clone has a biallelic single base pair 
deletion in exon 1 (data not shown). Atg7 protein expression is increased in the ATG7 KO clone over WT 
despite the introduced genetic modification. However, the Atg7 protein seems to be inactive as evidenced by 
the accumulation of p62 and the lack of lipid-conjugated LC3 (LC3-II).  
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 Representative Individual Autophagy Marker Histograms 
 
Figure A3. Representative histograms of unaltered and corrected and normalized autophagy panel 
antibody probes in WT L6 myoblasts. (a) representative histograms showing cell population distributions 
before correction and normalization. (b) representative histograms of the same data shown in (a), after 
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 Normalized ATG7 KO L6 Myoblast Titration Curves 
Figure A4. Corrected and normalized WT and 
ATG7 KO L6 myoblast titration curves for all 
autophagy panel markers. Autophagy panel 
antibodies were titrated in both WT and ATG7 KO 
L6 myoblasts, then subjected to the correction and 
normalization method. Resulting titration curves are 
shown above for Autophagy-related gene 5 (Atg5), 
Autophagy-related gene 4a (Atg4a), Mitofusin 1 
(Mfn1), Beclin1 (Bec1), Autophagy-related gene 7 
(Atg7), sequestome 1 (p62), and leucine-rich repeat 
kinase 2 (Lrrk2). Broken Lines show Langmuir fits 
to WT titration curves where significant (p>0.05). 
Error bars at each point represent 95% confidence 
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Figure A5. Unaltered WT and ATG7 KO L6 myoblast titration curves for all autophagy panel markers. 
Autophagy panel antibodies were titrated in both WT and ATG7 KO L6 myoblasts. Resulting titration curves 
are shown above for Autophagy-related gene 5 (Atg5), Autophagy-related gene 4a (Atg4a), Mitofusin 1 (Mfn1), 
Beclin 1 (Bec1), Autophagy-related gene 7 (Atg7), sequestome 1 (p62), and leucine rich repeat kinase 2 
(Lrrk2). Broken Lines show linear regression fits to WT titration curves with R2 values where significant 






 Corrected and Normalized Titration Curves for Rapamycin / Bafilomycin A1 
Treated C2C12 Myoblasts 
Figure A6. Corrected and normalized titration 
plots for rapamycin and bafilomycin A1 treated 
and negative control C2C12 myoblasts. 
Autophagy panel antibodies were titrated in both drug 
treated and negative control C2C12 myoblasts, then 
subjected to the correction and normalization 
method. Resulting titration curves are shown above . 
Error bars at each point represent 95% confidence 
intervals of the sample median. Broken Lines show 
linear regression fits to WT titration curves with R2 
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 Non-corrected or Normalized Titration Plots for Rapamycin / Bafilomycin A1 
Treated C2C12 Myoblasts 
Figure A7 Titration plots for unaltered 
rapamycin and bafilomycin A1 treated and 
negative control C2C12 myoblasts. Autophagy 
panel antibodies were titrated in both drug treated 
and negative control C2C12 myoblasts. Resulting 
titration curves are shown above. Error bars at 
each point represent 95% confidence intervals of 
the sample median. Broken lines indicate linear 
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 Correction and Normalization Return Consistent Results Across Isotype 
Antibody Clones and Separate Day Biological Replicates 
To establish the reproducibility of the correction and normalization method, 
two areas of potential variability were investigated, including: i) the variability in 
isotype antibody affinity and avidity between separate commercially available 
isotype antibody clones, and ii) the ability of the correction and normalization 
method to normalize inter-day staining and instrument variation. 
We tested the robustness of this method to changes in isotype antibody 
formulation. Isotype control antibodies have been used extensively in flow 
cytometry experiments to estimate non-specific antibody binding, though finding a 
“true” control with equal affinity, avidity, fluorescence / protein ratio, concentration, 
host species and type is often difficult. We adopted the concept for mass 
cytometry, where we have controlled for isotype control antibody type, host 
species, concentration, and metal atom per antibody content. However, we cannot 
control for differences in the affinity or avidity of an isotype control antibody clone. 
We investigated the effect of using different isotype control antibody clones on 
quantifying non-specific binding. Three separate clones (see Table A1) were 
purchased, metal-labeled and simultaneously titrated along with the corresponding 
specific antibodies. At each antibody staining concentration, the number of bound 
specific antibodies is the same regardless of the isotype antibody clone (Figure 
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Figure A8. Isotype clone does 
not affect correction and 
normalization titration data. To 
characterize the utility of this 
method, we needed to ensure the 
clonality of the isotype antibodies 
used did not return significantly 
different results. This plot shows 
the fold change between 
rapamycin and bafilomycin A1 
treated vs negative control cells 
at each point in a titration curve. 
Each series represents correction 
and normalization done using a 
separate mouse isotype clone. 
The overlap of the 95% 
confidence intervals for each 
clone at every concentration 
indicates no significant change 
with isotype clone. Error bars 
represent a 95% confidence 





To investigate the ability of the correction and normalization method to 
normalize between cell samples prepared and analyzed on separate days, C2C12 
myoblasts were titrated following the same procedure roughly one month apart. 
Titration plots showing the non-corrected and normalized data show linear trends 
with different sensitivities (Figure A9). After correction and normalization, the 
titration plots follow the expected trajectory and show a plateau at the same 
antibody staining concentration (2 μg/mL antibody, Figure A9). These data indicate 
that the correction and normalization method are resistant to inter-day variation 
































Figure A9. Correction and normalization corrects for day to day sample preparation and instrument 
variation. (a) unaltered titration plot of anti-LC3 antibody probe shows a linear trend on two separate days. 
(b) correction and normalization of titration data in (a) show titration curves with expected trajectories, through 































































































Figure 10. Representitative images of trypsinized culture of 120 h differentiated C2C12 cells. We sought 
to understand the morphological characteristics of differentiating myoblasts and myotubes subjected to 
protease treatment required to lift cells from the growth flask surface. (A) Culture of differentiating myoblasts 


















































Figure A11. Manual single cell gating strategy. (A) Identification of whole cells. (B) Identification of live 
cells. (C) Removal of bead-cell conjugates. (D) Identification of MyoDhi, MyoDlo, and MyoG+ populations. (E) 
Identification of MyoG+, MyoD+, MHC- and MyoG+, MyoD+, MHC- populations representative of cells in mid-
late differentiation time points. (F) Identification of MyoDlo, MHC- myoblasts vs MyoDlo, MHC+ terminally 
differentiated myotubes. 
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 Antibody Panel Characterization 
Table B1. Metal-Labeled Antibody Panel Characterization. The following antibodies were metal labeled 










LC3 142Nd rabbit Novus, NB100-2220 59.2 Y 
BF35 145Nd mouse DSHB / promab, custom 56.6 Y 
CC3 147Sm rabbit R&D Systems, MAB835 68.3 Y 
Atg5 149Sm mouse Novus, NB110-53818 31.3 Y 
MyoD 153Eu mouse BD Pharmingen, 554130 48.0 Y 
Goat IgG 155Gd ----- Invitrogen, 02-9602 66.9 Y 
Mfn1 156Gd mouse Abcam, ab57602 174.9 Y 
Mouse IgG 160Gd ------ Thermo Scientific, 10400C 48.8 Y 
Bec1 / Atg6 161Dy mouse R&D Systems, MAB 5295 92.1 Y 
Lrrk2 165Ho goat R&D Systems, AF6674 14.2 Y 
p62 166Er mouse Abnova, H00008878-M01 51.1 Y 
Rat IgG 168Er ----- R & D Systems, MAB005 69.8 Y 
Rabbit IgG 171Yb ----- Invitrogen, 026102 61.9 Y 
GAPDH 172Yb rabbit Rockland, 600-401-A33 98.8 Y 
Yb1 174Yb rabbit Abcam, ab12148 95.7 Y 
MyoG 175Lu mouse affymetrix, 14-5643 84.2 Y 
Atg4a 176Yb rabbit Novus, NBP1-68462 74.9 Y 
CD31 144Nd rat BD Pharmingen, 553708 33.1 Y 
F4/80 146Nd rat Fluidigm, 3146008B ----- N 
CD45 147Sm rat Fludiigm, 3147003B ----- N 
α-7-integrin 148Nd rat Ablab, 21-0010-05 49.9 Y 
VCAM1 151Eu rat BD Pharmingen, 553330 46.7 Y 
CD11b 154Sm rat Fluidigm, 3154006B ----- N 
Sca1 169Tm rat Fluidigm, 3169015B ----- N 
PDGFRα 158Gd rat BD Pharmingen, 562171 123.8 Y 






































































Figure B2. Manual single cell gating strategy. (a) Identification of whole cells. (b) Removal of bead-cell 
conjugates (c) . Identification of live cells. (d) splits endothelial (CD31+, Q3), immune (CD45+, Q1) cell subsets 
from everything else (Q4). (d-f) M1 and M2 macrophages are identified as CD11b+, and either F4/80+ or 
CD206+ , respectively. (d-i) Satellite cells are identified as α-7-integrin+/Sca1-, VCAM1+, and Pax7+. (g,j) FAP 
cells are identified as Sca1+/ α-7-integrin- and PDGFRα+. All gates are labeled by the positive marker and the 
% of parent gate. 










 Enumeration of unique cell subsets 
Table B2. Total number phenotypically identified cell populations of interest. The absolute number of 
cells detected for each population in each sample is listed in columns. The total number of intact cells detected 





 M1 Macrophages M2 Macrophages Satellite Cells FAP cells 
Total 
Cells 
Young - 1 35 2037 61 1054 
76087 
Young - 2 14 561 11 686 28000 
Young - 3 113 757 4 93 
32286 
Geriatric - 1 50 581 131 1888 18519 
Geriatric - 2 15 384 34 210 13636 
Geriatric - 3 5 331 465 3158 35714 






















 Antibody Panel Characterization 
Table C1. Metal-labeled antibody panel. Characteristics of the assembled metal-labeled antibody panel 
used to phenotype individual organelles via mass cytometry. 
Target Metal 
Isotope 
Host Isotype Clone # Metal Ions 
per Antibody 
Antibody Vendor & P/N 
TOMM22 154Sm Mouse, IgG2a κ 4G4 56 Sigma, WHO0056993M1 
LAMP2 162Dy Rabbit, IgG poly 78 Sigma, L0668 
LC3 142Nd Rabbit, IgG poly 76 Novus, NB100-2220 
Rabbit Isotype 171Yb Rabbit, IgG poly 62 Invitrogen, 026102 

























 Sample and Instrument Stability 
Figure C1. Intra-assay precision assessed via technical replicates. Intra-assay precision was assessed 
via acquisition of six technical replicates spaced over thirteen hours of data acquisition. Phenotypically unique 
organelle distributions from each replicate were binned into deciles and plotted on a quantile-quantile plot. If 
the replicate distribution is similar to the pooled distribution, the plot will approach the x=y line. Scales vary in 
each panel based on the marker represented. Replicates (shown as different colored series) show minimal 
deviation from x=y, indicating that all replicate distributions are similar enough to originate from the same 
pooled distribution. Where deviations do occur (i.e. panels a, b, c f, i-l) series that deviate were data collected 
at the end of 13 hours, indicating a potential limit in sample or instrument stability.  These observations apply 
to all phenotypically unique organelle populations, including: a) mitochondria (TOMM22+), b) lysosomes 
(LAMP2+), c) LC3+ autophagy organelles (LC3+), d-e) LC3+ autophagy organelles – mitochondria 
(LC3+TOMM22+), f-g) LC3+ autophagy organelles – lysosomes (LC3+LAMP2+), h-i) lysosomes – 
mitochondria (LAMP2+TOMM22+), and j-l) LC3+ autophagy organelles – mitochondria – lysosome 
(TOMM22+LAMP2+LC3+).  The number of organelles in each technical replicate were as follows: replicate 1, 
n = 20,440; replicate 2, n = 19,995; replicate 3, n = 22,195; replicate 4, n = 9,208; replicate 5, n = 22,410; 

















 Setting Individual Organelle Signal Thresholds and Application to Gating 
Strategies 
 
Figure C2. Calculation of Individual Organelle Signal Thresholds. To set a low threshold for each 
monitored m/z channel, an aliquot of organelle suspension (a) was filtered and the filtrate containing debris & 
unbound reporter (b) analyzed in solution mode on the CyTOF2. The low signal threshold (c) is calculated as 
the mean dual count signal in a given channel plus three times the standard deviation of the mean. This low 




Table C2. Calculated Low Signal Threshold Value. A threshold value was calculated for each m/z value in 
each organelle sample. B = brain, L = liver, M = skeletal muscle, R1 = biological replicate 1, R2 = biological 
replicate 2. 
Tissue - Replicate Calculated low signal threshold value (DC signal) 
142Nd-LC3 154Sm-TOMM22 DDD-159Tb 162Dy-LAMP2 
B-R1 0.5264 0.4218 8.2087 0.3114 
B-R2 0.9078 0.6404 9.9606 0.6100 
L-R1 0.4400 0.7324 26.3693 0.8331 
L-R2 0.7978 0.6900 15.9290 1.4507 
M-R1 0.7324 0.7189 8.9970 0.4163 







Figure C3. Gating Strategy for Phenotypically Unique Autophagy Organelles. Calculated low signal 
threshold values used as lower bounds for phenotypic identification. The first two panels (a-b) show sequential 
gates: (a) application of DDD-Tb low signal threshold, (b) removal of EQ normalization bead – organelle 
aggregate events. The lower three panels show the application of the calculated lower signal threshold to 









 Population level analyses of phenotyped organelles from liver and skeletal 
muscle tissue 
 
Figure C4. Percent identification of individual organelles from liver and skeletal muscle tissue. The 
percent contribution from each phenotypically unique organelle type to the total number of identified organelles 
was calculated for liver (a) and skeletal muscle (b) tissues. Tissue-specific differences in organelle content 
















LC3+: 2% LC3+, LAMP2+: 6% 
LAMP2+: 38% TOMM22+: 9% 
TOMM22+, LC3+, LAMP2+: 12% TOMM22+, LC3+: 1% 
a 
b 
LC3+: 7% LC3+, LAMP2+: 6% 
LAMP2+: 44% TOMM22+: 24% 





























Figure C5. Comparison of the number of specific marker antibodies bound to each organelle type. The 
calculated number of specific marker antibodies detected per organelle generally increases with progression 
to late autophagic organelles. The increase in markers is generally accompanied by an increase in the number 
of DDD-Tb molecules per detected organelle indicated an increase in total membrane volume. The number of 
specific marker antibodies per organelle was normalized to the DDD-Tb dual count signal, and the resulting 
plots are shown in Figure 2a-c. Error represented as 95% confidence intervals of the median. B = brain, L = 
liver, M = skeletal muscle, R1 = biological replicate 1, R2 = biological replicate 2. 
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Figure C6. Multi-dimensional t-SNE analysis of organelles from liver. t-SNE plots from murine liver tissue 
show phenotypically identified populations of organelles. Distributions of specific markers on individual 
organelles were binned into deciles and color-coded according to their assigned decile. Wide variation in color 
across specific markers in t-SNE plots indicate heterogenous sub-populations, which may have significantly 
different function. Triple + organelles represent autolysosomes associated with mitochondria, while LC3-
TOMM22 double + organelles represent autophagosomes associated with mitochondria, and LC3-LAMP2 




















































































































































































Figure C7. Multi-dimensional t-SNE analysis of organelles from skeletal muscle. t-SNE plots from 
murine skeletal muscle tissue show phenotypically identified populations of organelles. Distributions of 
specific markers on individual organelles were binned into deciles and color-coded according to their 
assigned decile. Wide variation in color across specific markers in t-SNE plots indicate heterogenous sub-
populations, which may have significantly different function. Triple + organelles represent autolysosomes 
associated with mitochondria, while LC3-TOMM22 double + organelles represent autophagosomes 



























































































































































































D.1 Synthesis of New Mitochondria-Targeting Functional Reagent for Mass 
Cytometry 
General Considerations 
1H NMR spectra were recorded on a Bruker AX 400 at 400 MHz at the Le 
Claire-Dow Characterization Facility of the Department of Chemistry of the 
University of Minnesota; the solvent residual peak was used as an internal 
reference. 1H NMR data are reported as follows: chemical shift (δ, ppm), multiplicity 
(s, singlet; d, doublet; t, triplet; m, multiplet), integration, coupling constant (Hz). 
Mass spectra (ESI MS = electrospray ionization - mass spectrometry) were 
recorded on a Bruker BioTOF II at the Waters Center for Innovation for Mass 
Spectrometry Facility at the Department of Chemistry at the University of 
Minnesota, Twin-Cities. Analytical HPLC was performed on a Variant pro star 
instrument (Agilent, Santa Clara, CA) equipped with a diode array detector a 
thermostat set at 25 °C, and a Zorbax Eclipse XDB-C18 column (9.4 × 250 mm, 5 
µm, Agilent, Santa Clara, CA). The mobile phase of a binary gradient (2 min 15 % 
B, 20 min 15 to 100 % B, 3 min, 100 % B, 4 min 100 to 15% B, 1 min 15% B) where 
A is water (0.1 % TFA) and B acetonitrile (0.1 % TFA at a flow rate of 1 mL/min 
was used for analytical and preparative HPLC. 
Unless otherwise noted, starting materials were obtained from commercial 
suppliers and used without further purification. The synthesis of TPP-Ho-DOTA (1) 
was completed in three steps. The synthesis of (10-aminodecyl) 
triphenylphosphonium bromide (2) was carried out following the procedure 
described by Zhixin Li.185 The condensation of bromododecyl phtalimide and 
triphenylphosphine was carried out in reflux of acetonitrile overnight. The 
phtalimide protective group was removed after an overnight reaction of hydrazine 
reflux in ethanol. The coupling between the amine (3) and the succinimide was 
adapted from the procedure described in X186 and allowed the formation of TPP-
Ho-DOTA. 
Synthesis of (10-phtalimidyl) triphenylphosphonium bromide (2)  
Bromodecyl phtalimide (7g, 0.019 mol) and triphenylphosphine (5g, 0.019 mol) 





was removed under reduced pressure. The crude product was purified using a 
combiflash system with silica gel and a gradient of EtOH in DCM (compound come 
out at 15% of EtOH) afforded a white solid (2) (6 g, 49%). ESI+ (m/z) calculated 
for [C36H39NO2P]+: 548.3; found: 548.3. 
 

















Synthesis of (10-aminodecyl) triphenylphosphonium bromide (3) 
To a solution of 1 (6 g, 9.2 mmol) in EtOH (70 mL) hydrazine was added (0.46 
mL, 9.2 mmol). The mixture was refluxed for 15 hours. The solvent was removed 
under reduced pressure. The product was purified using a combiflash system with 
on silica gel and a gradient of EtOH in DCM (compound eluted at 20 % EtOH) 
afforded a white solid (3) (3.4g, 73%). 
 
 
Figure D2. 31P NMR of (10-aminodecyl) triphenylphosphonium bromide (3). 31P NMR (161 MHz, CDCl3, 























Figure D3. 1H NMR of (10-aminodecyl) triphenylphosphonium bromide (3). 1H NMR (400 MHz, CDCl3, d, 
ppm): 7.86–7.75 (15H, m), 3.73–3.60 (2H, m), 2.03–2.2.91 (2H, m), 1.79-1.74 (2H, m), 1.63-1.52 (4H, m) 






















Figure D4. ESI (+) of (10-aminodecyl) triphenylphosphonium bromide (3). ESI+ (m/z) calculated for 




















TEA (17.1 mg, 9.3 mmol) was added to a nitrogen purged solution of p-SCN-
Bn-Ho-DOTA (37.3 mg, 52.6 mmol) and 3 (30.9 mg 63.4 mmol) in dry DMSO (10 
mL). The reaction mixture was stirred at room temperature overnight. The solvent 
was removed under reduced pressure and the residue was purified using 
combiflash system and reverse phase C18 with water and acetonitrile gradient 
both phases containing 0.1 % TFA (Mito-Ho-DOTA eluted at 40% of CH3CN) to 
afford a pinkish solid 1 (40 mg, 63%). 
 
 








Figure D6. 1H NMR of TPP-Ho-DOTA (1). 1H NMR (400 MHz, MeOH, d, ppm):8.55 (4H, brs), 8.26 ( 6H, brs), 
7.92 (2H, brs), 7.82 (5H, brs), 7.63 ( 2H, brs), 6.95 (1H, NH), 5.32 (2H, brs), 4.56 (2H, brs), 4.19 (2H, brs), 
3.97 (2H, brs), 3.60 (2H, brs), 3.37 (14H, brs), 2.84 (2H, brs), 2.68 (4H, brs),1.68 (3H, brs), 1.32 ( 5H, brs). (8 














Figure D7. ESI (+) of TPP-Ho-DOTA (1). ESI+ (m/z) calculated [C52H66HoN6O8PS]+ 1130.4, found: 1131.8.
